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1.1 TARGETING ANTIGENS TO ANTIGEN-PRESENTING CELLS AS A 
VACCINATION STRATEGY 
 
1.1.1 INTRODUCTION 
Vaccination is one of the most successful public health initiatives ever achieved [1]. While 
sanitation has markedly decreased deaths from infectious disease, vaccination has done so 
as well. The global eradication of the life-threatening disease smallpox, announced by the 
World Health Organization in 1979, is being considered “the greatest triumph of vaccination” 
[2]. In addition, the global eradication of rinderpest, declared eradicated by the World 
Organization for Animal Health in 2011, can be considered the greatest triumph of veterinary 
vaccination [3, 4]. The term vaccination stems from the Latin word for cow “vacca” [5]. 
Edward Jenner introduced this term based on the observation that a previous infection with 
cowpox, which elicits a mild illness in humans, could prevent disease upon exposure to 
smallpox [5]. This first milestone in the era of vaccine development was followed by Louis 
Pasteur’s discovery of attenuation. During his summer holiday in 1881, a culture of bacteria 
provoking chicken cholera was left on the bench. At his return in autumn, he used this culture 
to inoculate chickens and noticed no disease could be monitored. To his surprise however, a 
second inoculation with a fresh, pathogenic culture did not provoke disease either, hence 
leading to the concept of attenuation of a pathogen to induce immunity to a subsequent 
challenge with the original pathogen [6]. Ever since, multiple strategies for attenuation or 
complete inactivation of pathogens have been applied for the development of successful 
vaccines rendering several diseases vaccine-preventable (e.g. poliomyelitis, mumps, 
rubella,M) [6]. Nevertheless, many infectious diseases still exist for which development of an 
effective vaccine remains elusive based on these classical approaches (e.g. HIV, malaria, 
tuberculosis,M). In addition, continuously increasing safety demands for novel vaccine 
formulations encourage the search for more rational vaccine designs. As a result, a wide 
range of vaccines currently under development are based on isolated peptides, proteins or 
polysaccharides of pathogens, or naked DNA encoding a protective antigen. Whilst these 
can be safer and more immunologically defined compared to existing classical vaccines, they 
are often poor immunogens, and therefore require additional immunostimulation to induce 
protective immune responses [7]. The use of adjuvants however needs to be tightly 
controlled as there is a risk for serious adverse reactions, such as a systemic inflammatory 
response or the induction of autoimmunity [8]. As a consequence, finding safe, yet efficient 
ways to boost immunity has become an increasingly important area of research in current-
day vaccinology.  
The ultimate goal of a vaccine is to induce an antigen-specific memory immune response. To 
facilitate this, an interaction between antigen-loaded antigen-presenting cells (APCs) and 
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naïve lymphocytes needs to take place in secondary lymphoid tissues [2]. Therefore, one 
way to improve the efficiency of a vaccine is to improve the efficiency of the uptake of 
antigen by APCs [9]. As such, targeting antigen to uptake receptors expressed on the 
surface of APCs is increasingly studied. As the dogma establishes that dendritic cells (DCs) 
are the most efficient APCs stimulating naïve lymphocytes, most targeting studies have been 
focused on DCs and their different subtypes. However, recently also sialoadhesin-expressing 
(Sn+) macrophages are gaining increased attention as targets for vaccination strategies as 
their location in spleen and lymph nodes appears to be ideal for antigen capture and 
presentation [10]. These macrophages and more precisely the immune stimulatory effect of 
directly targeting antigens towards them, is the major subject of this dissertation.  
In this first part of the thesis, an overview will be given of the lessons learned from APC 
targeting studies for vaccination purposes up till now. Furthermore, a thorough introduction 
will be given on Sn (CD169, Siglec-1) and Sn+ macrophages to demonstrate the targeting 
potential of this cell type. Finally, targeting molecules to mediate antigen targeting will be 
summarized and compared. 
  
1.1.2 STATE-OF-THE-ART  
Three types of professional APCs exist: macrophages, B cells and DCs [2]. As DCs are 
generally considered to be the most potent APCs, most targeting studies performed aimed at 
targeting DCs. However, many receptors evaluated as candidates for targeting antigen to 
DCs are not DC-specific and can target macrophages and/or B cells as well. Below, each cell 
subset will be briefly introduced and an overview will be given of studies performed and 
lessons learned.   
 
Targeting dendritic cells 
A major contributor to the field of DC targeting has been Ralph Steinman, who has been 
fascinated by this cell type ever since he discovered it up until he passed away in 2011, just 
two and one-half days before receiving the Nobel Prize for Physiology or Medicine. An 
inspiring review of his own hand written just before he died describes some crucial steps 
from the discovery of DCs up till where we are now and challenges that remain for the future 
[11]. For DC targeting, his main focus has been on the C-type lectin endocytic receptor DEC-
205. As the natural ligands for DEC-205 were still unknown, it was decided early on to use 
antibodies as surrogate ligands [11]. The heavy chain of the anti-DEC-205 monoclonal 
antibody (mAb) was engineered to express different antigens. In this way, the consequences 
of targeting antigens to DCs could be studied in vivo without having to isolate the DCs or 
generate them from precursors. The first antigen that was engineered into an anti-DEC-205
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mAb was a peptide from hen egg lysozyme (HEL) that dominates the CD4+ T cell response 
of H-2k mice [12]. The injected antibody targeted to the DCs in the T cell area, but instead of 
an enhanced immune response to HEL, mice became specifically tolerant to HEL [12]. This 
led to the speculation that DCs perform tolerogenic functions under steady-state conditions 
and that inflammatory stimuli or adjuvants are required to enhance the induction of antigen-
specific immune responses. When such adjuvants were administered, DCs matured, 
expressed costimulatory molecules and the antigen dose required for an effective immune 
response could be greatly reduced by targeting the antigen specifically to DCs via DEC-205 
[13, 14]. Later on, Dudziak et al. elegantly showed that differential DC subsets in vivo 
process antigen in different ways, by targeting ovalbumin (OVA) either to CD8α+ DCs by a 
DEC-205-specific antibody or CD8α- DCs by a DCIR2-specific antibody [15]. CD8α+ DCs 
preferentially induced CD8+ T cell immunity, while CD8α- DCs preferentially induced CD4+ T 
cell immunity. At present, it is clear that DCs are not a homogenous population of cells, but 
represent a complex group of subsets that differ in ontogeny and specialized functions  
(Fig. 1) [16].  
 
Figure 1. The complex group of DC subsets in mice 
Plasmacytoid DCs provide an innate barrier against viral pathogens by the efficient production of type 
I interferon. Conventional DCs, which include both the lymphoid tissue-resident DCs and migratory 
DCs, drive the adaptive immune response. In the mouse spleen, the lymphoid tissue-resident DCs are 
divided into those that express CD8α (CD8
+
), CD4 (CD4
+
), or those that express neither CD4 or 
CD8α, the double negative (DN) DC subset. The lymph nodes also contain migratory DCs, which can 
be further segregated into at least three subsets: the CD103
+
 DCs, CD11b
+
 (dermal) DCs, and 
Langerhans cells. There is functional specialization between the DC subsets, where the CD103
+
 DCs 
and CD8
+
 DCs are most proficient at cross-presentation and activation of CD8
+ 
T cells. By contrast, 
splenic DN and CD4
+
 DCs and CD11b
+
 DCs and Langerhans cells are more efficient at driving CD4
+
 T 
cell responses. Nevertheless, under certain conditions CD4
+
 DCs, DN DCs and Langerhans cells have 
been shown to cross-present antigen [17, 18]. Figure adapted from Caminschi et al. [16]. 
 
The understanding that different DC subsets differ in their functional specialization has led to 
a search for subset-specific uptake receptors to enable fine-tuning of the immune response 
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generated [8]. This is of particular interest for the development of vaccines against 
intracellular pathogens for which it is believed that a strong cellular immune response is 
necessary to eliminate the cells that are infected with the causative agent, as most current 
preventative vaccines are designed to initiate protective humoral immune responses [19]. 
Prominent examples of such diseases are HIV-induced acquired immune deficiency 
syndrome, virus-induced hepatitis C or Mycobacterium-induced tuberculosis [20]. Also for 
therapeutic vaccines to treat cancer, the induction of a strong cellular antitumor immune 
response is required [16].  
For a long time it has been difficult to relate mouse DC subsets to human DC subsets due to 
difficulties of isolating large quantities of DCs from human tissue [21]. At present however, 
human BDCA3+ DCs are the proposed equivalent of the murine CD8α+ DCs, human dermal 
CD1a+ DCs of murine dermal CD103+ DCs, human BDCA1+ DCs of murine CD8α- DCs, 
while Langerhans cells and plasmacytoid DCs are equally present in both species [8]. 
Although DC subsets in human and mouse can be equivalent in function, they do not 
necessarily express identical uptake receptors, which can hamper translation from animal 
models towards clinical outcomes. An overview of uptake receptors identified on human and 
mouse DC subsets is given in Table 1. 
 
Table 1: Uptake receptors identified on human and mouse DC subsets  
DC subset Uptake receptor 
BDCA3+ H 
CD8α+ M 
Clec9A, LangerinM, DEC-205, Clec12A, DCAR1M 
Langerhans Langerin, DEC-205, Dectin-1, Dectin-2, DCIRH 
Dermal CD1a+ H 
Dermal CD103+ M 
Langerin, DEC-205, MGLH, DCIRH 
BDCA1+ H 
CD8α- M  
DCIR2M, Clec12A, DCIRH, Dectin-1H, DEC-205H, mMGL1M, mMGL2M 
Monocyte-derived DCH• DC-SIGN, DEC-205, MR, DCIR, Clec12A 
Plasmacytoid DC Siglec-H, BST-2, BDCA-2H, Clec9AM, Clec12A, Dectin-2, DEC-205H, 
DCIRH, Dectin-1M, mMGL1M 
M, mouse; H, human.  
• In vivo inflammatory-type DCs 
Table adapted from Kreutz et al. [8].  
 
As seen in Table 1, most uptake receptors are not specific for one DC subset. In addition, 
many of these receptors are also expressed on other cell types apart from DCs (Table 2). 
Therefore, it has not been possible up till now to deliver an antigen specifically to one DC 
subset [16]. Ubiquitous expression of a receptor is of importance, as it can reduce its 
targeting efficiency, which can result in less efficient stimulation of the envisaged immune 
response. Apart from not specifically targeting the DC subset that would most efficiently 
guide the immune response in the desired direction, expression by other cell types not 
involved in antigen presentation can clear the antigen from the system, thus reducing 
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vaccine efficiency. An overview of the expression of ‘DC-specific’ uptake receptors used for 
targeting applications is given in Table 2. 
 
Table 2: Expression pattern in mice and men of DC uptake receptors   
Receptor Synonyms Expression in men Expression in mice Reference 
DEC205 CD205; LY75; 
CLEC13B 
BDCA1+ DCs; monocytes; B 
cells; low levels on NK cells; 
pDCs and T cells 
Cortical thymic epithelium;  
CD11c+CD8+ thymic 
medullary/splenic/lymph node 
DCs, dermal/interstitial DCs and 
Langerhans cells 
[22-25] 
Mannose 
Receptor 
CD206; 
MRC1; 
CLEC13D 
Tissue macrophages and a 
subpopulation of DCs; lymphatic 
and hepatic epithelium; kidney 
mesangial cells 
Tissue macrophages and a 
subpopulation of DCs; lymphatic 
and hepatic epithelium; kidney 
mesangial cells 
[25-29] 
DC-SIGN CD209; 
CLEC4L 
DCs; specific macrophage 
subsets 
- [25, 30, 31] 
hMGL  CD301; 
CLEC10A; 
CLECSF14 
Immature DCs; macrophages - [25, 32] 
mMGL1 CLEC10A; 
CD301a 
- Macrophages; interstitial DCs; 
pDCs 
[25, 32-34] 
mMGL2 CD301b - Macrophages; DCs in dermis, 
small intestines and lymph 
nodes 
[25, 32-34] 
Langerin CD207; 
CLEC4K 
Langerhans cells Langerhans cells, CD103+ DCs 
and CD8α+ DCs 
[25, 35-38] 
hDCIR   LLIR; 
CLEC4A;  
CLECSF6 
Blood myeloid DCs; dermal 
DCs; pDCs; monocytes; 
macrophages; B cells; 
neutrophils; granulocytes  
- [39, 40] 
mDCIR2 CLEC4A2 - CD8α- splenic DCs [15] 
CLEC9A DNGR-1 BDCA3+ DCs CD8α+ DCs; pDCs; pulmonary 
CD103+ DCs  
[25, 41-44] 
Dectin-1 CLEC7A; 
CLECSF12;  
β-glucan 
receptor 
DCs; monocytes; macrophages; 
neutrophils; B cells; eosinophils; 
T cell subsets 
Monocytes; macrophages; DCs; 
neutrophils; T cell subsets 
[45, 46] 
Dectin-2 CLECSF10; 
CLEC6A; 
CLEC4N 
DCs; monocytes DCs; neutrophils; macrophages  [47, 48] 
CLEC12A CLL1; KLR1; 
MICL; DCAL2 
Monocytes; granulocytes; DCs; 
NK cells* 
DCs; macrophages; B cells [49, 50] 
DCAR1 CLEC4B2 - CD8α+ DCs; CD11b+ myeloid 
cells in bone marrow and spleen 
[47, 51] 
Siglec-H - - pDCs; low levels on 
macrophages 
[52] 
BST-2 CD317; 
PDCA-1; 
tetherin; 
HM1.24 
Monocytes; conventional DCs pDCs; low levels on 
conventional DCs, 
macrophages, B cells and T 
cells 
[53] 
BDCA-2 CD303; 
CLEC4C; 
CLECSF7; 
HECL; DLEC; 
CLECSF1; 
CLECSF11 
pDCs - [47, 54, 55] 
CD11c CR4; Itgax DCs; monocytes; macrophages; 
polymorphonuclear leukocytes 
DCs; monocytes; macrophages; 
polymorphonuclear leukocytes 
[9, 56, 57] 
* Conflicting data on expression on NK cells [50] 
h, human; m, mouse; pDCs, plasmacytoid dendritic cells 
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When aiming at specific immune responses, not only the choice of DC subset is taken into 
consideration, but also the type of adjuvant used in the vaccine formulation. Indeed, different 
types of adjuvants have been shown to skew the type of immune response generated (e.g. 
Th2 versus Th17) [16, 58]. From the DC targeting studies performed to date, it appears to be 
a general rule that in order to induce substantial cell-mediated immunity, the addition of 
adjuvants to mature the targeted DCs is required and can affect the type of immune 
response generated [16]. The induction of humoral immunity on the other hand can 
sometimes be obtained without the use of adjuvants [59]. A prominent example hereof is the 
targeted delivery of antigens to Clec9A [41, 60]. One proposed explanation for this 
phenomenon is that the restricted expression pattern of Clec9A prevents the clearance of 
antibody-antigen complexes by irrelevant cells, which then leads to a sustained antigen 
presentation that promotes the generation of follicular helper T cells driving B cell germinal 
centre development [59]. Also, the observation that Clec9A targeting can induce robust 
humoral immune responses, even without the addition of adjuvant, shows that the nature of 
the DC-surface molecule targeted can sometimes override DC subset specific antigen 
presentation biases, as Clec9A is present on CD8α+ DCs, which are supposed to primarily 
induce antigen cross-presentation and thus predominantly cell-mediated immunity [16]. 
Although the general rule for current DC-targeting studies appears to be to target particular 
DC subsets as specific as possible, also ‘more general’ APC receptors were evaluated for 
their potential as targeting receptor. These include MHC molecules [61-65], Toll-like 
receptors (TLRs) [66, 67], Fc receptors [68-70] and costimulatory molecules [71-73]. In the 
case of TLRs and costimulatory molecules, the targeting moieties can perform a dual role: 
targeting to APCs on the one hand and inducing an immune stimulatory (adjuvant) function 
on the other hand by influencing the maturation state of the DC. TLR and costimulatory 
molecule ligands are also often applied in studies merely for their adjuvant function and thus 
separated from the antigen and its targeting moiety (Table 3). To date, it is still a matter of 
debate whether it is best to physically link the antigen with the adjuvant to ensure co-delivery 
to the same cell or whether the adjuvant should be supplied by mere co-administration [8]. A 
recent study employing nanoparticles to deliver antigen and adjuvant showed better humoral 
immune responses upon injection of both agents in separate particles than when combined 
in a single particle [74]. Nevertheless, many studies aiming to induce cellular responses 
show that physically linking the antigen and adjuvant improves T cell responses [8].  One 
proposed explanation for this phenomenon is that antigens are better processed and 
presented due to co-localization of both antigen and stimulus in the same phagosome [75]. 
At the same time, this approach ensures activation of the cells that have seen the antigen, 
which is important for efficient T cell priming by DCs [2]. 
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Another point of attention is the endocytic capacity of the targeted receptor. A recent study 
by Chatterjee et al. targeted identical antigens to either CD40, the mannose receptor (MR) or 
DEC-205 by the use of respective mAbs [76]. They evaluated the amount of antigen 
presentation via MHCI or cross-presentation and found an inverse relationship between 
internalization or antigen degradation and cross-presentation. Antigens destined for more 
degradative late endosomes were poorly cross-presented relative to the same antigens 
targeted to early endosomes, an effect that was independent of the amount of antigen 
internalized. In addition, also the targeting mAb itself can affect the immunological outcome. 
In the absence of adjuvant one anti-Clec9A mAb induced follicular helper T cells [60], 
whereas another induced regulatory T cells (Tregs) [77]. This observation could be due to 
the different genetic background of the mouse species used (BALB/c versus C57/BL6 
respectively). Lahoud et al. suggest that a rat IgG1 mAb lacks appropriate epitopes for a 
direct response in C57/BL6 mice, while it contains the appropriate epitopes for a direct 
response in BALB/c mice, which was supported by unpublished experiments of their 
research group [60]. Furthermore, they suggest differences in antibody affinity, signal 
transduction upon receptor engagement or serum persistence of the antibody can contribute 
to the differences in immune outcome described. 
Taken together, it is clear that multiple factors can have an impact on the immune outcome 
of a DC-targeted vaccine formulation. Whether antigen targeting to DC results in the 
induction of a strong (humoral and/or cellular) immune response depends on an interplay 
between the DC subset targeted, the nature of the targeting receptor and its expression 
pattern, the targeting moiety, the antigen dose and co-administered adjuvants. In addition, 
also the route of immunization can have an impact on the efficiency of antigen encounter by 
the DCs and the subsequent immune response [78]. How these theoretical concerns turn out 
in vivo often have to be determined empirically [79]. In addition, although promising results in 
mouse models have been obtained, the translation of animal-derived experimental data into 
regimes applicable to human vaccination remains challenging [79]. An overview of DC 
targeting approaches studied for vaccine design is given in Table 3.     
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Table 3: Overview of APC vaccine targeting approaches showing representative in vivo targeting 
studies grouped by cell type, species and targeting receptor.  
Species Receptor Delivery 
system 
Antigen 
targeted 
Adjuvant
1
 Type of 
response
2
 
Route
3
 REF 
APC targeting 
Mouse TLR2 Pam2cys OVA, L. 
monocyto-
genes 
antigen, 
Inluenza 
antigen 
Pam2cys* Ab, CTL, 
IFNγ, 
antitumor 
activity 
s.c., i.v., 
i.n. 
[66] 
 MHCII M1 modified 
super-
antigen 
OVA α-GalCer CD4, CD8, 
CTL, IFNγ, 
antitumor 
activity 
i.v. [65] 
 CD40 CD40 
Ligand-
bearing 
adenovirus 
Melanoma 
peptides 
CD40 Ligand* IFNγ, 
antitumor 
activity 
i.d. [73] 
 FcγRI scFv Pneumo-
coccal 
surface 
protein A 
- Ab, IFNγ, 
protection 
from lethal 
challenge 
i.n. [70]• 
DC targeting 
Mouse DEC-205 Ab OVA, HIV-1 
gag p24, HEL 
peptide, 
CSP, 
HER2/neu 
antigen 
 
OVA 
αCD40 Ab, 
MALP-2, 
PAM3Cys, 
polyl:C, 
polylCLC, 
LPS, R848, 
CpG 
CpG* 
CD4, CD8, 
CTL, IFNγ, 
Ab, 
antitumor 
activity 
 
 
CTL, IFNγ, 
antitumor 
activity 
s.c., i.v., 
i.p. 
 
 
 
 
 
s.c./i.d. 
[12-15, 
80, 81] 
 
 
 
 
 
[82] 
  Ab-
conjugated 
MP 
Ab-
conjugated 
PLGA NP 
OVA 
 
 
OVA 
Particle 
composition* 
 
Polyl:C*, 
R848* 
CTL, IFNγ 
 
 
CD8, CTL, 
IFNγ 
s.c. 
 
 
i.v. 
[83] 
 
 
[84] 
  scFv-
conjugated 
liposome 
OVA IFN-γ* or 
LPS* 
CTL, 
antitumor 
activity 
i.v. [85] 
 CD11c scFv-
conjugated 
liposome 
OVA IFN-γ* or 
LPS* 
CTL, 
antitumor 
activity 
i.v. [85] 
 DCIR2 Ab OVA αCD40 Ab CD4 i.p., i.v. [15] 
 MR Ab OVA CpG Ab, CD4, 
CD8, CTL, 
antitumor 
activity 
s.c., i.p. [86]• 
  Mannose-
conjugated 
liposome 
ErbB2 
peptide 
epitopes 
PAM3CAG*, 
PAM2CAG*, 
PAM2CGD* 
IFNγ, 
antitumor 
activity 
s.c. [87] 
 Langerin Ab HIV gag p24 Polyl:C, 
PolylCLC, 
αCD40 Ab 
IFNγ, CD8 i.p. [88] 
 DC-SIGN Ab KLH -  T cell 
proliferation, 
antitumor 
activity 
s.c.  [89]•• 
 DC-SIGN scFv Tetanus 
toxoid 
peptides 
- T cell 
proliferation 
s.c. [89]•• 
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Species Receptor Delivery 
system 
Antigen 
targeted 
Adjuvant
1
 Type of 
response
2
 
Route
3
 REF 
 Dectin-1 Ab OVA Polyl:C CD4 s.c., i.v. [78] 
 CD103 Ab OVA LPS, αCD40 
Ab, Polyl:C  
CD4, CD8, 
IFNγ, CTL, 
Ab  
i.p. [90] 
   OVA - Tolerance i.t. [90] 
 Clec9A Ab OVA, HIV 
gag p24, 
melanocyte 
differentiation 
antigen 
peptides 
Polyl:C, 
PolylCLC, 
αCD40 Ab, 
Curdlan 
CD4, IFNγ, 
Ab, CD8, 
antitumor 
activity 
i.v., 
s.c./i.d., 
i.p. 
[77, 88, 
91] 
 Clec12A Ab OVA LPS, CpG, 
Polyl:C, 
αCD40 Ab 
Ab, CD4, 
CD8, minor 
CTL 
i.v. [50] 
 MGL Tn antigen Tn antigen CpG, alum, 
αCD40 Ab 
Ab i.d., s.c. [92] 
 BST-2 Ab OVA, HEL 
peptide 
CpG, Polyl:C CD4, CD8, 
Ab, IFNγ, 
CTL, 
antitumor 
activity 
i.p. [93] 
 DCAR1 Ab OVA αCD40 Ab Ab, CD4, 
CD8 
i.v. [51] 
 LOX-1 Ab OVA IFA Antitumor 
activity 
s.c. [94] 
 CD36 scFv OVA αCD40 Ab CD4, CD8, 
Ab, IFNγ, 
CTL, 
antitumor 
activity 
s.c./i.d. [95] 
Human MR Ab hCG-β R848,  
PolyICLC, 
GM-CSF 
Ab, IFNγ, 
minor 
beneficial 
clinical 
outcome 
i.d., i.v. [96] 
B cell targeting 
Mouse B cell 
receptor 
D domain of 
protein A 
OVA, 
Influenza 
antigen 
QuilA and A1 
subunit of 
cholera toxin-
containing 
ISCOM* 
T cell 
proliferation, 
IFNγ, Ab  
i.n. [97] 
 CD19 Ab OVA, MUC1 
peptide 
CpG CD4, CD8, 
IFNγ, Ab, 
antitumor 
activity 
i.v. [98] 
  Diabody Idiotype - Ab, IFNγ, 
antitumor 
activity 
i.d. [99] 
Macrophage targeting 
Mouse Sn Ab OVA αCD40 Ab CD8, IFNγ, 
CTL, 
antitumor 
activity 
i.v. [100] 
  Ab OVA - CD8 s.c./i.d. [101] 
  Glycan-
coated 
liposome 
α-GalCer - iNKT 
activation 
i.v. [102] 
Pig Sn Ab HSA - Ab i.m., i.v. [103] 
  Ab Ab - Ab, T cell 
proliferation 
s.c. [104] 
 CD163 Ab Ab - Ab, T cell 
proliferation 
s.c. [104] 
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Ab, antibody; -, none; scFv, single chain fragment variable; REF, reference; CSP, circumsporozoite protein Plasmodium 
yoelii; MP, microparticle; NP, nanoparticle; PLGA, poly(lactic-co-glycolic acid); ISCOM, immune stimulating complex 
1 Adjuvants followed by * were physically linked to the antigen 
2 CD4, CD4 T cell proliferation; CD8, CD8 T cell proliferation; CTL, cytotoxic T cell mediated killing; IFNγ, T cell IFNγ 
production; Ab, antibody induction 
3 i.m., intramuscular; i.n., intranasal; i.p., intraperitoneal; i.v., intravenous; s.c., subcutaneous; i.d., intradermal; i.t., 
intratracheal 
• human receptor transgenic mice 
•• human immune cell engrafted mice 
 
Targeting B cells 
B cells are conventionally considered to be antibody-secreting cells and are, just like 
macrophages, much less appreciated for their APC capacity than DCs. However, B cells can 
serve as professional APCs to prime both CD4+ and CD8+ T cells and were also shown to be 
able to induce T cell tolerance [105-109]. Also, noncognate B cells can carry antigen in the 
follicles towards follicular DCs, which can present the antigen for days to weeks to allow 
encounter of the antigen by cognate B cells [110]. In the lymph nodes, these noncognate B 
cells can either directly retrieve antigen that arrives through specialised channels (conduits) 
or through gaps in de subcapsular sinus (SCS; low molecular weight antigens) or they can 
retrieve antigen from SCS macrophages displaying the antigen on their surface [111, 112]. 
Recently, Ng et al. reasoned that a low molecular weight molecule targeting B cells that 
carries an antigen should be able to reach the follicle B cells by passing through the special 
conduits and generate potent immune responses [99]. Indeed, using such low molecular 
weight molecule (diabody) targeting CD19 on B cells, an antibody response was evoked 
against a tumour antigen which was absent when the tumour antigen was coupled to a non-
targeting molecule and partial protection was observed in a subsequent tumour protection 
model. Nevertheless, in a study by Ding et al., similar results could be obtained using a 
conventional B cell targeting αCD19 antibody coupled to a tumour antigen [98]. Lastly, 
Helgeby et al. made use of the affinity of protein A for immunoglobulins to target their antigen 
towards the B cell receptor [97]. Via intranasal immunization they were able to prime T cells 
and induce antigen-specific antibody responses at both mucosal and systemic sites. These 
few studies performed are also listed in Table 3. 
 
Targeting macrophages 
Elie Metchnikoff, who received the Nobel Prize in Medicine in 1908, was the first person to 
use the term “macrophage” to describe large mononuclear phagocytic cells he observed in 
tissues [113, 114]. The term is derived from the Greek words “macros”, meaning large, and 
“phagein”, to eat, and refers to the observation that these cells are able to take up and digest 
harmful bodies such as pathogens, much alike the process of digestion in micro-organisms. 
Since their discovery, macrophages have been found in every organ and in different tissues 
of the human body where they show functional specialization which varies with the organ or 
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tissues [115, 116]. These functions include immune surveillance, repair and remodelling, as 
shown in Figure 2.   
 
Figure 2. Tissue macrophages show functional specialization based on their anatomical 
location  
Specialized tissue-resident macrophages include osteoclasts (bone), alveolar macrophages (lung), 
histiocytes (interstitial connective tissue) and Kupffer cells (liver). The gut is populated with multiple 
types of macrophages and DCs, which work together to maintain tolerance to the gut flora and food. 
Secondary lymphoid organs also have distinct populations of macrophages that perform unique 
functions, including subcapsular sinus macrophages of lymph nodes (LNs), which clear viruses from 
the lymph and initiate antiviral humoral immune responses. Distinct macrophage subpopulations also 
patrol so-called immune-privileged sites – such as the brain (microglia), eye and testes – where they 
are assumed to have central functions in tissue remodelling and homeostasis. These tissue-specific 
macrophage subpopulations ingest foreign materials and recruit additional monocytes from the 
circulation to differentiate into macrophages during an infection or following injury. Figure adapted 
from Murray and Wynn [116]. 
 
Besides performing functions during steady-state conditions, macrophages can also become 
activated and adopt context-dependent phenotypes [115, 116]. These ‘inflammatory 
macrophages’ can either be locally activated resident tissue macrophages or monocytes 
recruited from the blood to differentiate into mature macrophages in the tissues. As such, 
several macrophage subsets with distinct functions have been described. Classically 
activated macrophages (M1 macrophages) mediate defence of the host from a variety of 
bacteria, protozoa and viruses, and have roles in antitumor immunity [116, 117]. Alternatively 
activated macrophages (M2 macrophages) have anti-inflammatory function and regulate 
wound healing. ‘Regulatory’ macrophages can secrete large amounts of interleukin-10 (IL-
10) in response to FcγR ligation [118]. Tumor-associated macrophages (TAMs) suppress 
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antitumor immunity, and myeloid-derived suppressor cells (MDSCs) are linked to TAMs and 
may be their precursors [119]. Thus, when stimulated, macrophages adopt context-
dependent phenotypes that either promote or inhibit host antimicrobial defence, antitumor 
immunity and inflammatory responses. It is generally believed that macrophages represent a 
spectrum of activated phenotypes rather than discrete stable subpopulations [116, 119]. 
Indeed, numerous studies have documented flexibility in their functional programming, with 
macrophages switching from one functional phenotype to another in response to the variable 
signals of the local micro-environment [120-122].  
Macrophages are sometimes described as a classical double-edged sword [116, 117]. Their 
actions on the one hand help to integrate many physiological functions, yet on the other hand 
also result in their contribution to many pathological processes. Macrophages have been 
implicated in the onset and/or progression of various pathogenic conditions, either through 
normal pro-inflammatory or pro-angiogenic activities or through defects in their activity [123]. 
Under- or overactivity of macrophage clearance, immune effector functions and responses to 
metabolic abnormalities contribute to common disorders such as autoimmunity, rheumatoid 
arthritis, chronic granulomatous disease, atherosclerosis, diabetes, systemic lupus 
erythrematosis, Wiskott-Aldrich syndrome, Alzheimer’s disease and the growth and spread of 
malignant tumours [114, 116, 117, 124]. In addition, certain pathogens can parasitize these 
cells and may replicate within them, using these macrophages as a safe haven and a 
reservoir [125-127]. As such, macrophages have attracted attention for their potential as 
therapeutic target, to either eliminate, activate of immunomodulate them. Examples of 
macrophage surface receptors under study for targeted therapy are the folate receptor [128], 
CD163 [129] and also Sn [130].  
As macrophages were not as much appreciated for their antigen-presenting cell capacity, 
few studies have been performed to date to specifically target antigens towards them as a 
vaccination strategy. One study investigates Ag targeting to CD163 in pigs [104] and as the 
MR was first described to be a macrophage-restricted receptor [131], some early studies 
might fit better in the Chapter targeting macrophages than DCs. Other receptor targeting 
strategies that will reach macrophages as well include the more general APC receptors 
under study for vaccination strategies (Table 3), which obviously also target macrophages. In 
addition, it should be mentioned that many receptors studied to specifically target DCs are 
also expressed on macrophages. This observation is perhaps not so surprising, as 
macrophages and myeloid DCs both arise from common myeloid precursors and are thus 
likely to express common cell surface markers [116]. The most prominent example might well 
be CD11c, a marker widely used to specifically isolate DCs, which appears to be expressed 
by almost all macrophages as well. At present, it has even been argued that it might be
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impossible to distinguish macrophages and DCs from each other and that it might be better 
to speak of a mononuclear phagocyte system that comprises both cell types and their 
different subsets that complement each other in function [132]. Indeed, recent evidence 
indicates that certain cells defined as macrophages can migrate, some macrophages are 
only weakly phagocytic and TIP-DCs (tumour-necrosis factor/inducible nitric oxide synthase-
producing DCs) might rather be inflammatory macrophages than DCs [116, 133]. Be this as it 
may, it is nonetheless clear that many markers studied to specifically target antigens towards 
DCs are also expressed by cell subsets defined as macrophages and consequently evoked 
immune responses are often hard to establish as purely DC (and DC-subset)-mediated. 
Only recently, Sn+ macrophages have received attention for vaccination strategies as well. In 
spleen and lymph nodes, these macrophages are situated at the border of circulating fluids 
and thus appear to be ideally positioned for antigen capture and processing [134]. Studies 
targeting Sn have been performed and they will be discussed in more detail in the next 
Chapter on Sn and Sn+ macrophages.  
 
1.1.3 SIALOADHESIN AND SIALOADHESIN-EXPRESSING MACROPHAGES 
 
Sialoadhesion: a member of the sialic acid-binding immunoglobulin-type lectin 
(Siglec) family 
Sialoadhesin (Sn; also referred to as CD169 or Siglec-1) belongs to the family of sialic acid-
binding immunoglobulin-like lectins or Siglecs [135, 136]. This family name reflects their 
binding specificity for carbohydrates containing sialic acids and the presence of 
immunoglobulin (Ig)-like domains in their protein structure. Siglecs therefore represent a 
subgroup of Ig-type or I-type lectins belonging to the Ig superfamily, one of the largest protein 
families in the vertebrate proteome.  
Siglecs are type 1 transmembrane proteins comprising a sialic acid-binding N-terminal 
variable (V) Ig-like domain followed by a variable number of constant (C) Ig-like domains, a 
transmembrane region and a cytosolic tail (Fig. 3) [137]. A conserved arginine residue in the 
V domain is essential for the sialic acid binding capacity of all Siglecs. Based on sequence 
similarities and evolutionary conservation, two primary subsets of Siglecs have been 
identified: the first includes Sn, Siglec-2 (CD22), Siglec-4 (myelin-associated glycoprotein or 
MAG) and Siglec-15, which are quite distantly related (~25–30% sequence identity) but have 
orthologues in all mammalian species studied and are therefore referred to as well-
conserved [52, 137]. The second, rapidly evolving, subset is designated the CD33-related 
Siglecs, which share ~50-99% sequence identity, yet very poor species homology, thereby 
impeding the assignment of orthologues [138]. As a consequence, a different numbering 
Chapter 1 | Sn and Sn
+
 macrophages 
 
 15 
system is used for the human and mouse CD33-related Siglecs. An overview of the structure 
and nomenclature of the Siglec family is given in Figure 3. 
 
Figure 3. Nomenclature and structure of Siglecs in humans and mice 
Siglecs are single-pass transmembrane proteins that comprise a single sialic acid-binding N-terminal 
V-set domain, variable numbers of C2-set domains, a transmembrane region and a cytosolic tail. The 
evolutionary conserved Siglec subgroup is shown on the left; the rapidly evolving CD33-related 
subgroup is depicted on the right (human CD33-related Siglecs on the top, murine on the bottom). 
Siglec-12 (now renamed Siglec-XII) is not depicted, as it has lost its lectin activity in humans. C, 
constant; Grb2, growth factor receptor-bound protein 2; Ig, immunoglobulin; ITIM, immunoreceptor 
tyrosine-based inhibitory motif; MAG, myelin-associated glycoprotein; N, amino; V, variable. Figure 
adapted from Jandus et al. [139]. 
 
Since their classification in 1998, Siglecs have emerged as a novel family of regulatory 
receptors expressed in a cell-type specific manner, predominantly on immune and 
haematopoietic cells [52, 135, 139]. With the exception of resting T cells, virtually all cell 
types in the human and mouse immune system express at least one Siglec family member, 
with some cells expressing multiple CD33-related Siglecs [139]. The Siglec expression 
pattern of a given haematopoietic cell can also change during differentiation, with acquisition 
of specific Siglecs at later developmental stages [140, 141]. In addition, the surface 
expression and function of several Siglec members have also been shown to be influenced 
by cytokines, TLR activation, viral and bacterial infections, inflammatory and autoimmune 
diseases and cancer [139]. Many Siglecs undergo endocytosis upon ligand binding, and 
most Siglecs have also been shown to contain cytoplasmic tyrosine motifs, commonly found 
in receptors involved in regulation of cell signalling (Fig. 3) [137]. Many Siglecs contain ITIM 
(immunoreceptor tyrosine-based inhibitory motif) and ITIM-like motifs in their cytoplasmic 
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tails and can function as inhibitory receptors by dampening tyrosine kinase-driven signaling 
pathways. Other Siglecs have no tyrosine motifs, but some contain a positively charged 
transmembrane spanning region which permits association with adapter proteins such as 
DNAX-activating protein 12 kDa (DAP-12), an ITAM (immunoreceptor tyrosine-based 
activation motif)-containing adaptor that can trigger both activating and inhibitory signalling 
[52, 137]. Taken together, while the functions of the Siglecs are still being elucidated, there is 
growing evidence that the majority are endocytic receptors that contribute to the regulation of 
cell signaling (inhibition or activation) in immune cells that mediate innate and adaptive 
immunity [142]. Furthermore, each Siglec has a unique preference for one or more distinct 
sialic-acid containing carbohydrates expressed on the same cell (cis) or on adjacent cells 
(trans) [52, 143], resulting in cell-specific, unique and non-redundant functions of each family 
member in defined immune cell types [139].  
 
Sialoadhesin structure 
Sn was the first protein to be described of the later defined Siglec family. In the mid-1980s, 
some macrophage types were found to form rosettes with sheep erythrocytes in vitro, which 
could be abolished by sialidase pretreatment of the erythrocytes [144]. This sialic acid-
dependent receptor was therefore first named sheep erythrocyte receptor (SER). Later on, 
the receptor was purified and shown to be a large protein of 185.000 MW and was renamed 
Sn [145]. As shown in Figure 3, Sn is the largest member of the Siglec family, displaying a 
total of 17 extracellular Ig-like domains, which can be subdivided into 16 C2-set domains and 
an N-terminal V-set domain [146]. It has been postulated that the extracellular region of Sn 
may function to extend the V-set domain away from the glycocalyx so as to enable 
interaction with ligands in a trans fashion [134, 147]. However, even with the 17 Ig-like 
domains, extension of Sn above the glycocalyx may not always be guaranteed, as Sn can 
interact with sialic-acid containing carbohydrates expressed on the same cell (cis). A 
comparison of Sn activity in rat splenic and lymph node (LN) macrophages has indicated that 
splenic macrophages are masked considerably by endogenous sialylglycoconjugates 
through cis-type interactions, which can be ablated by sialidase treatment, whereas LN 
macrophages are relatively unaffected by this masking [148]. In addition, the extracellular 
region of Sn itself contains several potential N-linked glycosylation sites and carries complex 
N-glycans, which can be sialylated [127, 146] and sialylation of Sn may affect binding of the 
receptor to its ligands [149]. Sialylation of Sn, and Siglecs in general, by specific 
glycosyltransferases, may be a common mechanism by which Sn- and Siglec-mediated 
adhesion is regulated.  
The V-set domain of Sn is necessary and sufficient for sialic acid binding and three 
conserved amino acid residues have been identified that are important for the sialic acid-
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binding activity: tryptophan 2, arginine 97 and tryptophan 106 [150-153]. Arginine 97 was 
shown to be crucially important for binding to sialic acid as it was demonstrated that even a 
conservative substitution of arginine with lysine resulted in a 10-fold loss in binding affinity 
[154]. Sn binds preferentially to 5-N acetylated-neuraminic acid (Neu5Ac), which is α(2,3)-
linked to preceding carbohydrates [146, 155]. Neu5Ac is the most abundant of the 
mammalian sialic acids, two other common sialic acids Neu5Gc and Neu5Ac9Ac are not 
recognized by Sn [156]. In common with many other lectins, the glycan binding site of Sn 
exhibits low millimolar binding affinities for naturally sialylated ligands [154]. It is thought that 
simultaneous multivalent low-affinity associations will create sufficient high avidity and lead to 
biologically meaningful interactions of Sn with sialic acids on cells or microbial particles, 
which is supported by in vitro data demonstrating increased binding capacity of Sn with 
increasing saccharide content [134, 157].  
Apart from its large extracellular domain, Sn also contains a transmembrane domain and a 
short cytoplasmic tail, which is poorly conserved between mammalian species and will be 
discussed later (see section: sialoadhesin as an endocytic receptor involved in signalling) 
[127, 158]. So far, no evidence has been found for the existence of soluble Sn variants in 
vivo. 
 
Sialoadhesin expression and regulation  
Sn is exclusively expressed on cell subsets of the monocyte/macrophage lineage [52, 156]. 
In addition, in man [158], mouse [159], rat [160] and pig [161] Sn is most abundantly 
expressed by macrophage subsets occupying secondary lymphoid tissue (Table 4).  
 
Table 4: Sn expression in secondary lymphoid tissues 
Tissue/Cell type Rat Human Mouse Pig 
Marginal metallophilic macrophage (MMM) + D.N.E. + N.D. 
Marginal zone macrophage (MZM) + - +/- + 
Periarteriolar lymphoid sheath (PALS) +/- - - N.D. 
Splenic perifolicular zone macrophage (PFZM) D.N.E. + D.N.E. D.N.E. 
Periarteriolar-associated macrophage (PAM) D.N.E. + D.N.E. +1 
Red pulp +/- +/- +/- - 
Lymph node subcapsular sinus + +² + + 
Lymph node medulla + +² + + 
Key: D.N.E., do not exist; N.D., not described; -, undetected; +/-, low expression; +, expression. 
1 Ellipsoidal vessels associated with Sn expression, possibly equivalent to PAM [161]. 
² Sinusoidal expression throughout LN [162]. 
Table adapted from O-Neill et al. [134]  
 
In all the species studied, macrophages lining the SCS as well as the medulla of the LNs 
highly express Sn [134]. In rodents, Sn+ macrophages expressing CD11c have been 
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observed within the B cell follicle and at the boundary between B and T cell areas (Fig. 4) 
[10]. In pigs, Sn expression has also been observed at the periphery of follicles and on some 
follicular cells [161]. It has been suggested these cells might correspond to activated Sn+ 
macrophages [10].  
A schematic of a LN showing the major zones and sinuses is given in Figure 4. Afferent 
lymphatics enter the LN tissue at the capsule at the periphery and open into the SCS [163], 
where just underneath a rim of Sn+ macrophages is present. Many of these macrophages 
have a ‘head’ that projects into the sinus and long ‘tail’ processes that extend into the 
underlying follicle, with the ‘neck’ tightly inserted across the lymphatic lining cell layer. Lymph 
then further travels through cortical and medullary sinuses directly or percolates through the 
diffuse tissue and medullary cords to reach the medullary sinuses. All lymph leaves the node 
through the centrally located efferent lymph vessels. This LN structure shown in Figure 4 is 
found in most mammals, but the pig, along with the rhinoceros, the dolphin and the elephant, 
has a specific LN structure that is called inverted [163, 164]. In these species, the tissue 
lacks a large central medullary area and is preferentially composed of B cell and T cell areas 
[164]. Parts of the diffuse tissue however are arranged into sinuses and cords in a manner 
similar to the medullary tissue in other species and a SCS is also present around the diffuse 
tissue [165]. Afferent lymphatics enter the LN centrally at the capsule at one or more sites 
and penetrate via the trabeculae deep into B cell and T cell areas [163]. Occasionally, 
branches may arise from the afferent lymphatics outside the LN and join with a SCS where B 
cell follicles are located peripherally [165]. Where the trabeculae end, their associated 
sinuses are continuous with many interstitial spaces, which allows lymph to penetrate into 
the diffuse tissue [165]. The lymph then filters into the peripheral sinuses, which converge 
and form several efferent vessels at the periphery of the node [163]. Consequently, the flow 
of the lymph in pigs is identical to that in LNs of other animals, first reaching the area of the 
node that is rich in B cell follicles and traversing through T cell and medullary areas before 
exiting the LN. Sn+ macrophages have been identified at the subcapsular and medullary 
sinuses in pigs [161] and thus appear, just like in the other species studied, readily 
positioned to sample incoming lymph for antigens.    
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Figure 4. Schematic of the lymph node structure found in most mammals   
Boxed regions are enlarged on the right to show more details. Upper box: subcapsular sinus and 
interfollicular region with B cell follicle shown in green shading, T cell zone in blue and interfollicular 
region in purple. Lower box: medullary region in cross-section showing medullary cords in light brown. 
Sinuses are shown in white and sinus-lining lymphatic endothelial cells are yellow. The macrophages 
are labelled subcapsular sinus macrophages (SSM), medullary sinus macrophages (MSM) and 
medullary cord macrophages (MCM) and their sialoadhesin (CD169), CD11b and F4/80 phenotype is 
summarized, although it is not yet established whether the physical segregation of cells with the 
indicated MSM and MCM marker patterns is as distinct as shown. A DC is shown in dark blue (upper) 
and a polymorphonuclear cell in brown (lower). Reticular fibers within medullary sinuses are in grey. B, 
B cell; T, T cell; PC, plasma cell. Figure adapted from Gray and Cyster [166]. 
 
Splenic distribution of Sn+ macrophages varies between species (Fig. 5) [134]. Marginal 
metallophilic macrophages (MMM), a population that lines the marginal sinus at the periphery 
of the white pulp in rodents, express high levels of Sn. In rats marginal zone macrophages 
(MZM) exhibit similar Sn levels to MMM, whereas in mice Sn expression on MZM is relatively 
lower. Both species demonstrate low levels of Sn expression in red pulp macrophages. With 
differing splenic architecture in primates, Sn+ macrophages are located in a compartment 
found between the red pulp and the marginal zone identified as the perifollicular zone [167]. 
In the absence of a marginal sinus and MMM in primate spleens, the macrophage sheaths 
that line capillaries of the perifollicular zone are speculated to be equivalent to the MMM 
found in rodents. In pigs, splenic Sn expression is observed in the marginal zone and 
elliptical vessels [161], which may be comparable to the periarterial macrophage sheaths 
observed in humans. Regardless of their equivalence, both the marginal zone and 
perifollicular zone environments do at least permit a close contact between Sn+ macrophages 
and the circulation and this could be relevant in the context of the physiological function of 
Sn.   
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Figure 5. Comparison of the distribution of Sn
+
 macrophages in the splenic microenvironment.    
A framework of reticular fibroblasts (blue) forms the basis of the marginal zone (MZ) and is continuous 
with the reticular fibroblasts in the red pulp and the sinus-lining cells (green) of the marginal sinus. In 
rodents, Sn
+
 macrophages are observed as a line of cells at the internal border of the white pulp (the 
so-called marginal metallophilic macrophages (MMM)). The white pulp is separated from the MZ by a 
marginal sinus, and in the case of the rat spleen, Sn
+
 macrophages are observed in the MZ. In 
humans, no marginal sinus is present and the MZ is devoid of Sn
+
 macrophages, but the unique 
structure known as the perifollicular zone contains Sn
+
 macrophages both sporadically and clustered 
around arteriolae (known as periarteriolar-associated macrophages (PAM)). MZM, marginal zone 
macrophage. Figure adapted from O-Neill et al. [134] 
 
In essence, the LN and the white pulp area of the spleen function as focal centres where 
microbial particles, antigen-presenting cells (which may carry antigen from the periphery or 
acquire antigen locally) and their corresponding antigen-specific lymphocytes engage and 
initiate adaptive immune responses [134]. In the spleen, Sn+ macrophages are present 
where blood enters the tissue, while in LN, Sn+ macrophages are present where lymph 
enters the tissue. This positioning at the borders of circulating fluids is consistent with the 
idea that these cells and their Sn have a role in antigen capture/processing and in cell-cell 
communication. These observations strongly suggest that Sn+ macrophages may function as 
mediators of adaptive immunity.  
Sn expression can also be found on macrophages residing in non-lymphoid tissues [134]. 
Both mice and humans express quite high levels of Sn on resident bone marrow 
macrophages, whereas in rats Sn is apparently absent from this population. Expression of 
Sn is also observed in the lungs of all species tested [158-160, 168], in the skin of mice 
[159], in the intestines of mice [159], rats [160] and humans [158], in the brain of mice [159] 
and humans [158], and in the placenta of the pig [169]. In the thymus, weak Sn expression 
was found in rats [160] and pigs [170]. In the liver, Sn expression is consistently found on 
Kupffer cells of all species examined. So far, no evidence exists that Sn is expressed on DCs 
in vivo under normal physiological conditions [156, 171]. Remarkably, a recent study by Gray 
et al. [172] described the acquisition of Sn by IL-17 committed IL7Rαhi CCR6+ T cells and 
natural killer (NK) cells and small numbers of CD11chi DCs through the acquisition of 
membrane blebs derived from SCS macrophages. However, the authors stated it cannot be 
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ruled out that this acquisition was due to tissue preparation. Taken together, under normal 
physiological conditions, Sn expression is highly regulated and restricted to certain 
subpopulations of tissue macrophages, whereas it is not found on their precursor cells, the 
monocytes, nor on DCs.  
Certain mediators present in secondary lymphoid tissues have been shown to be crucial for 
the Sn+ macrophage population [134]. Colony-stimulating factor 1 (CSF-1) is an important 
cytokine responsible for macrophage maturation and migration and interference with CSF-1 
signalling has been shown to rapidly deplete Sn+ macrophages in the spleen [173]. A 
naturally occurring CSF-1 knockout mouse, the op/op mouse, has no Sn+ macrophages in its 
lymphoid tissues [174]. Upon CSF-1 administration however, the Sn+ macrophage population 
can be restored [175]. Together, this strongly suggests a regulatory role of CSF-1 production 
on Sn+ macrophage populations. Lymphotoxin (LT) is another mediator shown to be crucial 
for the Sn+ macrophages. LT is responsible for generating and maintaining the architecture 
of secondary lymphoid organs as its knockout causes loss of structural organization in mice 
[176]. Deficiency of LT-α [177] and LT-β [178] secretion leads to absence of Sn+ 
macrophages in lymphoid organs. As B cell depletion affects Sn+ macrophages in the SCS 
as well as the marginal zone [179, 180], LT expression by B cells was shown to be directly 
implicated in this phenomenon [179, 181]. Systemic treatment with LT antagonists replicates 
the phenotype of B cell depletion, and this leads in the SCS to the replacement of Sn+ 
macrophages with a phenotype associated with medullary macrophages [182]. Altogether, 
these data demonstrate how intrinsic Sn macrophages are to lymphoid tissue and that their 
emergence is governed by its proper structuring.  
Besides homeostatic regulation of Sn expression, inflammatory stimuli can rapidly upregulate 
Sn expression on subsets of inflammatory macrophages and monocytes. In vitro, Sn 
induction on peripheral blood mononuclear cells (PBMC) and various macrophage subsets 
isolated from humans [158, 183, 184], mice [185], rats [186, 187] and pigs [188] can be 
achieved by type I or II interferon (IFN) stimulation. Rat [186, 187], mouse [185] and human 
[158] Sn induction has also been shown following tumour necrosis factor-α (TNF-α) 
exposure, and additionally, by ligation of human TLRs involved in viral and bacterial sensing 
(which also induce IFN-α secretion) [183]. On top of that, Sn expression can be induced in 
vitro on monocyte-derived DC populations after treatment with inactivated human rhinovirus, 
probably via intracellular RNA sensors that drive type I IFN production [189]. Interestingly, in 
the case of both mice and pigs an unidentified component of autologous serum has been 
shown to induce Sn expression [188, 190]. This modulation of expression by circulating 
factors may well explain the observed changes in Sn expression on macrophage populations 
following disruption of the blood-brain barrier [191] and afferent lymphatics [192]. The factors 
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negatively regulating Sn are not as clear. T helper type 2 cytokines in mice [193] and both 
virus-sensing and bacteria-sensing TLRs in humans [183] have been shown to down-
regulate expression, whereas IL-2 and IFN-γ demonstrated some inhibitory effects in rats 
[194]. 
In vivo, Sn+ macrophages have been identified in a variety of inflammatory disease settings 
(see section: Sn+ macrophages as immunomodulators in disease settings) which is in line 
with the regulation of Sn by inflammatory cytokines. Also, the great impact of type I and type 
II IFN on Sn expression suggest a function in anti-viral activity which is consistent with the 
observed interaction between Sn and viral particles as well as with a functional role for Sn+ 
macrophages in mediating adaptive immune responses (see sections: Sn as a pathogen 
receptor and Sn+ macrophages as mediators of innate and adaptive immunity). However, it is 
less clear how Sn expression can be negatively regulated, and how both up- and 
downregulation of Sn relate to Sn function in vivo. 
 
Sialoadhesin in cell-cell interactions 
As mentioned before, it has been proposed that Sn has evolved the unusually large number 
of 17 Ig domains to extend the sialic acid binding site above the dense glycocalyx to avoid 
cis-inhibition by the abundant sialic acids at the cell surface, thereby permitting trans 
interaction with ligands on other cells [146, 156]. In line with this, Sn displays binding to 
various cell populations, including cells of the granulocytic lineage [195]. Initially, Sn was 
defined as a sheep erythrocyte receptor, as Sn+ macrophages were found to form rosettes 
with sheep erythrocytes in vitro [144]. Later on, Sn was identified as a lymphocyte adhesion 
molecule involved in the binding of T and B cells, while differential binding to T cells was 
recorded depending on T cell maturity [196]. In an artificial disease model, Sn+ macrophages 
in the liver were observed to form clusters with CD4+ and CD8+ T cells during a successful 
graft-versus-leukaemia response. Following infusion of anti-Sn antibody, macrophage-T cell 
cluster formation, along with survival rate, were reduced, suggesting a regulatory role for Sn-
Sn ligand interactions [197]. A direct impact of Sn-mediated interaction on lymphocyte 
behaviour is shown by studies on experimental allergic encephalitis (EAE). Here, it was 
noted that Tregs in the afflicted tissue displayed increased Sn ligand and that in vitro, the 
absence or blocking of Sn expression on macrophages can lead to efficient proliferation of 
isolated Tregs [198]. In vivo, Sn knock-out mice showed reduced disease severity along with 
reduced numbers of infiltrating T helper type 1 (Th1) and type 17 (Th17) cells in the central 
nervous sytem, while higher numbers of Tregs were present [198]. In a more recent study, in 
vitro activation and analysis of all splenic CD4+ T cells showed that an upregulation of Sn 
ligand expression can also be observed on highly activated CD4+ effector T cells (Teffs), 
which comprise about 20% of all CD4+ Teffs [199]. Coculture of these activated Teffs with 
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Sn+ macrophages or Sn+ Chinese hamster ovary (CHO) cells resulted in increased cell death 
of Teffs, again showing a direct impact of Sn-Sn ligand interactions on lymphocyte 
behaviour. This interaction however might indicate that Sn can perform a dual role in 
autoimmune diseases. On the one hand, Sn-induced inhibition of Sn ligand-expressing Tregs 
proliferation can lead to reduced suppression of Teffs and enhanced inflammation as 
demonstrated in EAE. On the other hand, Sn-induced death of Sn ligand-expressing Teffs 
could lead to elimination of a hyperactive subset of Teffs and consequently reduced 
inflammation. The in vivo relevance of these observations however still needs to be 
confirmed. Remarkably, previously described Sn counterreceptors CD43 and P-selectin 
Glycoprotein Ligand-1 (PSGL-1) [200] were shown to be both dispensable for the Sn-Teffs 
interaction, leaving the protein carrier of the Sn ligand currently unidentified. In coronary 
artery disease patients, increased Sn expression on monocytes was related to increased T 
cell proliferation and pro-inflammatory cytokines secretion [201]. Down-regulation of Sn on 
the other hand could attenuate proliferation and activation of cocultured CD4+ and CD8+ T 
cells. Taken all data together, it is clear that Sn-Sn ligand interactions can influence 
lymphocyte behaviour. Mostly, these interactions appear to be pro-inflammatory, although a 
recent study suggests interactions might sometimes also be anti-inflammatory.  
The observation that Sn can interact with ligands on other cells led to the search for 
counterreceptors of Sn. The membrane mucin MUC1, expressed on breast cancer cells, was 
the first counterreceptor identified for Sn, expressed on macrophages infiltrating breast 
cancer cells [202]. Both MUC1 and the later defined counterreceptor CD43 were shown to 
bind Sn in a sialic acid-dependent manner, while binding of Sn to membrane receptors via a 
sialic acid-independent mechanism has also been described [114]. Specific glycoforms of Sn 
were shown to interact with the cysteine-rich domain of the MR [203, 204] and macrophage 
galactose-type C-type lectin 1 (MGL1) [205]. Both receptors are lectins that interact with N-
glycans on Sn and are expressed by macrophages and DCs. The interaction of Sn with 
MGL1 is thought to be important to direct cells to the SCS of LN during immune responses 
[206]. The Sn-glycoform recognized by the MR is mainly expressed on MZM and SCS 
macrophages and this interaction is thought to be important in the transport of native antigen 
to follicular zones of the spleen and LNs [203]. Taken together, the interaction of Sn with 
these lectins may be important to direct antigen (free or cell-associated) to B and T cell 
zones to enhance antigen-specific immune responses. 
 
Sialoadhesin as a pathogen receptor 
Although sialic acids are abundant in all higher organisms, they are less common amongst 
microorganisms and potential pathogens [156, 207]. However, several important pathogens 
have evolved various mechanism to synthesize or capture sialic acids and display them on 
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their surfaces. In line with this several pathogens have already been identified that can be 
recognized by Sn. So far, human immunodeficiency virus 1 (HIV-1), porcine reproductive and 
respiratory syndrome virus (PRRSV), Campylobacter jejuni, Neisseria meningitides and 
Trypanosoma cruzi are known to engage Sn. Due to the strategic positioning of Sn+ 
macrophages in the spleen and LNs on the border of lymphocyte rich regions and the entry 
of blood or lymph, this Sn-dependent recognition can promote pathogen uptake in 
macrophages which could be important in antigen presentation and immune activation. In 
line with this, a recent study with a prototypic cytopathic virus (vesicular stomatitis virus) 
showed that viral replication in Sn+ macrophages in the splenic marginal zone was necessary 
to ensure the production of sufficient viral antigen for effective activation of the adaptive 
immune response [208]. On the other hand, Sn-dependent recognition can also be misused 
by pathogens to their advantage. In the case of PRRSV, sialylated envelope glycoproteins 
M/GP5 mediate binding to Sn on alveolar macrophages leading to subsequent infection [209]. 
In the case of HIV-1, Sn is misused by the virus to mediate trans infection of CD4+ T cells 
[210]. Taken together, Sn-pathogen interactions can be of benefit both to the host as well as 
to the pathogen and in which direction the balance shifts will probably be pathogen-specific.   
 
Sialoadhesin as an endocytic receptor involved in signalling 
Initially, Sn was described as a non-phagocytic receptor [144], though later on Sn was shown 
to be involved in the endocytosis of pathogens like PRRSV, Neisseria meningitides and 
Trypanosoma cruzi. Also, it was established that Sn-specific mAbs and their antigen binding 
fragments (Fab) are internalized into porcine alveolar macrophages upon engagement with 
their receptor via clathrin-mediated endocytosis [103]. Internalization was only partial, as the 
receptor was still detected at the cell surface at all time points tested, and it was shown that 
internalized antibodies resided for prolonged times in early endosomes. Together, these data 
demonstrate the involvement of Sn in internalization processes, yet the signalling motifs 
involved in its internalization remain to be discovered [103]. As mentioned before, Sn 
contains only a short, poorly conserved, cytoplasmic domain, devoid of tyrosine-based, di-
leucine-based or other known motifs that are implicated in signal transduction and 
endocytosis (Fig. 6). A study performed by Genini et al. however showed that cross-linking of 
Sn with an antibody resulted in subtle alterations to the MAP kinase and Wnt signalling 
pathways, suggesting that Sn is able to activate intracellular signalling pathways and thus 
serves as a signalling molecule [211]. Further research will be needed to clarify the events 
occurring upon receptor engagement and to identify currently unknown signalling motifs.  
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Figure 6. Alignment of the cytoplasmic tails of (predicted) mammalian sialoadhesin.     
Clustal W (1.83) multiple sequence alignment of the cytoplasmic domain of (predicted) mammalian 
Sn, which is poorly conserved between mammalian species. Amino acids (AA) with similar properties 
are marked with similar colours. Colour code: blue, acidic AA (DE); green, contains: hydroxyl, 
sulfhydryl or amine group and G (STYHCNGQ); magenta, basic AA without H (RK); red, small AA + 
hydrophobic AA (including the aromatic AA F and W) (AVFPMILW). Figure adapted from De Baere 
2012 [114].  
 
To gain insight in the effect of ligand binding to Sn on macrophage effector functions, a study 
performed by De Baere et al. investigated the effect of antibody binding to porcine Sn (pSn) 
on macrophage viability, pSn surface expression, reactive oxygen/nitrogen species 
production, phagocytosis of microspheres, uptake and processing of soluble antigens, MHC I 
and MHC II cell surface expression and cytokine production [212]. This was done by 
treatment of porcine primary alveolar macrophages with a pSn-specific mAb in comparison to 
an isotype-matched control mAb in vitro. No significant effect on the effector functions under 
study were observed, except for a significant reduction of phagocytosis of fluorescent 
carboxylate-modified beads. Further research is required to assess whether these 
observations can be of relevance in vivo for the clearance of pathogens through 
phagocytosis after Sn engagement.  
 
Sn+ macrophages as immunomodulators in disease settings 
As discussed before, Sn is expressed by macrophage populations located in a variety of 
tissues, with the highest expression levels present in the secondary lymphoid organs. Also, 
under inflammatory stimuli Sn is rapidly upregulated on subsets of inflammatory 
macrophages and monocytes. This regulation by inflammatory cytokines is in line with the 
identification of Sn+ monocytes and macrophages in a variety of inflammatory disease 
settings. So far, Sn+ monocytes/macrophages have been found in models of chronic 
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rejection [213], neointima injury [214], cerebral vasculature injury [215], atherosclerosis [216, 
217], rheumatoid arthritis [218, 219], experimental autoimmune uveoretinitis [220], 
experimental allergic encephalomyelitis [198], systemic lupus erytematosus [221, 222], 
primary biliary cirrhosis [223], proliferative glomerulonephritis [224, 225] and diabetic 
nephropathy [226]. As previously discussed, the interaction between Sn and its ligands 
present on T cells, can alter lymphocyte behaviour, most strikingly shown by interaction of Sn 
with Tregs in EAE, negatively controlling their expansion and hence autoimmune disease 
progression [198]. In other mouse models of central nervous system inflammation, 
experimental autoimmune uveoretinitis [220] and myelin degeneration models [227, 228], Sn 
knock-out mice exhibit reduced disease severity which correlates with reduced lymphocyte 
invasion as well. In a rat model of rheumatoid arthritis, accumulation of Sn+ macrophages 
into the arthritic synovium and joint space occurs within a day following induction and 
parallels lymphocyte influx [218, 229, 230]. In addition, treatment with clodronate-laden small 
unilamellar vesicles reduces overall macrophage burden (including Sn+ macrophages) and 
arthritis severity [231], although it is unclear whether this effect resulted specifically from the 
Sn+ macrophage subset. Similarly, in humans suffering from glomerulonephritis, analysis of 
kidney tissue from patients has shown that Sn+ macrophage accumulation correlated with 
glomerular injury and that successful glucocorticoid therapy correlated with reduced numbers 
of glomerular Sn+ macrophages [225]. As with arthritis, a functional role for Sn+ macrophages 
has yet to be established. Until such a role has been established, it remains possible that Sn+ 
macrophages are simply byproducts of the inflammatory environment generated in these two 
diseases. However, taken together, it is clear that Sn+ macrophages can have a negative 
impact on disease progression of inflammatory diseases, because of their immune 
stimulatory role. This makes these Sn+ macrophages attractive targets to manipulate or 
eliminate in a cell-directed therapy strategy. A striking example of this approach is a recent 
targeted delivery of an anti-TNF-α oligonucleotide to Sn+ macrophages, which resulted in the 
relief of lupus-like symptoms in mice [130]. 
In addition to the inflammatory diseases discussed, Sn+ macrophages have also been found 
in a variety of cancer models, where they are thought to activate recruited T cells and hence 
promote a tumoricidal response. In murine graft-versus-leukaemia reactivity models, 
increased Sn expression in liver and spleen correlated with lymphoma stasis/regression 
[232-234]. In a rat model of prostate adenocarcinoma, the number of Sn+ macrophages 
showed a strong positive correlation with tumour apoptosis and a strong negative correlation 
with tumor growth [235]. As in mice, rat Sn expression was found to coincide with lymphocyte 
recruitment. Clinically, increased Sn expression has been recorded in splenic marginal cell 
lymphoma [162] as well as in macrophage infiltrates of MUC-1-positive breast carcinoma 
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[202], underscoring the possibility that Sn+ macrophages may play an important role in the 
host antitumor immune response.  
Taken together, the available data show that Sn knock-out and inhibition diminish the 
adaptive immune response in the above models. As such, it is tempting to speculate that the 
purpose of Sn is to somehow promote adaptive immune responses mediated by 
macrophages [134]. An intriguing example of this might be the development of Guillain-Barré 
syndrome (GBS). Here, molecular mimicry between Campylobacter jejuni sialylated 
lipooligosaccharides and human nerve gangliosides can trigger the production of cross-
reactive antibodies which induce GBS [236]. As C. jejuni has been shown to engage Sn, it 
has been suggested that although C. jejuni can be efficiently killed by Sn+ macrophages, the 
subsequent enhanced antigen presentation can be the key event leading to the induction of 
cross-reactive antibodies and ultimately GBS [236]. 
 
Sn+ macrophages involved in haematopoiesis 
Initial studies identifying Sn localization at the contact points of resident bone marrow 
macrophages and erythroblastic islands suggested a role in haematopoiesis [237]. Although 
the development of Sn knock-out mice did not go on to demonstrate haematopoietic defects 
[191], a recent study by Chow et al. demonstrates that Sn+ macrophages do have a role to 
play in vivo in erythropoiesis under homeostatic conditions and in disease [238]. Depletion of 
Sn+ macrophages (by clodronate liposomes or by the use of the CD169-difteria toxin receptor 
mouse model) was shown to markedly reduce the number of erythroblasts in bone marrow, 
although this did not result in overt anemia under homeostatic conditions, probably because 
of concomitant alterations in red blood cell clearance. However, under conditions of 
haemolytic anemia, acute blood loss or myeloablation, Sn+ macrophage depletion 
significantly impaired erythropoietic recovery. Having demonstrated the role of Sn+ 
macrophages in recovery after erythropoietic insufficiency, it was tested subsequently 
whether macrophage depletion could be beneficial in the context of an overactive erythron in 
a mouse model of polycythemia vera. Here, it was noticed that Sn+ macrophage depletion 
normalized the erythroid compartment, suggesting that erythropoiesis in polycythemia vera 
remains under the control of macrophages in the bone marrow and splenic 
microenvironments. These results indicate that Sn+ macrophages promote late erythroid 
maturation and that modulation of the macrophage compartment may be a new strategy to 
treat erythropoietic disorders. These findings also correlate with the functional specialisation 
of macrophages based on their location. While Sn+ macrophages play a role in 
haematopoiesis in the bone marrow, they are involved in the stimulation of adaptive immunity 
in lymph nodes and spleen.  
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Sn+ macrophages as mediators of innate and adaptive immunity 
Apart from several disease models where Sn+ macrophages appear to behave as promoters 
of the adaptive immune response, several other studies highlight the ability of Sn+ 
macrophages to enhance innate and adaptive immunity as well. Innate immune stimulation 
has so far been shown to depend on type I IFN secretion. In a study by Garcia et al., type I 
IFN secretion by Sn+ macrophages upon the local administration of a modified vaccinia virus 
Ankara vaccine in mice resulted in NK cell accumulation in the subcapsular area of the 
draining LN and in the activation of the NK cells [239]. In a study performed by Iannacone et 
al., SCS macrophage secretion of IFN-α in response to vesicular stomatitis virus (VSV) 
infection prevented viral access to the central nervous system [240]. This demonstrates 
classical innate immune cell behaviour of pathogen scavenging and release of inflammatory 
mediators [134]; however, further data illustrate a direct action of Sn+ macrophages in 
supporting adaptive immune responses. Junt et al. showed that in LNs Sn+ macrophages 
capture viral particles (VSV) within minutes after subcutaneous injection, transported them 
across the SCS floor and directly presented them to migrating B cells in the underlying 
follicles [241]. Moreover, also particulate antigen (fluorescent particles loaded with the model 
antigen hen egg lysozyme) and immune complexes are captured and displayed by Sn+ 
macrophages to B cells [110, 179, 242]. However, SCS macrophages might not be involved 
in B cell activation in response to all antigens [10]. For example, although SCS macrophages 
are targeted by inactivated influenza virus after immunisation, medullary 
CD11c+CD11b+SIGNR-1+ DCs carry antigen to the follicles and are required for induction of 
humoral responses [243]. Targeting of influenza virus to SCS macrophages is dependent on 
mannose-binding lectin [243], whereas targeting of VSV is independent from complement or 
secreted immunoglobulins [241]. This suggests that antigen opsonisation could have a major 
effect on how antigen is processed by SCS macrophages. 
Sn+ macrophages can also present lipid antigens in a CD1d dependent manner to invariant 
natural killer T cells (iNKT cells), leading to iNKT cell activation and population expansion in 
the LNs [244].  iNKT cells are a specialized subset of classical αβ T lymphocytes, which upon 
activation rapidly secrete large amounts of cytokines and induce downstream activation of 
different cell types, including DCs, NK cells, B cells and conventional T cells [244], making 
them important immune cells involved in coordinating both innate and adaptive immunity. 
Although purified CD11chi DCs are also able to activate iNKT cells in vitro, they are unable to 
activate iNKT cells when recovered from draining LNs from immunised animals, suggesting 
they do not have access to the antigen in vivo, again highlighting the prime access to 
incoming antigen in the lymph of Sn+ macrophages [244].  
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The spleen similarly locates Sn+ macrophages in the vicinity of lymphocyte-rich tissue and 
flowing fluid (in this case blood rather than lymph) [134]. Interestingly, a recent study using 
mouse VSV showed that Sn+ macrophages in the marginal zone of the spleen formed a 
compartment of enhanced viral replication [208]. This was essential for the induction of 
adaptive antiviral immune responses and, therefore, for preventing the fatal outcome of 
infection. As such, the authors suggested that enforced viral replication in MZM is an 
immunological mechanism that ensures the production of sufficient antigen for effective 
activation of the adaptive immune response. Also, a recent study by Nikbakht et al. showed 
that Sn+ macrophages in the spleen are required for the localization of antigen-activated B 
cells to the follicular perimeter and the subsequent formation of germinal centres by the use 
of hapten-keyhole limpet hemocyanin (KLH) conjugates [245], again supporting a role for Sn+ 
macrophages in the induction of efficient adaptive immune responses. 
Sn+ macrophages have also been implicated in the activation of CD8+ T cells through two 
potential mechanisms: 1/ antigen (OVA) transfer to CD8α+ DCs in the spleen [100] and 2/ by 
direct antigen presentation to CD8+ T cells (dead cell-associated antigens and T. gondii-
derived antigens) [246, 247]. The process by which antigen is transferred to CD8α+ DCs is 
however still unknown [10] and a possible direct activation role for Sn+ macrophages has not 
been eliminated. Cognate interaction between SCS macrophages and CD8+ T cells occurs 
as these cells are activated, and thus SCS macrophages are probably able to internalise, 
process and present antigen on MHCI molecules [10]. This however also implicates that Sn+ 
macrophages can become a target of CD8+ T cell dependent killing as well. This has been 
reported in the case of splenic Sn+ macrophages after infection with Plasmodium chabaudi 
[248] and proposed in the case of SCS macrophages after Toxoplasma gondii infection 
[247].  
Subcutaneous vaccination with irradiated necrotic tumour cells activates antigen-specific 
CD8+ T cells to elicit a protective antitumor immune response [246]. This effect was 
abolished by selective depletion of Sn+ macrophages in the LNs. Systemic apoptotic cell 
administration on the other hand revealed the importance of marginal zone Sn+ 
macrophages in debris clearance and maintenance of tolerance. Depletion of macrophages 
via clodronate liposomes [249] or use of transgenics [250] here resulted in autoimmunity. 
These findings illustrate once again the importance of Sn+ macrophages in regulating 
immune responses. 
From the findings that marginal zone and SCS macrophages participate in the induction of 
an adaptive immune response, targeting antigen to Sn+ macrophages has been explored as 
a means of inducing immunity [134]. Targeting OVA antigen to Sn+ macrophages using an 
anti-Sn antibody delivered intravenously in the presence of an agonist anti-CD40 antibody as 
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adjuvant, promoted CD8+ T cell activation to a similar extent as does antigen targeting using 
DEC205 on CD8α+ DCs [10, 100]. The Sn+ macrophages mediated response is protective 
against challenge with tumor cells that express OVA. Recently, Kawasaki et al. used high-
affinity glycan ligand–bearing liposomes to selectively deliver lipid antigens to Sn+ 
macrophages via the Sn endocytic pathway [102]. They found that ligand-targeted liposomes 
were captured by Sn+ macrophages and potently primed iNKT cells in liver and spleen. 
These effects occured in an Sn-dependent manner, because no activation was seen with the 
targeted liposomes in Sn-deficient mice. In pigs, an enhanced humoral immune response 
and increased reactivity of peripheral blood mononuclear cells was observed after injection of 
an Sn-specific mouse mAb in comparison to an irrelevant control antibody [104, 161]. In 
addition, our own research group observed an enhanced humoral immune response to the 
model antigen human serum albumin (HSA) after Sn-directed targeting of HSA using an Sn-
specific mAb [103]. These observations clearly illustrate the importance of Sn+ macrophages 
in generating effective immune responses and therefore contribute to the growing interest of 
Sn+ macrophages for vaccination strategies. 
 
1.1.4 TARGETING MOLECULES 
When speaking of targeting molecules, a distinction should be made between passive and 
active targeting. Passive targeting is based on the intrinsic properties of the delivery system. 
A good example of this targeting strategy is the enhanced permeability and retention effect in 
anti-cancer therapy. Here, macromolecular anticancer drugs administered intravenously 
escape renal clearance due to their large size, while they can selectively extravasate in 
tumor tissues due to the abnormal vascular nature present in tumor tissues [251]. For Sn+ 
macrophages, one passive targeting strategy has been described by Huang et al. [130]. 
Using a cationic agarose hydrogel, TNF-α anti-sense oligonucleotides were shown to 
accumulate in Sn+ macrophages in the spleen. In a mouse model of systemic lupus 
erythrematosus this resulted in significant amelioration of lupus symptoms. For vaccination 
strategies in general, passive targeting is also widely employed, with the largest interest 
going towards nanoparticles (NPs) as delivery vehicles for vaccines; the most prominent 
examples being virus-like particles (VLPs), liposomes, immune-stimulating complexes 
(ISCOMs), polymeric NPs and non-degradable NPs [7] (Fig. 7).  
Using NPs to deliver antigens, the efficiency of uptake by antigen-presenting cells in 
comparison to soluble antigen alone can be significantly increased [254]. A further increase 
in uptake by APCs can however be achieved through active targeting, where cell-surface 
receptor-specific ligands are attached to the NPs or used on their own to actively target 
antigens to specific APC subsets. These ligands can be natural ligands like CD40 ligand that 
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binds to CD40 on APC. Also glycans are explored as targeting vehicles for antigen delivery, 
as many surface receptors used as address labels for APCs are glycan-binding proteins 
(lectins). A limitation to the use of ligands of lectins however is the overlap in the ligand 
specificity of these receptors, and the degree to which they are expressed on single types of 
APCs [185]. For example, mannose containing glycans recognized by the MR and the Lewis 
X structures recognized by DC-SIGN are also recognized by other C-type lectins expressed 
on DCs and macrophages [255]. However, in-silico aided design strategies can be employed 
to develop ligands with high affinity and specificity. To target Sn+ macrophages Nycholat et 
al. developed such a high affinity ligand that is an analogue of the natural ligand and which is 
capable of targeting liposomes specifically to Sn+ macrophages in vivo [256]. Also, Kawasaki 
et al. used high-affinity glycan ligand–bearing liposomes to selectively deliver lipid antigens 
to Sn+ macrophages via the Sn endocytic pathway [102]. They found that ligand-targeted 
liposomes were captured by Sn+ macrophages and potently primed iNKT cells in liver and 
spleen.  
 
Figure 7. Schematic representation of different nanoparticle delivery systems. 
(A) Virus-like particles (VLPs) are viral proteins that self-assemble into structures resembling the 
conformation of the native virus but devoid of viral genetic material [252]. VLPs can be produced either 
without modification or by genetically engineering the viral capsid subunit by bioconjugation of the viral 
capsid subunit with antigenic peptides or other ligands or by site-directed mutagenesis of the intact 
VLP to create a functional scaffold for multivalent surface presentation of antigens [253]. (B) 
Liposomes are self-assembling like VLPs but consist of a phospholipid bilayer shell with an aqueous 
core. (C) Immune-stimulating complexes ISCOMs are colloidal saponin containing micelles of around 
40nm that can be used as self-adjuvanting vaccine delivery systems. (D) Polymeric nanoparticles are 
biodegradable and can be prepared from a range of polymers (e.g. PLGA) to create a vesicle which 
can either accommodate or display antigens. The release kinetics of incorporated antigens can be 
controlled by compositional changes to the copolymer. (E) Non-degradable nanoparticles are typically 
comprised of a gold, carbon or silica shell on which surface antigens can be covalently attached. 
Figure adapted from Gregory et al. [7]. 
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Although cell-surface receptor-specific natural ligands can be employed to target APC, The 
most widely used targeting molecules are antibodies (Table 3), as their inherent specificity 
and high affinity for their target makes them ideal candidates for this purpose. In addition, 
antibodies can be rather easily purified using standard chromatography techniques (protein 
G, protein A), thus representing a major advantage as compared to natural protein ligands. 
Antigens can be chemically conjugated to the antibodies. Chemical conjugation however has 
some disadvantages, like potential affinity loss of the antibody and poor control over the 
number of antigens conjugated which yields a heterogeneous product [257]. Genetic 
constructs where the DNA sequence of the antigen is genetically fused to the sequence 
encoding the mAb therefore represents a more elegant approach [59]. As the induction of an 
effective T cell response requires the addition of an adjuvant to DC-targeting formulations, 
targeting both antigen and adjuvant to the DCs is currently being investigated. To further limit 
potential off-target effects of the adjuvant, new approaches have emerged that shift the use 
of NPs from passive targeting to active targeting by coupling receptor-specific mAbs or 
derivatives (e.g. single chain fragment variable) to the NPs (Table 3 and Figure 8). As such, 
both antigen and adjuvant can be incorporated into the NPs or displayed on their surface [8, 
16].  
 
Figure 8. Methods for targeting antigen to APCs in vivo 
(A) The heavy and light chain of the whole mAb or the single-chain fragments of the variable regions 
(scFv) are sequenced and genetically engineered to carry antigen (star). Alternatively, (B) antigen can 
be chemically conjugated to whole mAbs. (C) The scFv or the mAb recognizing APC-specific 
molecules can also be engrafted into stealth liposomes. The liposomes can carry both antigen and 
adjuvant. (D) Nanoparticles carrying antigen and/or adjuvant are modified to permit the attachment of 
APC-specific mAb and have been used to target antigen. Figure adapted from Caminschi et al. [16]. 
 
For Sn+ macrophages, our own research group developed immunoconjugates by the 
cheminal linkage of the model antigen HSA to a pSn-specific mAb. An enhanced HSA-
specific humoral immune response was observed in comparison to a non-targeting control 
immunoconjugate or HSA alone [103]. Also, Backer et al. used a mouse Sn-specific mAb to 
target OVA antigen to Sn+ macrophages in the presence of an agonist anti-CD40 antibody as 
adjuvant [100]. CD8+ T cells were activated to a similar extent as by targeting antigen to 
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CD8α+ DCs using DEC205. The Sn+ macrophages mediated response was protective 
against challenge with tumor cells that expressed ovalbumin. Finally, Kratzer et al. designed 
fusion proteins of antigen with tandem Ig binding domains of protein G [101]. These fusion 
proteins were shown to efficiently bind to a range of surface receptor-specific mAbs, 
including one specific for mouse Sn. Also here, an enhanced OVA-specific CD8+ T cell 
response was observed by targeting OVA to Sn+ macrophages.    
Although most published targeting studies up till now made use of conventional mAbs to 
target antigens towards APCs (Table 3), antibody engineering approaches and the discovery 
of ‘nanobodies’ has created a wealth of Ab derivatives that could be used for targeting 
approaches as well (Fig. 9). Camelids and sharks produce high-affinity antibodies that are 
devoid of light chains [258, 259]. Their variable domain (for camelids called ‘nanobody’) 
contains the antigen-binding site, which is formed by only 3 complementarity-determining 
regions (CDRs) instead of 6 in conventional antibodies. The CDR3 region has an 
extraordinary capacity to form long fingerlike extensions that can extend into cavities on 
antigens, like e.g. cryptic epitopes present on infectious agents, which are mostly not 
accessible by conventional mAbs [260]. Also, nanobodies, Fab fragments and single chain 
fragment variable (scFv) can be engineered into multivalent molecules to increase functional 
affinity (also called avidity) or in multispecific molecules targeting more than one specific 
epitope (Fig. 9). An extensive toolbox is thus also available to further optimize the targeting 
molecule used in the APC-targeting vaccine formulation.   
  
Figure 9. Schematic representation of different antibody formats 
A ‘classic’ IgG molecule (~150kDa) is depicted alongside camelid VhH-Ig and shark Ig-NAR 
immunoglobulins. Camelid VhH-Ig and shark Ig-NARs are unusual immunoglobulin-like structures 
comprising a homodimeric pair of two chains of V-like and C-like domains (neither has a light chain), in 
which the displayed V domains bind their targets independently. Shark Ig-NARs comprise a 
homodimer of one variable domain (V-NAR) and five C-like constant domains (C-NAR). A variety of 
antibody fragments are depicted, including Fab, scFv, single-domain VH, VhH and V-NAR and 
multimeric formats, such as minibodies, bis-scFv, diabodies, triabodies, tetrabodies and chemically 
conjugated Fab´ multimers (sizes given in kilodaltons are approximate). Figure adapted from Holliger 
and Hudson [261]. 
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Traditionally, vaccines are based on live attenuated or inactivated pathogens. Although 
successful in many instances, many infectious diseases still exist for which the development 
of an effective vaccine remains elusive based on these classical approaches (e.g. HIV, 
malaria, tuberculosis,M). In addition, continuously increasing safety demands for novel 
vaccine formulations encourage the search for more rational vaccine designs. As such, a 
wide range of vaccines under development now are based on isolated peptides, proteins or 
polysaccharides of pathogens, or naked DNA encoding a protective antigen. Although 
promising, such antigens are often poorly immunogenic and require the addition of an 
immune-stimulating compound to generate an effective immune response. As a 
consequence, finding safe, yet efficient ways to boost immunity has become an increasingly 
important area of research in current-day vaccinology.  
To induce an antigen-specific memory immune response, an interaction between antigen-
loaded APCs and naive lymphocytes needs to take place in secondary lymphoid tissues. 
Therefore, one way to improve the efficiency of a vaccine is to improve the efficiency of the 
uptake of antigen by APCs. As such, targeting antigen to uptake receptors expressed on the 
surface of APCs is increasingly studied. While most targeting strategies focus on delivery of 
antigens to different subsets of DCs, Sn+ macrophages, most abundantly present in spleen 
and lymph nodes, appear to be strategically placed to capture and process antigens and may 
thus be an attractive target for vaccination strategies as well. Previously, our research group 
used a pSn-specific mAb to target the model antigen HSA, which was chemically cross-
linked to the mAb, to pSn expressing macrophages. In a porcine model, this resulted in an 
enhanced immune response to HSA. Although successful, this system implies that the 
antigen to be targeted is independently produced and purified, which translates into 
significant optimization for each separate conjugate. Also, chemical coupling to antibodies 
depends on the presence and distribution of reactive groups, e.g. primary amines on lysine 
residues, that can be located in or near the antigen-binding region. Upon coupling, this might 
result in partial or complete loss of the antibody’s capacity to bind to the target antigen. In 
addition, there is limited stoichiometric control because of the large number of reactive 
groups present in an antibody, leading to a heterogeneous mixture that makes batch to batch 
consistency hard to effectuate. A first aim of this thesis therefore was to develop a versatile 
recombinant antibody vector that allows easy production and purification of defined genetic 
antibody fusion constructs, in order to overcome the problems associated with chemical 
conjugation of a cargo to an Sn-specific mAb.    
A second aim of this thesis was to move away from model antigens and make a fusion 
construct of our targeting antibody with an antigen derived from an actual pathogen. As such, 
we selected a linear B cell epitope of PRRSV, known to be a target of virus-neutralizing 
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antibodies. During the course of an immune response to PRRSV, the induction of virus-
neutralizing antibodies is hampered. Also, currently commercially used inactivated vaccines 
do not succeed in inducing robust virus-neutralizing antibody responses in the pig. To 
evaluate if targeting a neutralizing epitope towards pSn-expressing macrophages can 
enhance the induction of epitope-specific and virus-neutralizing antibodies, four copies of the 
epitope were genetically fused to our recombinant pSn-targeting antibody. These fusion 
constructs were used to immunize pigs after which a viral challenge was performed. 
A third aim of this thesis was to develop a potential immunocastration vaccine candidate. As 
immunocastration relies on the induction of antibodies against gonadotropin releasing 
hormone (GnRH), a 10 amino acid peptide, four copies of GnRH were genetically fused to 
our recombinant Sn-targeting antibody. For the production of recombinant antibodies, the 
most commenly used expression systems are mammalian cells growing in suspension, so as 
to enable the rapid scale up of productions. In addition, chemically defined, serum-free media 
– with no animal-derived components – have become industry standard to further simplify 
regulatory approval. In this study, we made use of a commercially available suspension 
adapted CHO cell line to develop cell lines expressing recombinant antibody-GnRH fusion 
constructs.      
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Background Sn+ monocytes/macrophages have been associated with several diseases like 
inflammatory and autoimmune disorders as well as viral infections, and they also appear to 
play a role in the initiation of an adaptive immune response. This makes Sn-expressing cells 
not only attractive targets for cell-directed therapies, but also an appealing target for 
vaccination. Furthermore, since Sn was shown to be an endocytic receptor, the conjugation 
of effector molecules to an Sn-specific ligand should allow intracellular delivery of these 
conjugates. Previously, we developed functional Sn-specific immunoconjugates that were 
generated via chemical coupling. Although successful, the system requires significant 
optimization for each immunoconjugate to be made. To generate a more flexible and 
controlled system, we developed a recombinant antibody vector allowing the creation of 
genetic antibody fusion constructs. This paper reports on the characterization of the 
recombinant antibody and the evaluation of its use for Sn-directed targeting. 
Results The variable domains of the porcine Sn-specific monoclonal antibody 41D3 were 
sequenced and cloned in frame with a mouse IgG1 backbone. Transfection of HEK-293T 
cells with the resulting plasmid led to the secretion of fully assembled IgG into the culture 
medium. This recombinant antibody rec41D3 was shown to specifically bind to porcine Sn 
with a comparable affinity as the native monoclonal antibody. In addition, rec41D3 also 
induced Sn endocytosis in primary macrophages and resided for prolonged times in 
early/late endosomes. To allow the generation of antibody fusion constructs, a multiple 
cloning site was introduced at the C-terminus of the heavy chain. Two fusion constructs were 
generated, one containing a V5 peptide tag and one containing an eGFP molecule. Both 
constructs were shown to be efficiently produced in HEK-293T cells and easily purified using 
standard protein G chromatography. In addition, both V5 and eGFP were shown to be co-
internalized together with rec41D3 into Sn-expressing primary macrophages. 
Conclusions A recombinant antibody allowing targeted delivery of peptides and proteins to 
Sn-expressing macrophages was developed. Production and purification of antibody fusion 
constructs was possible without major optimization and with batch to batch consistency, 
confirming the development of a versatile antibody vector to evaluate Sn-directed targeting 
strategies in a porcine animal model.  
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3.1 INTRODUCTION 
 
Sn+ macrophages have gained increased attention lately because of their unique distribution 
in lymphoid organs and their redistribution upon immune activation [1]. Situated in the spleen 
and other secondary lymphoid tissues, Sn+ macrophages appear to be strategically placed 
for antigen acquisition and delivery to lymphocytes. Junt et al. showed that in lymph nodes, 
Sn+ macrophages capture viral particles (vesicular stomatitis virus) within minutes after 
subcutaneous injection, transport them across the SCS floor and present them to migrating B 
cells in the underlying follicles [2]. Moreover, also particulate antigen and immune complexes 
have been shown to be captured and displayed by Sn+ macrophages [3-5]. Besides, Sn+ 
macrophages present lipid antigens in a CD1d dependent manner to iNKT cells, leading to 
iNKT cell activation and population expansion [6]. Also, Sn+ macrophages have been 
implicated in the activation of CD8+ T cells by either directly presenting antigen to CD8+ T 
cells [7] or by transferring the antigen to CD8+ DCs in the spleen [8]. Ultimately, several 
independent research groups showed an enhanced cellular and/or humoral immune 
response upon Sn-targeted antigen delivery [9-13].  Together, this suggests that Sn+ 
macrophages may act as specialized antigen presenting cells involved in the antigen 
transport chain and contribute to the growing interest in Sn+ macrophages for vaccination 
strategies, as recently reviewed by Martinez-Pomares and Gordon [1]. 
Sn (CD169, Siglec-1) is also present on inflammatory macrophages and activated 
monocytes [14, 15]. In affected tissue samples of rheumatoid arthritis patients for instance, 
high expression of Sn was found on inflammatory macrophages [14]. In addition, abundant 
Sn expression on inflammatory monocytes/macrophages was shown to correlate with 
disease severity in pathological conditions like multiple sclerosis, atherosclerosis and breast 
cancer [16-18]. These observations promote the idea of an Sn-directed cell therapy aimed at 
elimination or immunomodulation of these cells. Recently, targeted delivery of an anti-TNF-α 
oligonucleotide to Sn+ macrophages resulted in the relief of lupus-like symptoms in mice [19], 
further showing the potential of Sn+ macrophages as a target for immunomodulation. Sn 
seems thus a promising target for cell-directed therapy, a strategy that is further encouraged 
by the restricted expression pattern of Sn limiting unwanted side effects. Furthermore, since 
Sn was suggested to be an endocytic receptor [10, 13], the conjugation of antigens, toxins or 
drugs to an Sn-specific antibody should allow intracellular delivery of these conjugates.  
So far, three systems have been used to selectively target Sn+ macrophages, namely 
antibodies, glycan-coated liposomes and cationic agarose hydrogels [9-13, 19, 20]. While the 
latter was unintentionally identified as an Sn-targeting system [19], the glycans on the 
glycan-coated liposomes were specifically designed to be ligands with a high specificity and 
Chapter 3 | Development of rec41D3 to target Sn
+
 macrophages 
 54 
affinity for Sn [20]. Previously, our research group has made use of an Sn-specific mAb to 
generate functional Sn-specific immunoconjugates via chemical coupling [10]. Although 
successful, this system implies, just like the two other described Sn-targeting systems, that 
the cargo to be targeted is independently produced and purified, which translates into 
significant optimization for each separate conjugate. Also, chemical coupling to antibodies 
depends on the presence and distribution of reactive groups, e.g. primary amines on lysine 
residues, that can be located in or near the antigen-binding region. Upon coupling, this might 
result in partial or complete loss of the antibody’s capacity to bind to the target antigen. In 
addition, there is limited stoichiometric control because of the large number of reactive 
groups present in an antibody, leading to a heterogeneous mixture that makes batch to batch 
consistency hard to effectuate [21]. To overcome these problems associated with the 
chemical conjugation of a cargo to an Sn-specific mAb, we report here on the development 
of a versatile recombinant antibody vector that allows easy production and purification of 
defined genetic antibody fusion constructs. The obtained vector will allow us to generate 
functional antibody-cargo constructs to evaluate Sn-targeting strategies in a porcine animal 
model. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 ETHICS STATEMENT 
The experimental procedure for the collection of porcine alveolar macrophages was 
authorized and supervised by the Ethical and Animal Welfare Committee of the Faculty of 
Veterinary Medicine of Ghent University. 
 
3.2.2 CELL CULTURE AND MONOCLONAL ANTIBODIES 
Porcine alveolar macrophages (PAM) were isolated from 4- to 6-week-old conventional 
Belgian Landrace pigs as described [36], and cultivated in RPMI-1640 medium 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 1% non-essential amino 
acids and 1 mM sodium pyruvate. HEK-293T were grown in DMEM medium supplemented 
with 10% heat-inactivated FBS, 2 mM L-glutamine and 1 mM sodium pyruvate. CHO-K1 cells 
and CHO-K1 cells stably expressing recombinant pSn [22] were cultivated in F-12 medium 
supplemented with 10% FBS and 1mM sodium pyruvate. All culture media were 
supplemented with a mixture of antibiotics and cell cultures were kept in a humidified 5% 
CO2 atmosphere at 37°C.  
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MAb 41D3, directed against pSn [37, 38], and an isotype matched (IgG1) control mAb 
13D12, directed against pseudorabies virus glycoprotein gD [23] were purified from 
hybridoma supernatants using protein G sepharose column chromatography (GE 
Healthcare), dialyzed to PBS and stored at -70°C until use.  
 
3.2.3 CONSTRUCTION, PRODUCTION AND PURIFICATION OF REC41D3, REC13D12 
AND FUSION CONSTRUCTS 
 
The variable domains of mAb 41D3 were sequenced and cloned into the pVITRO1-neo-mcs 
vector (Invivogen), in frame with a mouse IgG1 backbone (Fusion Antibodies Ltd). For the 
construction of rec13D12, total RNA from 107 hybridoma cells was isolated (RNeasy® mini 
kit, Qiagen) and cDNA was synthesized by RT-PCR (Superscript® III First-Strand Synthesis 
System, Life technologies). DNA sequences of mAb 13D12 VH and VL were obtained based 
on the protocol described by the Mouse Ig-Primer Set of Novagen®. Subsequently, the 
variable domains of rec41D3 in pVITRO1-neo-mcs were exchanged by the variable domains 
of mAb 13D12, yielding a plasmid encoding rec13D12.  
To construct both rec41D3- and rec13D12-V5, a (G4S)2-V5 DNA sequence was introduced at 
the 3’ end of the heavy chain sequence using forward primer 5’-
AAACGATCGGGCGGGGGAGGCTCAGGGGGAGGCGGGAGCGGTAAGCCTATCCCTAAC
CCTCTCCTCGGTCTCGATTCTACGGCGGCCGCATGAACGCGTAAA-3’ and reverse 
primer 5’-
TTTACGCGTTCATGCGGCCGCCGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGC
TTACCGCTCCCGCCTCCCCCTGAGCCTCCCCCGCCCGATCGTTT-3’. To construct both 
rec41D3- and rec13D12-eGFP, a (G4S)4 DNA sequence was introduced first at the 3’ end of 
the heavy chain sequence using forward primer 5’-
AAACGATCGGGCGGGGGAGGCTCCGGGGGAGGCGGGTCTGGAGGCGGGGGAAGTGG
CGGGGGAGGCTCAGCGGCCGCAAA-3’ and reverse primer 5’- 
TTTGCGGCCGCTGAGCCTCCCCCGCCACTTCCCCCGCCTCCAGACCCGCCTCCCCCG
GAGCCTCCCCCGCCCGATCGTTT-3’, followed by the eGFP sequence of pCeMM 
CTAP(SG) (GenBank Accession number EF467048) amplified by PCR using forward primer 
5’- AAAGCGGCCGCAATGGTGAGCAAGGGCGAGGAG-3’ and reverse primer 5’- 
AAAGGCCGGCCTTACTTGTACAGCTCGTCCAT-3’. Underlined sequences represent 
enzyme restriction sites, sequences in italics represent linker DNA sequences. 
For production of all recombinant antibodies and fusion constructs, HEK-293T cells were 
transiently transfected using calcium phosphate. Transfected cells were cultured in DMEM 
supplemented with 10% IgG depleted, heat-inactivated FBS, 2 mM L-glutamine, 1 mM 
sodium pyruvate, and a mixture of antibiotics in a humidified 5% CO2 atmosphere at 37°C. 
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Culture supernatant was collected and IgG were purified from the supernatant using 
standard protein G sepharose chromatography following the manufacturer’s instructions (GE 
Healthcare). Fractions of the eluate containing the purified protein were pooled and the buffer 
was exchanged to PBS by dialysis. Purified protein was stored at -70°C until use. Yields of 
recombinant antibodies and fusion constructs from HEK293-T supernatant were ± 500µg/l for 
rec41D3, rec13D12 and V5 fusion constructs and ± 250µg/l for eGFP fusion constructs. 
 
3.2.4 SDS-PAGE, COOMASSIE BLUE STAINING AND WESTERN BLOT ANALYSIS OF 
REC41D3 AND FUSION CONSTRUCTS 
 
Samples of purified proteins were mixed with (non-) reducing Laemmli buffer, boiled for 5 min 
and subjected to SDS-PAGE (6% non-reducing gel, 10% reducing gel) using a BioRad Mini 
Protean 3 system. For Coomassie Blue staining, the SDS-PAGE gel was incubated 
successively in Ultra Pure water, ImperialTM protein staining solution (Thermo Scientific) and 
Ultra Pure water as destaining solution. Alternatively, for Western blot analysis, proteins were 
transferred from the SDS-PAGE gel to a PVDF membrane (Membrane Hybond-P, GE 
Healthcare) via Western blotting (BioRad Mini Trans Blot). The membrane was blocked 
overnight in PBS + 0.1% Tween 20 + 5% skimmed milk. Detection of recombinant antibodies 
was performed by subsequent incubation of the blot with peroxidase-labeled polyclonal goat 
anti-mouse antibodies (Dako), followed by visualization using enhanced chemiluminiscence 
(ECL; GE Healthcare). Alternatively, rec41D3-V5 protein was detected using peroxidase-
labeled anti-V5 antibodies (Life technologies) and rec41D3-GFP protein was detected using 
a recombinant rabbit monoclonal GFP-specific antibody (ABfinityTM, Life technologies) and 
peroxidase-labeled polyclonal goat anti-rabbit antibodies (Dako), followed by ECL 
visualization. 
 
3.2.5 SURFACE PLASMON RESONANCE 
The generation of a soluble Fc-tagged pSn has been described before [24]. For surface 
plasmon resonance experiments, a pSn4D-Fc protein was used containing a single point 
mutation in the first pSn Ig-like domain, since production levels of this protein are significantly 
higher. mAb 41D3 has been shown to equally bind to this protein [24]. After production and 
purification, pSn4D-Fc was coupled to an activated CM5 chip to 300 response units (RU). 
mAb 41D3 (300, 108, 39, 14 nM) or rec41D3 (250, 90, 32, 12 nM) diluted in HBS-EP buffer 
was injected (30µl/min) for 2 min, followed by dissociation for 5 min. Surface regeneration 
was performed with 10 mM NaOH for 60 s followed by a recovery phase. The sensorgrams 
were fitted to a bivalent model accounting for mass-transfer effects. 
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3.2.6 IMMUNOFLUORESCENCE STAININGS 
To assess pSn specificity, CHO cells or CHO cells expressing pSn (CHO-pSn) were seeded 
on poly-L-lysine (Sigma) coated coverslips and incubated with mAb 41D3,  rec41D3 or 
isotype-matched control antibodies mAb 13D12 and rec13D12 for 1h at 4°C. Cells were then 
fixed with 4% (w/v) paraformaldehyde (Sigma) in PBS, permeabilized using 0.5% (w/v) 
saponin (Sigma) in PBS and stained with FITC-labelled goat-anti-mouse IgG to visualize 
antibodies bound to the cell. 
To evaluate pSn endocytosis of rec41D3 in comparison to mAb 41D3, PAM were incubated 
with 2µg/200µl purified antibodies and cells were fixed with 4% paraformaldehyde at the 
indicated time points. Afterwards, cells were permeabilized using 0.5% saponin and stained 
with FITC-labelled goat-anti-mouse IgG to visualize antibodies bound to and internalized in 
the cells. As a control, cells were fixed (time 0) and incubated with the respective antibodies 
afterwards. For double immunofluorescence staining with markers of the endosomal 
compartments, the respective primary antibodies for each endosomal compartment followed 
by appropriate Texas Red-labelled secondary antibodies was used for their visualization. The 
primary antibodies used were an affinity purified goat pAb (sc-6414; Santa Cruz 
Biotechnology), a rabbit pAb (ab32815; Abcam) and a rabbit pAb (sc-5570; Santa Cruz 
Biotechnology), for early endosome antigen 1 (EEA1), cation-independent mannose-6-
phosphate receptor (CI-M6P) and lysosome-associated membrane protein 1 (Lamp1) 
respectively. Cell nuclei were visualized using Hoechst 33342 (Life Technologies). 
To evaluate pSn endocytosis of rec41D3 fusion constructs, CHO-pSn and PAM were 
incubated with 2µg/200µl purified rec41D3-V5, rec41D3-GFP or their respective isotype 
controls rec13D12-V5 and rec13D12-eGFP for 1h at 37°C. Cells were then fixed with 4% 
paraformaldehyde, permeabilized using 0.5% saponin and stained with AF594-labelled goat-
anti-mouse IgG1 in addition to FITC-labelled mouse anti-V5 (IgG2a) or rabbit anti-GFP in 
combination with FITC-labelled goat-anti-rabbit polyclonal antibodies respectively. Cell nuclei 
were visualized using Hoechst 33342 (Life Technologies). 
 
3.2.7 CONFOCAL LASER SCANNING MICROSCOPY  
Z-section images of samples were acquired using a Leica TCS SPE-II laser scanning 
spectral confocal system (Leica Microsystems GmbH) linked to a Leica DM2500 microscope 
(Leica Microsystems GmbH). Image acquisition was done using the Leica LAS AF confocal 
software package and analysis of colocalization was done using CoLocalizer Pro [39]. For 
the colocalization analysis between Sn and the endosomal markers, the Sn-positive plasma 
membrane was excluded from the analysis and only internalized Sn was considered. 
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3.3 RESULTS 
 
3.3.1 DEVELOPMENT OF A SIALOADHESIN-SPECIFIC RECOMBINANT ANTIBODY, 
REC41D3 
 
To allow production and purification of genetic fusion proteins of an Sn-specific mAb and 
other peptides/proteins, a recombinant Sn-specific mAb was made. mAb 41D3 was 
previously described to selectively bind pSn and to be internalized into pSn-expressing 
macrophages [10]. The variable domains of mAb 41D3 were sequenced and cloned in frame 
with a mouse IgG1 backbone. The IgG1 backbone was modified so that the resulting plasmid 
p41D3 contains a C-terminal heavy chain multiple cloning site, allowing removal of the 
antibody’s heavy chain stop codon and insertion of protein encoding sequences (Fig. 1A).  
Transfection of HEK-293T cells with plasmid p41D3 led to the secretion of a fully assembled 
IgG into the culture medium of the same size as mAb 41D3, as shown by Western blot 
analysis of cell culture supernatants using polyclonal antibodies specific for mouse 
immunoglobulins (Fig. 1B). Recombinant antibodies were purified from cell culture medium 
using protein G chromatography and dialyzed to PBS. To assess the purity of rec41D3 after 
purification, protein samples were resolved via SDS-PAGE under non-reducing and reducing 
conditions and Coomassie Blue staining was performed (Fig. 1C). The presence of a single 
band under non-reducing conditions and the presence of two bands under reducing 
conditions consistent with the sizes of the heavy and light chains of an Ig showed that protein 
G purification yields pure rec41D3. Western blot analysis further confirmed that the bands 
present were antibody light and heavy chain fragments (Fig. 1D).  
Immunofluorescence stainings of CHO cells expressing recombinant pSn (CHO-pSn, [22]) 
were performed to assess the specificity of rec41D3 for pSn (Fig. 1E). With rec41D3, a bright 
surface staining, similar to that of the native mAb 41D3, was seen only on CHO-pSn cells, 
but not on wild type CHO cells, indicating specific pSn recognition of rec41D3. Control 
stainings were performed with isotype matched irrelevant mAb 13D12 (gD of pseudorabies 
virus, [23]), and its recombinant form rec13D12. Development, production and purification of 
rec13D12 was identical to the procedures used for rec41D3.    
Since the final goal is to use rec41D3 as a targeting molecule for pSn, the affinity of rec41D3 
for pSn is highly important. Therefore, its affinity was determined using Biacore. As a target, 
a soluble form of the pSn receptor, consisting of the first 4 N-terminal Ig-like domains of pSn 
fused to a human IgG Fc (pSn4D-Fc), was coated on the affinity chips. Previously, mAb 
41D3 was shown to bind to this pSn4D-Fc [24]. As seen in Figure 1F, both mAb 41D3 and 
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rec41D3 bound with high affinity to pSn4D-Fc, their equilibrium dissociation constants (KD) 
were determined to be 35 and 250 pM respectively.   
 
Figure 1. Development, production and purification of a pSn-specific recombinant antibody, 
rec41D3  
(A) Vector map of p41D3 (B) Non-reducing Western blot analysis of hybridoma supernatant of mAb 
41D3 compared to p41D3-transfected HEK-293T cell supernatant using polyclonal antibodies specific 
for mouse immunoglobulins (C) SDS-PAGE of protein G purified transfected cell supernatants to 
evaluate rec41D3 purity (D) Western blot analysis of purified rec41D3 using polyclonal antibodies 
specific for mouse immunoglobulins (E) Confocal microscopical analysis of CHO cells and 
recombinant pSn expressing CHO cells (CHO-pSn) incubated with mAb 41D3, rec41D3 or isotype 
matched controls mAb 13D12 and rec13D12 at 4°C for 1 hour. Cells were fixed and stained with FITC-
labelled goat-anti-mouse IgG. Images represent a single confocal z-section through the middle of the 
cell. Scale bar: 5µm (F) Kinetic profile of the pSn-41D3/pSn-rec41D3 interaction by Surface Plasmon 
Resonance measurements. Immobilized pSn4D-Fc was flowed with rising concentrations of mAb 
41D3 or rec41D3, after which injection was halted and dissociation was monitored during 5 minutes. 
Sensorgrams were fitted to a bivalent model and an approximation of the equilibrium dissociation 
constant was calculated. M, protein marker; mAb, mAb 41D3; rec, rec41D3; KD, equilibrium 
dissociation constant. 
 
3.3.2 REC41D3 INDUCES pSN ENDOCYTOSIS IN PRIMARY MACROPHAGES   
As our ultimate goal is to target pSn+ macrophages in vivo, we studied the capacity of 
rec41D3 to bind pSn and induce its internalization in in vitro cultivated primary cells. Primary 
PAM were isolated and incubated with the recombinant antibody for different time periods, 
after which they were fixed and stained to visualize membrane-bound and internalized 
antibodies. As for mAb 41D3, a clear membrane staining was observed at time zero, while 
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with increasing time, pSn-positive endocytic vesicles became readily apparent (Fig. 2A). 
Also, at early time points, endocytic vesicles of both antibodies were mainly present in the 
vicinity of the plasma membrane, while with increasing time endocytosed pSn was also 
localized closer to the perinuclear region. Similar to mAb 41D3-induced pSn endocytosis, 
rec41D3-induced pSn endocytosis is only partial, as confocal microscopical analysis showed 
that a clear membrane staining remains visible besides the endocytic vesicles. As a control, 
PAM were incubated with irrelevant, isotype matched mAb 13D12 and rec13D12. No cell 
staining was observed with these antibodies (data not shown).  
 
Figure 2. Analysis of rec41D3-induced pSn endocytosis and analysis of co-localization 
between internalized antibody and endo/lysosomal compartments  
(A) Confocal microscopical analysis of mAb 41D3- and rec41D3-induced pSn internalization in primary 
macrophages. Cells were incubated for the indicated time periods with either antibody at 37°C, fixed, 
permeabilized and stained with FITC-labelled goat-anti-mouse IgG. Images represent a single 
confocal z-section through the middle of the cell. (B) Analysis of co-localization between internalized 
mAb 41D3 or rec41D3 (green) and early endosomes (EEA1), late endosomes (CI-M6P) or lysosomes 
(Lamp1) (red) in primary macrophages. Co-localization was calculated from confocal z-sections of 25 
randomly selected cells of 2 independent experiments at the indicated time points. Data represent the 
means ± standard deviations. Representative images of macrophages that were incubated for 60 
minutes at 37°C with either antibody are shown as overlays of the green and red signal with a yellow 
colour indicating co-localization. Scale bar: 5µm 
 
In a previous study, we have shown that mAb 41D3 resides for prolonged times in early 
endosomes [10]. To analyze the intracellular localization of internalized rec41D3 in 
comparison to mAb 41D3, double immunofluorescence stainings were performed with EEA1, 
CI-M6P or Lamp1, markers for early endosomes, late endosomes and lysosomes 
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respectively. For both antibodies, the majority of internalized antibody was localized to early 
endosomes (around 60%, Fig. 2B), while the remainder was localized to late endosomes. 
Occasionally, a very limited number of internalized antibodies were localized in a lysosomal 
compartment. These results show that rec41D3 follows an endocytic pathway similar to mAb 
41D3 and resides for prolonged times in early/late endosomes.     
 
3.3.3 REC41D3 TARGETS ITS CARGO V5 AS WELL AS eGFP TOWARDS pSN+ CELLS 
The previous results clearly show that rec41D3 can be used to target Sn-expressing 
macrophages. To be able to evaluate targeting of a cargo, we aimed at generating functional 
antibody fusion constructs in which a cargo is coupled to the C-terminus of the heavy chain 
of the antibody. During the generation of the rec41D3 plasmid, a multiple cloning site was 
introduced at the C-terminus to facilitate this. Also, a flexible glycine-serine (GS) linker [25] 
was introduced between the C-terminal Fc part and the cargo linked to rec41D3. This 
minimizes the risk that unwanted interactions occur between rec41D3 and its cargo, which 
could result in non-functional antibody and/or cargo. Two fusion constructs were generated: 
one construct containing a (G4S)2 linker fused to a V5 peptide tag (rec41D3-V5), the other 
one containing a (G4S)4 linker fused to eGFP (rec41D3-eGFP). The GS linker used to 
generate rec41D3-eGFP is long, to ensure eGFP has the opportunity to fold into a functional 
protein. HEK-293T cell transfection followed by protein G purification of the supernatant 
clearly predominantly yields intact fusion proteins as shown by SDS-PAGE (Fig. 3A). Under 
non-reducing conditions a single band was visible for both fusion proteins, shifted in size in 
comparison with unmodified rec41D3. Under reducing conditions, it became clear that the 
antibody’s light chains remained unchanged, while the heavy chains were shifted in size, 
showing the acquisition of extra protein sequences. The presence of V5 or eGFP at the 
heavy chains of rec41D3 was further confirmed by Western blot analysis (Fig. 3B). These 
results indicate that rec41D3-V5 contains a V5 peptide tag, while rec41D3-eGFP contains an 
eGFP molecule. 
To further analyze whether or not rec41D3-V5 and rec41D3-eGFP carry their cargo towards 
pSn+ cells and induce internalization into the cells, we incubated CHO-pSn and PAM with the 
fusion constructs for one hour at 37°C. As shown in Figure 3C, both V5 and eGFP were co-
internalized together with rec41D3 in both cell types. As a control, CHO-pSn and PAM were 
incubated with irrelevant, isotype matched rec13D12 fusion constructs rec13D12-V5 and 
rec13D12-eGFP. No staining was observed with these constructs (data not shown). In 
conclusion, these data show that rec41D3 allows the targeting of peptides and/or proteins 
towards pSn+ cells.  
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Figure 3. Development of fusion constructs rec41D3-V5 and rec41D3-eGFP and analysis of 
their internalization into pSn-expressing cells   
(A) SDS-PAGE analysis of protein G purified rec41D3-V5 and rec41D3-eGFP constructs in 
comparison to unmodified rec41D3 (B) Western blot analysis of rec41D3-V5 and rec41D3-eGFP 
samples in comparison to unmodified rec41D3 using mouse immunoglobulin-specific goat polyclonal 
antibodies (GαM), a V5-specific mAb (αV5) and an eGFP-specific mAb (αGFP). (C) Confocal 
microscopical analysis of rec41D3-V5 and rec41D3-eGFP internalization in CHO-pSn cells and 
primary macrophages (PAM). Cells were incubated with rec41D3-V5 or rec41D3-eGFP for 1 hour at 
37°C, fixed, permeabilized and stained with AF594-labelled goat-anti-mouse IgG1 in addition to FITC-
labelled mouse anti-V5 (IgG2a) or rabbit anti-GFP in combination with FITC-labelled goat-anti-rabbit 
polyclonal antibodies respectively. Since the rec41D3-eGFP fluorescence was weak, the signal was 
enhanced to obtain good microscopical images. Images represent a single confocal z-section through 
the middle of the cell. M, protein marker; -, rec41D3; V5, rec41D3-V5; eGFP, rec41D3-eGFP. Scale 
bar: 5µm.  
 
3.4 DISCUSSION 
Monoclonal antibodies and their derivatives are currently the fastest growing class of 
therapeutic molecules [26]. Their inherent promise to minimize side effects by selectively 
targeting specific target cells has fuelled their development, leading to several FDA-approved 
antibody therapeutics so far and many more in the pipeline. Although unmodified mAbs 
proved their worth, the conjugation of effector molecules (like toxins, drugs, radionuclides,M) 
to mAbs broadened their therapeutic potential, especially in the domain of cancer 
therapeutics. Besides cancer, other diseases could also benefit from antibody-directed 
therapies, the only prerequisite being the identification of a receptor exclusively expressed on 
those immune cells involved in the induction of pathology. In this respect, Siglecs are 
compelling candidates for therapy, as they display very restricted expression patterns on 
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subsets of immune cells and may regulate immune cell functions. Furthermore, siglecs are 
endocytic receptors allowing therapeutic agents conjugated to a mAb to be carried efficiently 
into the cell [27, 28].  
Sn or Siglec-1 is expressed on cells of the monocyte/macrophage lineage, notably on 
subsets of resident tissue macrophages and inflammatory monocytes/macrophages [15, 27]. 
A recent report describes the expression of Sn on human mature DCs treated with LPS in 
vitro [29], suggesting that Sn may be present on mature DCs during inflammation in vivo as 
well. Not only have Sn+ monocytes/macrophages been described in several diseases like 
inflammatory and autoimmune disorders as well as viral infections, they also appear to play a 
role in the initiation of an adaptive immune response as recently shown by different 
independent research groups and nicely reviewed by Martinez-Pomares and Gordon [1]. 
Together, this makes these Sn+ cells not only attractive targets for cell-directed therapies, but 
also an appealing target for vaccination. In our previous study, we developed 
immunoconjugates by the chemical linkage of the model antigen HSA or a toxin to the pSn-
specific mAb 41D3 [10]. Although these immunoconjugates proved efficient for boosting 
immune responses and killing pSn-expressing cells respectively, the chemical linkage of the 
cargo to a targeting antibody has many disadvantages. First of all, chemical coupling 
procedures rely on the presence and distribution of reactive groups, like e.g. primary amines 
on lysine residues, that can be located in or near the antigen-binding region, which upon 
coupling might result in partial or complete loss of the antibody’s affinity for the target 
antigen. Secondly, because of the large number of reactive groups present in antibody 
molecules, a typical distribution can be observed of zero to eight molecules per antibody [30, 
31], resulting in high variation of the final conjugate. This variation is unwanted, as it may 
lead to a heterogeneous mixture of components with distinct affinities, stabilities, 
pharmacokinetics, efficacies, and safety profiles [21]. Moreover, chemical coupling implies 
that both antibody and cargo to be linked are independently produced and purified, which 
represents a significant challenge, especially when the cargo is also a biologic. To 
circumvent these problems, we opted to generate a recombinant form of the pSn-specific 
mAb 41D3. As shown in this study, this recombinant antibody displays a comparable affinity 
for pSn compared to the native  mAb. In addition, the recombinant mAb also induces pSn 
endocytosis in primary macrophages, a feature important to allow functionality of antibody-
cargo constructs. As protein sequences are attached to the C-terminus of the antibody’s 
heavy chain, they are less likely to hinder antigen binding by the variable immunoglobulin 
domains. In addition, each heavy chain will contain only one cargo fused to the C-terminal 
end. This will result in an antibody with 2 cargos in a defined position and a high intra and 
inter batch consistency. Furthermore, we could purify the antibody-cargo fusion proteins 
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using standard protein G chromatography, which represents a major advantage compared to 
chemical coupling in which purification is needed for both cargo and antibody before, as well 
as after chemical conjugation. 
In this study we managed to make genetic fusion constructs of a peptide or a protein linked 
to our recombinant mAb. Obviously, the recombinant antibody vector does not allow to make 
genetic fusion constructs with chemical compounds. For vaccination strategies however, this 
limitation is not expected to pose any problems, as most antigens used in vaccines are 
protein based. One challenge however would be to ensure correct folding of the antigen 
upon genetic fusion to the antibody and to maintain this fold during purification procedures. 
Similarly, immunotoxins can be made using the Sn targeting vector. Although the production 
of immunotoxins in eukaryotic cells has been limited due to potential toxicity to the producing 
cells, several independent research groups have reported on the successful production of 
immunotoxins in mammalian cell lines, including HEK-293T [32-34]. In case a specific 
application would require the chemical linkage to an antibody, e.g. when vaccines are based 
on glyco-epitopes, a recombinant mAb has some major advantages. It allows addition of 
specific amino acid modifications to the antibody, which will result in site-specific 
incorporation of drug molecules through chemical linkage yielding batch to batch consistency 
of antibody-drug conjugates. Examples of such already implemented modifications are the 
THIOMABTM technology of Genentech Inc [35] or the methodology of Axup et al. [21].  
As our future plans include the use of the developed recombinant antibody to target antigens 
towards pSn-expressing macrophages in vivo, one might be concerned about the 
immunogenicity of mouse antibodies in pigs. Poderoso et al. previously used mouse mAbs 
as surrogate antigens in pigs to evaluate the role of Sn in the induction of humoral responses 
and noticed an enhanced anti-mouse antibody response in comparison with a non-targeting 
isotype control mAb [11]. The induction of anti-mouse antibodies was however low after 
primary injection of the mAb, only after a booster vaccination antibody titres rose 
significantly. Previously, we have observed an enhanced anti-HSA antibody response after a 
single dose vaccination of HSA coupled to mAb 41D3 without adverse clinical effects [10]. 
Therefore, in our future experiments, we will use a single dose of rec41D3-antigen to 
evaluate the protective efficacy of antigen targeting to pSn. If further experiments confirm the 
applicability of this targeting technology, ‘porcinization’ of the recombinant antibody will be 
examined to enable prime-booster vaccination schedules.  
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3.5 CONCLUSIONS 
A recombinant antibody that targets Sn was developed. In addition, we constructed a vector 
that allows the genetic linkage of a protein cargo in a defined position at the C-terminus of 
both heavy chains of a fully assembled antibody. This vector was shown to be versatile, as 
both a peptide and a more complex, larger protein could be fused. Furthermore, production 
and purification of the antibody fusion constructs did not require major optimization. In 
comparison to other Sn targeting strategies (glycan-coated liposomes and cationic 
hydrogels), the one-step production of the final carrier-cargo product together with the high 
specificity and affinity of the recombinant antibody may be considered an advantage for drug 
development. Future research will mainly focus on the development of functional antibody-
antigen fusions allowing the evaluation of Sn-directed vaccination strategies.  
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Targeting antigens to professional antigen presenting cells resident at the sites where 
effective immune responses are generated is a promising vaccination strategy. As such, 
targeting Sn+ macrophages, abundantly present in spleen and lymph nodes where they 
appear to be strategically placed for antigen capture and processing, is recently gaining 
increased attention. Previously, we have shown that humoral immune responses to the 
model antigen human serum albumin can be enhanced by using a porcine Sn-specific 
monoclonal antibody to target the model antigen to Sn-expressing macrophages. To date 
however, no studies have been performed to evaluate whether Sn-targeted delivery of a 
pathogen-derived antigen can enhance the pathogen-specific immune response. Therefore, 
we selected a linear epitope on glycoprotein 4 of PRRSV, which is known to be a target of 
virus-neutralizing antibodies. This paper reports on the targeted delivery of this viral peptide 
to porcine Sn-expressing macrophages and the evaluation of the subsequent immune 
response in a vaccination-challenge set-up. 
Four copies of the selected PRRSV epitope were genetically fused to a previously developed 
porcine Sn-targeting recombinant antibody or an irrelevant isotype control. Fusion proteins 
were shown to be efficiently purified from HEK293T cell supernatants and subsequently, only 
Sn-specific fusion proteins were shown to bind to and to be internalized into Sn-expressing 
cells. Subsequent immunizations with a single dose of the fusion proteins showed that 
peptide-specific immune responses and neutralizing antibody responses after PRRSV 
challenge were enhanced in animals receiving a single 500µg intramuscular dose of the Sn-
targeting fusion protein, although correlations between the two read-outs were hard to 
effectuate. Furthermore, a minor beneficial effect on viral clearance was observed. Together, 
these data show that viral peptide targeting to porcine Sn-expressing macrophages can 
improve the anti-viral immune response, although more research will be needed to optimise 
vaccine design. 
Chapter 4.1 | PRRSV peptide targeting to Sn
+
 macrophages 
 
 73 
4.1.1 INTRODUCTION 
 
Traditionally, vaccines are based on inactivated pathogens, live attenuated pathogens or 
pathogen-derived toxins [1, 2]. Although successful in many instances, there may be 
significant drawbacks of these approaches, including the risk of reversion to virulence, 
unwanted host reactions such as inflammation or the induction of an autoimmune response. 
In addition, manufacturing constraints may occur with microorganisms that are hard to 
cultivate in vitro. For veterinary vaccines, also the need to discriminate between infected and 
vaccinated animals contributes to the growing interest in a more sophisticated vaccine 
design [3]. Starting from the exclusion of specific protein antigens in vaccine formulations, 
research has evolved towards the development of true subunit vaccines, containing only 
fragments of a pathogen. Going even further, the selection of a minimal, protective and 
immunogenic region of a protein antigen has led to the development of epitope-based 
peptide vaccines, allowing a precise direction of immune responses. This reductionist 
approach, although challenging, can result in vaccines that are more immunologically defined 
and with a better safety profile compared to vaccines generated by traditional empirical 
approaches.  
Although promising, peptides are traditionally poorly immunogenic on their own [4]. 
Therefore, there is a clear need for potent immunostimulatory adjuvants. In addition, these 
adjuvants also need to be safe. An alternative to this approach is making the peptide-based 
vaccines self-adjuvanting by the use of nanoparticular carriers [4] or by targeting the peptides 
directly to APCs. While most targeting strategies aim at delivery of the antigens to DCs [5-7], 
Sn+ macrophages, among other situated in spleen and lymph nodes, appear to be 
strategically placed for antigen capture and processing and may be an attractive target for 
vaccination strategies as well [8]. Previously, we used a pSn-specific mAb to target the 
model antigen HSA, which was chemically cross-linked to the mAb, to pSn-expressing 
macrophages. In a porcine model, this resulted in an enhanced immune response to HSA 
[9]. To circumvent the drawbacks associated with the chemical linkage of antigens, we 
recently developed a pSn-specific recombinant antibody [10]. This antibody allows targeted 
delivery of peptides or proteins towards pSn-expressing macrophages and thus represents 
an elegant tool to evaluate Sn targeting as a vaccination strategy.  
PRRSV is a single-stranded, positive sense RNA virus that belongs to the family of the 
Arteriviridae, order Nidovirales [11]. PRRSV is the causative agent of porcine reproductive 
and respiratory syndrome, a disease present in the majority of swine-producing countries 
around the world, which causes major economic losses [12, 13]. Although protective PRRSV 
immunity is a complex matter, it has been shown that sufficiently high titres of virus-
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neutralizing (VN) antibodies in serum can offer in vivo protection against PRRSV [14, 15]. 
Currently used inactivated vaccines however, do not induce VN antibodies and are of limited 
efficacy at best [16, 17]. To test if targeting to Sn increases the induction of VN antibodies, 
we selected an epitope on glycoprotein 4 (GP4) of the European Lelystad virus (LV) strain 
which is known to be a target for VN mAbs in continuous cell lines as well as in porcine 
alveolar macrophages [18, 19]. In addition, during the course of an infection pigs produce 
antibodies against this linear epitope which are able to neutralize the virus in vitro [20]. The 
GP4 epitope was genetically linked to the pSn-specific recombinant antibody rec41D3 and 
the resulting product was used to immunize pigs, evaluate the induction of peptide-specific 
antibodies and assess the efficacy upon a viral challenge.  
 
4.1.2 MATERIALS AND METHODS 
 
4.1.2.1 ETHICS STATEMENT 
Animal experiments were approved and supervised by the Ethical and Animal Welfare 
Committee of the Faculty of Veterinary Medicine of Ghent University. The named institution 
approved the experiments and provided a permit for this study (Permit Numbers: EC 
2011/105 and 2012/038). The experimental procedure for the collection of porcine alveolar 
macrophages was authorized and supervised by the named institution as well. 
 
4.1.2.2 CELLS AND VIRUS 
Primary macrophages were isolated by bronchoalveolar lavage from four- to six-week-old 
conventional Belgian Landrace pigs as described before [21], and cultivated in RPMI-1640 
medium supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 1% non-essential 
amino acids and 1 mM sodium pyruvate. HEK293T were grown in DMEM medium 
supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine and 1 mM sodium 
pyruvate. CHO-K1 cells and CHO-K1 cells stably expressing recombinant pSn (CHO-pSn) 
[22] were cultivated in F-12 medium supplemented with 10% FBS and 1 mM sodium 
pyruvate. All culture media were supplemented with a mixture of antibiotics and cell cultures 
were kept in a humidified 5% CO2 atmosphere at 37°C.  
The PRRSV LV strain was propagated in primary macrophages that were derived from 
gnotobiotic piglets. The fifth passage of infected cell culture supernatant was purified by 
ultracentrifugation as previously described by Vanhee et al. (2009).  
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4.1.2.3 CONSTRUCTION, PRODUCTION AND PURIFICATION OF REC41D3- AND 
REC13D12-GP4 
 
Construction of the plasmids encoding pSn-specific rec41D3 and isotype matched control 
rec13D12, directed against pseudorabies virus glycoprotein gD [23], was described 
previously [10]. To generate both rec41D3- and rec13D12-GP4 plasmids, a (G4S)2-GP4 DNA 
sequence was synthesized (Genscript Inc.) and introduced at the 3’ end of the heavy chain 
sequence by restriction enzyme digestion and ligation. Sequencing confirmed the fusion 
constructs were correctly assembled. HEK293T cells were transiently transfected with the 
plasmids using calcium phosphate and cultured in DMEM supplemented with 10% IgG 
depleted, heat-inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and a mixture of 
antibiotics in a humidified 5% CO2 atmosphere at 37°C. Culture supernatant was collected 
and recombinant IgG were purified from the supernatant using standard protein G sepharose 
chromatography following the manufacturer’s instructions (GE Healthcare). Fractions of the 
eluate containing the purified protein were pooled and the buffer was exchanged to DPBS 
(Life Technologies) by dialysis. Purified protein was stored at -70°C until use.  
 
4.1.2.4 SDS-PAGE, COOMASSIE BLUE STAINING AND WESTERN BLOT ANALYSIS 
OF REC41D3- AND REC13D12-GP4 
 
Samples of purified proteins were mixed with (non-)reducing Laemmli buffer, boiled for 5 min 
and subjected to SDS-PAGE (6% non-reducing gel, 10% reducing gel) using a BioRad Mini 
Protean 3 system. For Coomassie Blue staining, the SDS-PAGE gel was incubated 
successively in Ultra Pure water, ImperialTM protein staining solution (Thermo Scientific) and 
Ultra Pure water as destaining solution. Alternatively, for Western blot analysis, proteins were 
transferred from the SDS-PAGE gel to a PVDF membrane (Membrane Hybond-P, GE 
Healthcare) via Western blotting (BioRad Mini Trans Blot). The membrane was blocked 
overnight in PBS + 0.1% Tween-20 + 5% skimmed milk. Detection of recombinant antibodies 
was performed by subsequent incubation of the blot with peroxidase-labelled polyclonal goat 
anti-mouse antibodies (Dako), followed by visualization using enhanced chemiluminescence 
(ECL; GE Healthcare). Alternatively, GP4 peptides were detected using the mouse mAb 
XVI11C (IgG2a, [18]) and peroxidase-labeled rabbit anti-mouse IgG2a antibodies (Life 
Technologies), followed by ECL visualization.  
 
4.1.2.5 IMMUNOFLUORESCENCE STAINING AND CONFOCAL LASER SCANNING 
MICROSCOPY 
 
To evaluate pSn binding and endocytosis CHO-pSn and primary macrophages were 
incubated with 2µg/200µl purified rec41D3-GP4 or its isotype control rec13D12-GP4 for one 
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hour at 37°C. Cells were then fixed with 4% (w/v) paraformaldehyde (Sigma), permeabilized 
using 0.5% (w/v) saponin (Sigma) and stained with FITC-labelled goat anti-mouse IgG1 in 
addition to mAb XVI11C in combination with AF594-labelled goat anti-mouse IgG2a 
antibodies respectively. Cell nuclei were visualized using Hoechst 33342 (Life Technologies). 
Z-section images of samples were acquired using a Leica TCS SPE-II laser scanning 
spectral confocal system (Leica Microsystems GmbH) linked to a Leica DM2500 microscope 
(Leica Microsystems GmbH). Image acquisition was done using the Leica LAS AF confocal 
software package. 
 
4.1.2.6 EXPERIMENTAL DESIGN OF ANIMAL STUDIES  
 
All piglets were derived from a PRRS-negative farm and their PRRSV seronegative status 
was confirmed by immunoperoxidase monolayer assay (IPMA) as previously described [24]. 
The animals were housed in isolation units with HEPA-filtered air and kept during seven days 
to allow adaptation to the new conditions. 
Dose experiment with 50µg or 500µg rec41D3-GP4 
In a first preliminary experiment, nine piglets were randomly assigned to three treatment 
groups. All three groups received one intramuscular (i.m.) injection at six weeks of age. A 
first group served as mock-vaccinated control group and received an injection of 500µl PBS. 
The second group received an injection of 50µg rec41D3-GP4 in 500µl PBS. The third group 
received an injection of 500µg rec41D3-GP4 in 500µl PBS. Seven weeks after the i.m. 
injection, all pigs were challenged by intranasal inoculation of 106 TCID50/ml LV as previously 
described [25]. Blood was taken weekly after vaccination and post challenge. An extra blood 
sample was taken at five days post challenge when peak viremia was expected. Serum was 
collected and stored at -70°C. Serum samples for peptide-specific and VN antibody detection 
were inactivated by incubation during 30 min at 56°C prior to freezing.  
Vaccination experiment with rec41D3-GP4 in comparison to rec13D12-GP4 
In a second experiment, 30 piglets were randomly assigned to five treatment groups. All 
treatment groups received one i.m. injection at six weeks of age. A first group (PBS) served 
as mock-vaccinated control group and received an injection of 500µl PBS. The other 
treatment groups received an injection of either 150µg rec13D12-GP4, 150µg rec41D3-GP4, 
500µg rec13D12-GP4 or 500µg rec41D3-GP4 in 500µl PBS. Four weeks after the i.m. 
injection, all pigs were challenged by intranasal inoculation of 106 TCID50/ml LV. Blood was 
taken weekly after vaccination and at days 0, 1, 3, 5, 7, 10, 14, 21, 28 and 35 post challenge. 
At the start of the experiment, one animal died due to a hemolytic E. coli infection. No other 
pigs showed clinical signs of E. coli infection, but as a preventive measure, all animals 
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received a three day antibiotic treatment (Baytril®). Further on in the experiment, a second 
animal died during blood taking. This resulted in a group size of five animals instead of six for 
the 150µg rec13D12-GP4 and the 500µg rec41D3-GP4 groups. Serum was collected and 
stored at -70°C. Serum samples for peptide-specific and VN antibody detection were 
inactivated by incubation during 30 min at 56°C prior to freezing.  
 
4.1.2.7 GP4 PEPTIDE-SPECIFIC ELISA   
 
GP4 peptide for use in ELISA was synthesized by JPT Peptide Technologies as a 
biotinylated peptide (BioTide). Antibodies against the GP4 peptide were detected by ELISA 
as previously described [20] with the following modifications. Two-fold serial dilutions of 
serum samples (starting from 1/100 diluted) were incubated on the peptide-coated plates, 
followed by washing and incubation with peroxidase-conjugated goat anti-swine IgG 
antibodies (Abcam) or goat anti-swine IgM antibodies (AbD serotec). For IgG antibody titre 
determination, the optical density at 450nm (OD450) was measured and OD450 values 
obtained were expressed relative to the OD450 value obtained with a serum sample of the 
same animal at the time of vaccination (day 0). If this OD450 sample/negative was more than 
2 it was considered a specific signal. Subsequently, antibody titres were determined as the 
reciprocal of the highest dilution for which an OD450 sample/negative of 2 or more was 
observed. As serum background levels were higher and more variable in the IgM peptide-
specific ELISA, another approach for antibody titre determination was used. Here, the mean 
of all OD450 values of all PBS mock-vaccinated animals of all time points before challenge 
was calculated together with the standard deviation (for each serum dilution). If OD450 
values obtained were ≥ the mean calculated + 3 times the standard deviation, it was 
considered a specific signal. Subsequently, antibody titres were determined as the reciprocal 
of the highest dilution for which an OD450 value was obtained ≥ the mean calculated + 3 
times the standard deviation. 
 
4.1.2.8 SINGLE REPLICATION CYCLE VIRUS-NEUTRALIZATION TEST ON PRIMARY 
MACROPHAGES   
 
Single replication virus-neutralization test on primary macrophages was essentially 
performed as described before [20]. Two-fold serial dilutions of sera in PBS were mixed with 
equal volumes of LV virus resulting in a final titre of 105.5 TCID50/ml. PBS without serum was 
included as mock condition. Virus-antibody mixtures were incubated for one hour at 37°C 
and transferred to a 96-well plate (100µl/well) with primary macrophages (105 cells/well) that 
were cultivated during 72h prior to use. The inoculum was removed after one hour and 
replaced by medium, after which the cells were further incubated for another 10h, fixed by 
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drying, and stored at -20°C. The cells were stained for PRRSV infection with mAb 13E2 [26] 
against the nucleocapsid protein of PRRSV and peroxidase-conjugated goat anti-mouse 
polyclonal antibodies (Dako), followed by development with 3-amino-9-ethylcarbazole. The 
number of infected cells in each well was counted in three fields at 200x magnification, and 
expressed relative (%) to the mean number of infected cells for all mock conditions. VN 
antibody titres were determined as the reciprocal of the highest dilution that resulted in more 
than 90% reduction of infected cells. 
 
4.1.2.9 VIRUS TITRATION AND RT-qPCR 
 
Virus titres in serum were determined by virus titration on primary macrophages using 
standard procedures [24], followed by immunoperoxidase staining with mAb 13E2 against 
the nucleocapsid protein of PRRSV [26]. 
RNA was extracted with the QIAamp® Viral RNA Mini Kit (Qiagen GmbH, Hilden, Germany, 
Cod. 51906) according to the manufacturer’s recommendations, and finally eluted in 60 µl kit 
elution buffer. The commercially available TaqMan PRRSV Reagents (Applied 
Biosystems/Ambion, Cod. 4405547) for PRRSV detection was used according to the 
manufacturer’s recommendations. Real time PCR assays were carried out in a final volume 
of 12.5 µl including 4 µl of purified RNA as template and run on a 7900HT Fast Real-Time 
PCR System (Applied Biosystems). 
   
4.1.2.10 STATISTICAL ANALYSIS 
 
Statistical analysis was performed by Kruskall-Wallis test, followed by Dunn’s multiple 
comparisons test to determine differences between area under the curves (AUC). AUC were 
calculated for each test with its respective detection limit as baseline value. Differences were 
considered significant if the overall P-value was below 0.05 (**) or 0.1 (*). All statistical 
analyses were performed using GraphPad Prism version 5.01.     
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4.1.3 RESULTS 
 
4.1.3.1 CONSTRUCTION AND CHARACTERIZATION OF REC41D3-GP4 AND 
REC13D12-GP4 FUSION PROTEINS 
 
We previously described the development of a pSn-specific recombinant antibody rec41D3 
and an irrelevant isotype control rec13D12 [10]. In the present study, we generated fusion 
constructs of rec41D3 and rec13D12 containing four repeats of a known neutralizing epitope 
of GP4 of PRRSV, separated from each other by a short spacer and separated from the 
antibodies by a GS linker. The amino acid sequence following the antibodies’ heavy chains is 
shown in Figure 1A.    
HEK293T cell transfection followed by protein G purification of the supernatant clearly 
yielded intact fusion proteins as shown by SDS-PAGE (Fig. 1B). Under non-reducing 
conditions, a shift in size compared to unmodified rec41D3 and rec13D12 was visible for 
both fusion proteins. Under reducing conditions, the antibody light chains remained 
unchanged, while the heavy chains have shifted in size, showing the acquisition of extra 
protein sequences. The presence of the GP4 peptide at the heavy chains of rec41D3 and 
rec13D12 was further confirmed by Western blot analysis using mAb- and peptide-specific 
antibodies (Fig. 1C). 
To further analyze whether rec41D3-GP4 is able to bind to pSn-expressing cells and is 
internalized afterwards, CHO cells expressing pSn (CHO-pSn) and primary macrophages 
were incubated with the fusion protein for one hour at 37°C. As shown in Figure 1D, the GP4 
peptide was co-internalized together with rec41D3 in both cell types. As a control, CHO-pSn 
and macrophages were incubated with irrelevant, isotype matched rec13D12-GP4 fusion 
proteins. No binding and internalization was observed with this protein. Together, these data 
show that rec41D3-GP4 and rec13D12-GP4 proteins remain functional and both contain the 
GP4 sequences at the C-terminus of the heavy chain.  
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Figure 1. Development of fusion proteins rec41D3-GP4 and rec13D12-GP4 and analysis of their 
internalization into pSn-expressing cells.  
(A) Primary amino acid sequence following the C-terminus of the antibodies’ heavy chains. GP4 
peptides are indicated in bold (B) SDS-PAGE analysis of protein G purified rec41D3-GP4 and 
rec13D12-GP4 constructs in comparison to unmodified rec41D3 and rec13D12 respectively (C) 
Western blot analysis of rec41D3-GP4 and rec13D12-GP4 samples in comparison to unmodified 
rec41D3 and rec13D12 respectively using mouse immunoglobulin-specific goat polyclonal antibodies 
(GαM) or a GP4-specific mAb (αGP4). (D) Confocal microscopical analysis of rec41D3-GP4 
internalization in CHO-pSn cells and primary macrophages (mφ) in comparison to its irrelevant control 
rec13D12-GP4. Cells were incubated with rec41D3-GP4 or rec13D12-GP4 for one hour at 37°C, fixed, 
permeabilized and stained with FITC-labelled goat anti-mouse IgG1 in addition to mouse anti-GP4 
(IgG2a) in combination with AF594-labelled goat anti-mouse IgG2a. Images represent a single 
confocal z-section through the middle of the cell. M, protein marker; -, antibody without GP4; +, 
antibody with GP4. Scale bar: 5µm.   
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4.1.3.2 VACCINATION DOSE EXPERIMENT WITH REC41D3-GP4   
To determine the optimal dose to administer in a large vaccination experiment, a preliminary 
experiment was performed with nine pigs randomly assigned to three treatment groups. The 
first group served as a mock-vaccinated control group and received one i.m. injection of 
500µl PBS. The second group received 50µg rec41D3-GP4 in PBS and the third group 
500µg in PBS. All pigs were challenged with LV seven weeks post vaccination. 
GP4 peptide-specific IgG response 
Antibodies against the GP4 peptide were detected by ELISA. As shown in Figure 2A, none of 
the animals showed detectable levels of peptide-specific antibodies in their serum after 
vaccination. Upon challenge however, a clear difference was noticed between the three 
treatments. Two weeks post challenge, all animals that received a 500µg dose of rec41D3-
GP4 showed high titres of peptide-specific antibodies, which remained as high during the 
rest of the experiment. For the 50µg treatment group, one pig responded as strong as the 
500µg group starting from two weeks post challenge, one pig responded weakly at two 
weeks post challenge and its antibody titre rose during the rest of the experiment, while the 
last pig only showed GP4 peptide-specific antibodies at four weeks post challenge. For the 
PBS treatment group, peptide-specific antibodies were only detected in two out of three pigs 
at four weeks post challenge. These observations are reflected in the analysis of the AUC as 
shown in Figure 2A.   
Virus neutralization 
To evaluate the ability of the vaccine to inhibit virus replication in vitro, serum samples were 
used in a single replication virus-neutralization test with LV on primary macrophages. As 
shown in Figure 2B, no VN antibodies were detected after vaccination except for one animal 
in the 50µg group at three weeks post vaccination. After viral challenge however, VN 
antibodies appeared at two weeks post vaccination in all 50µg or 500µg vaccinated animals, 
with the highest titres in the 500µg group. VN antibodies could not be detected in the PBS 
vaccinated animals at any time point tested. These results led to a significant difference in 
AUC between the mock-vaccinated animals and the group that received the 500µg dose of 
rec41D3-GP4 (Fig. 2B).   
Viremia 
All animals in all groups showed viremia after challenge (Fig. 2C). Viral clearance from blood 
however was observed in the 500µg group at one week post challenge for two animals and 
at two weeks post challenge for the third animal. In the 50µg group, one animal showed viral 
clearance after one week, another after three weeks and the third animal only after four 
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weeks. In the PBS group, all animals showed viral clearance as well, though only at three 
weeks post challenge.  
Overall, it is clear that a single dose of rec41D3-GP4 has beneficial effects on the induction 
of antibodies against the GP4 neutralizing epitope after challenge, as well as on the induction 
of neutralizing antibodies after challenge. In addition, a reduction of the duration of viremia 
was noted in all animals which received a 500µg dose of rec41D3-GP4, but not in the group 
with a 50µg dose.  
 
Figure 2. Analysis of serum antibody responses and viremia after vaccination with either 50µg 
or 500µg rec41D3-GP4 or PBS as mock-control.  
Peptide-specific IgG antibody titres (log2) (A), serum neutralizing antibody titres (log2) (B) and virus 
titres (log10 TCID50  ml-1) (C) together with their respective AUC are shown. Symbols represent 
individual animals and lines represent median (A) or mean titres (B,C) calculated on all animals 
present in each group. Bars indicate mean AUC ± SEM for each group. The dotted line represents the 
limit of detection. Data represent means of at least two independent experiments. ↑ = challenge, * = P 
< 0.1, ** = P < 0.05.  
 
4.1.3.3 VACCINATION EXPERIMENT WITH REC41D3-GP4 IN COMPARISON TO THE 
NON-TARGETING CONSTRUCT REC13D12-GP4 
 
As it is clear that the 500µg rec41D3-GP4 dose outperformed the 50µg dose in the previous 
experiment, this dose was selected for a larger vaccination experiment. As the 50µg dose 
also had some beneficial effects in some pigs, but showed variation, a low dose of 150µg 
rec41D3-GP4 was added in this experiment. To be able to assign the beneficial effects to 
pSn targeting, animals receiving a 150µg or 500µg dose of the non-targeting rec13D12-GP4 
control construct were included in the experiment as well.   
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GP4 peptide-specific response 
As shown in Figure 3A, no animals had detectable levels of peptide-specific IgG antibodies 
after vaccination. After challenge however, a clear difference was noticed between the 
different treatment groups. Animals that received a 500µg rec41D3-GP4 dose responded the 
earliest starting from 10 days post challenge, followed by the 500µg rec13D12-GP4 and the 
150µg rec41D3-GP4 group at two weeks post challenge. Animals that received a 150µg 
rec13D12-GP4 dose or the PBS mock-control responded the latest, starting from three 
weeks post challenge. At four weeks post challenge, all treatment groups reached 
comparable serum antibody titres. When the AUC values were analysed, it was clear that 
although differences between groups were not statistically significant, a trend is present 
towards the best response with the highest rec41D3-GP4 dosage. 
Peptide-specific IgM antibody titres were analysed as well. As shown in Figure 3B, all 
treatment groups displayed an IgM response that arose earlier than the IgG response and 
lasted for two to three weeks. No significant differences between the AUC of different 
treatment groups were observed.  
Virus neutralization 
As shown in Figure 3C, no VN antibodies were detected after vaccination. After viral 
challenge however, VN antibodies were detected in all treatment groups except for the PBS 
mock-control. Antibody titres and the number of animals responding were however low in 
most treatment groups except for the 500µg rec41D3-GP4 group. Overall, the VN antibody 
response appears to be biphasic, with a rise in antibody titre until two weeks post challenge, 
a drop at three weeks post challenge and another rise starting from four weeks post 
challenge. When AUC values were analysed, a significant difference was noted between 
mock-vaccinated animals and the 500µg rec41D3-GP4 group. 
Viremia and viral load 
All animals in all groups showed viremia after challenge (Fig. 3D). For the 150µg rec41D3-
GP4 group, viral clearance from blood was observed in five out of six animals at seven days 
post inoculation. This resulted in a significant difference in AUC with the 500µg non-targeting 
control group. Although this was the only statistically significant difference, it is to be noted 
that the pSn-targeting doses overall showed lower AUC than the non-targeting controls. For 
the 500µg rec41D3-GP4 group, a similar virus titre as the group receiving the 150µg dose 
was expected based on our preliminary dose experiment, but however could not be repeated 
in this experiment. As viral titres overall were low, it was decided to include a PCR analysis 
of serum samples to determine the viral load (RNA copies ml-1 serum, Fig. 3D). Here, the 
two groups having the smallest AUC values were the 150µg and 500µg pSn-targeting 
groups, though differences were not statistically significant. 
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Figure 3. Analysis of serum antibody responses, viremia and viral load after vaccination with 
either 150µg or 500µg rec41D3-GP4, 150µg or 500µg of the non-targeting control rec13D12-GP4 
or PBS as mock-control.  
Peptide-specific IgG antibody titres (log2) (A), peptide-specific IgM antibody titres (log2) (B), serum 
neutralizing antibody titres (log2) (C), and virus titres (log10 TCID50 ml-1) and viral load (log10 RNA 
copies ml-1) (D) together with their respective AUC are shown. Symbols represent individual animals 
and lines represent median (A,B) or mean titres (C,D) calculated on all animals present in each group. 
Bars indicate mean AUC ± SEM for each group. The dotted line represents the limit of detection. ↑ = 
challenge, * = P < 0.1, ** = P < 0.05. 
 
4.1.4 DISCUSSION 
Sn-expressing macrophages are gaining interest as targets for vaccination strategies, as 
they may act as specialized antigen presenting cells involved in the antigen transport chain, 
as recently reviewed by Martinez-Pomares and Gordon [8]. Like DCs, Sn-expressing 
macrophages have been shown to be able to prime naive lymphocytes [27, 28]. In addition, 
their location in spleen and lymph nodes at the borders of circulating fluids, makes them ideal 
target candidates to achieve a high antigen load at the sites where effective immune 
responses are generated. Also, the restricted expression pattern of Sn can prevent removal 
of antigen by irrelevant cells not involved in antigen presentation. This can be a major asset, 
as the most promising DC receptor targets to induce humoral immunity appear to be those 
that show the most selective expression pattern [7]. Indeed, targeting antigen to Clec9A-
expressing DCs does not seem to require the addition of an adjuvant to induce antibody 
responses, while targeting to DEC-205 does [29-32]. One proposed explanation for this 
phenomenon is that absence of removal of antibody-antigen complexes by irrelevant cells 
leads to a sustained antigen presentation which promotes the generation of follicular helper T 
cells driving B cell germinal centre development, while ensuring antigen is available to B cells 
as well as the antigen processing DCs [7]. Targeting antigens to Sn-expressing 
macrophages might in a similar way represent a way of inducing immunity without the need 
to add strong adjuvants to the vaccine formulation. Previously, we have made use of a pSn-
specific mAb to target the model antigen HSA to pSn-expressing macrophages, which 
resulted in an enhanced antibody response to HSA after a single, non-adjuvanted injection 
[9]. To date however, no studies have been performed in which an actual pathogen-derived 
antigen is targeted to the Sn-expressing macrophages and the immune response is 
evaluated in a challenge model. Hence we selected a linear epitope on GP4 of PRRSV, 
known to be a target of virus-neutralizing antibodies [18]. Four copies of the epitope where 
genetically fused to a previously developed pSn-targeting recombinant antibody [10]. The 
incorporation of four copies of the epitope at each heavy chain was chosen over one, as it 
has been shown previously that peptide repeats can enhance peptide-specific immune 
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responses [33, 34]. The resulting fusion proteins were subsequently used to immunize pigs, 
after which a viral challenge was performed. 
Upon vaccination, no peptide-specific IgG responses could be detected. After viral challenge 
however, it was clear that the IgG response against this specific peptide developed more 
rapidly compared to an infection in non-immunized animals. Clearly, some level of B cell 
priming had occurred. This is of interest, as it has been shown that targeting antigen towards 
most DC receptors in the absence of adjuvant induces tolerance to recall antigen [35, 36]. In 
agreement with targeting antigen to Clec9A on DCs however [7], targeting antigen to Sn in 
the absence of adjuvant seems to be able to prime the immune system for robust antibody 
responses to recall antigen. However, we cannot ignore the observation that a high dose of 
the non-targeting control construct accelerated the onset of the peptide-specific antibodies 
after viral challenge as well. Although we cannot state a definite reason for this phenomenon, 
irrelevant mAb might engage with Fc receptors on antigen presenting cells, including Sn-
expressing macrophages in the lymph nodes. Immune-complexes have been shown before 
to be captured by Sn-expressing macrophages and to be subsequently delivered to lymph 
node B cells [37]. Nevertheless, the B cell priming observed seemed to be the most efficient 
with the highest pSn-specific targeting dose administered, as IgG titres in this group rose 
most rapidly. Although we cannot exclude the possibility that other antigen presenting cells 
were involved in the priming of the immune system, a beneficial effect of Sn-directed 
targeting cannot be neglected. This observation is in agreement with previous reports 
showing that antigen delivery to Sn-expressing macrophages enhances the humoral immune 
response and drives B cell affinity maturation [9, 38-40].  
The observation that no peptide-specific response was generated after vaccination however, 
was rather disappointing, as we previously showed that a single, non-adjuvanted injection of 
HSA linked to an antibody generated a HSA-specific antibody response [9]. Of course, 
generation of antibodies towards a peptide represents a bigger challenge compared to 
generation of antibodies towards an entire protein. Firstly, an entire protein contains T-cell 
epitopes besides B-cell epitopes, which provide the necessary T-cell stimulation for efficient 
antibody induction. Our reasoning however was that the recombinant antibody would be a 
source of these necessary T-cell epitopes. In the future, it might be interesting to include an 
additional epitope, more precisely a PADRE epitope which is engineered to bind most 
common HLA-DR molecules with high affinity and acts as a powerful immunogen [41]. Few 
studies have however been performed using a PADRE epitope in pigs, so the question if 
similar efficiencies are reached in pigs remains to be elucidated. As more information on 
swine SLA molecules is however being continuously generated, the development of a swine-
specific PADRE epitope might not be too far away in the future. Apart from T-cell help, also 
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the accessibility of the B cell epitope for B-cell receptors is of great importance. Although we 
showed in vitro that the B-cell epitope is accessible for a mAb recognizing this epitope, we 
cannot conclude that the conformation in vivo allows engagement with B-cell receptors. 
Clearly, more research is needed to clarify the obtained results in this study and to enhance 
the induction of a peptide-specific IgG response after immunization.   
Besides the peptide-specific antibody response, also the serum neutralizing response was 
monitored. A significant difference was observed between PBS mock-vaccinated animals 
and animals that received a high dose of the pSn-targeting construct. This rapid neutralizing 
antibody response observed after challenge clearly shows that some level of boosting 
immune responses immediately after challenge had occurred. Also, this rapid neutralizing 
antibody response might account for the initial reduction of viremia observed immediately 
after challenge. Unfortunately however, after an initial rise of neutralizing antibody titre in the 
first two weeks after challenge, a drop in antibody titre is observed at three weeks post-
challenge, which might be attributed to suppression of neutralizing antibody responses by 
viral replication. In this respect, it might be interesting to perform a booster vaccination before 
viral challenge, so as to be able to limit viral replication to a much lower level. A booster 
vaccination might be able to generate effective immune responses before challenge. In 
addition, it might also be interesting to study the effect of the addition of adjuvant to the 
vaccine formulation, as co-administration of maturation stimuli could also enhance the 
induction of effective immune responses before challenge.  
Although the difference in serum neutralizing response between PBS and targeting construct 
vaccinated animals was significant in both animal experiments, no clear correlation could be 
drawn between the peptide-specific response and the virus neutralizing response. In our first 
experiment, peak neutralization coincides with the highest obtained peptide-specific IgG 
antibody titre, but later on this antibody titre remains as high while the neutralizing activity 
declines. In our second animal experiment, one animal showed a high neutralizing activity at 
day 42, while no peptide-specific IgG response could be monitored. Therefore, it was 
decided to examine the peptide-specific IgM response as well, but no significant differences 
between groups could be detected. The animal with the highest neutralizing antibody 
response in particular did have detectable levels of peptide-specific IgM antibodies in its 
serum, but two other animals of the same group showed higher peptide-specific IgM 
antibodies while not showing any PRRSV-neutralizing response. Also, no differences could 
be observed between groups in IPMA antibody titres (data not shown), which was to be 
expected as IPMA assays mostly detect antibodies against the nucleocapsid protein [42]. 
Together, these data show that an increase in virus neutralizing activity after viral challenge 
is obtained by administering a single 500µg dose of our pSn-targeting construct, but it is 
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difficult to correlate this with the presence of GP4 peptide-specific antibodies. Given the 
complex nature of PRRSV protective immunity however, the underlying cause of this lack of 
correlation may be diverse. In addition, the lack of neutralizing capacity of the GP4 peptide-
specific antibodies in vitro is perhaps not surprising. When focussing on only one GP4 
epitope, antibody titres might have to be exceptionally high to be able to cover enough GP4 
molecules on each virion to inhibit infection. Of interest, we indeed observed in vitro that 
antibodies against our epitope purified from a PRRSV-infected pig were able to inhibit virus 
infection in a concentration-dependent manner, but that a high antibody concentration 
(500µg/ml) was necessary to yield a more than 90% reduction of infected cells [20]. The 
antibody titres obtained in our experiments therefore, although reaching a maximum of 14.64 
log2 in ELISA readouts, are probably still insufficient to efficiently inhibit viral infection of 
primary macrophages.  
Going one step further towards in vivo relevance, viremia and viral load were examined. 
Here, a minor beneficial effect was observed for both 150µg and 500µg pSn-targeting 
groups. Although differences were not statistically significant, it should be noted that these 
two groups show the smallest AUC, especially when analysing viral load. Although a full 
protection was not observed, it is still clear that targeting of the viral epitope to pSn did have 
some beneficial effects on the anti-viral immune response. More research is clearly needed 
to find out if the vaccination efficacy can be enhanced. 
In conclusion, targeting the GP4 neutralizing epitope towards pSn-expressing macrophages 
improves the peptide-specific IgG antibody response upon challenge, enhances the virus-
neutralizing response and displays a minor beneficial effect on protection against viral 
challenge. Sn-directed targeting thus remains interesting to explore as a vaccination 
strategy. Obviously however, more research is needed to find out if vaccine efficacy can be 
enhanced. For PRRSV in particular, development of rationally designed polypeptide vaccines 
remains an interesting path to follow, as PRRSV is known to ‘fool’ immunity for instance by 
displaying an immunodominant decoy epitope adjacent to a major neutralization epitope and 
additionally by glycan shielding of that neutralization epitope [43, 44]. The real challenge 
however will be to identify protective B- and T-cell epitopes of PRRSV which are conserved 
and thus can confer broad protection against various field strains [17]. Until such a good and 
encompassing knowledge about PRRSV neutralizing epitopes present on the different viral 
glycoproteins is known, development of epitope based PRRSV vaccines remains elusive.  
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4.2.1 INTRODUCTION 
 
Surgical castration of male piglets is common practice in pig farming to prevent aggressive 
behaviour and the occurrence of an unwanted meat odour known as boar taint [1]. Animal 
welfare concerns however, are increasing the pressure on pig producers to stop this practice 
[2]. Presently, surgical castration is being questioned in the European Union and major 
European pork chains committed themselves to voluntarily end this practice by 2018 [3]. A 
number of alternatives have been considered to address the issue, including surgical 
castration with anaesthesia (local or general) and/or analgesia, immunocastration and raising 
entire male pigs [4]. Of these alternatives, immunocastration appears to be the most 
promising strategy, as it improves growth performance in comparison to surgical castrates [5-
7] while reducing the aggressive behaviour displayed by entire males.   
Immunocastration relies on the induction of antibodies against GnRH which prevent GnRH 
from binding to its pituitary receptor. This disruption of the hypothalamic-pituitary-gonadal 
axis disrupts the production of testicular steroids, including androstenone (Fig. 1). 
Androstenone and skatole are the two primary substances responsible for the occurrence of 
boar taint when accumulated in porcine adipose tissue. The reduction of skatole, produced in 
the intestine, by immunocastration is most likely due to enhanced metabolic clearance by the 
liver after suppressed steroid production, as occurs in surgically castrated pigs [8]. 
 
Figure 1. Schematic illustration of the production of 
androstenone. 
Gonadotropin-releasing hormone (GnRH) is secreted by 
the hypothalamus and stimulates the anterior pituitary to 
secrete luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH). Stimulation of the testes especially by LH 
is responsible for the production of androstenone. Figure 
adapted from [9]. 
 
 
 
 
In Europe, Improvac® (Pfizer Animal Health) is a commercially available immunocastration 
vaccine. It is composed of a GnRH analogue bound to the surface of diphtheria toxin, and 
combined with a particulate adjuvant, Diethylaminoethyl (DEAE)-Dextran. This vaccine is 
administered in a prime-boost schedule, at least 4 weeks apart, with the final dosis 
administered 4-6 weeks before slaughter. Special equipment, the Improvac® vaccinator gun, 
is required to prevent self-injection, thereby injecting the vaccine in the skin of the pigs. 
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Tissue reactions due to injection of the vaccine have been observed in 15 to 20% of injection 
sites [5]. The efficiency of the vaccine in reducing boar taint is high, although in a field study 
including 319 vaccinated boars, 2,5% and 2% of the vaccinated pigs still had values above 
the threshold for androstenone and skatole, respectively [4]. Clearly, some room for 
improvement of the vaccine is left. 
The biggest hurdle to overcome in the development of an immunocastration vaccine is the 
low immunogenicity of GnRH. Being a self antigen, strong immunostimulatory compounds 
are needed to trigger the development of a GnRH-specific antibody response. An alternative 
to this approach might be to target the peptide directly to APCs. Indeed, targeting antigen to 
Clec9A on DCs has been shown to induce antigen-specific antibody responses without the 
need to add adjuvant to the vaccine formulation [10-12]. One proposed explanation for this 
phenomenon is the restricted expression pattern of Clec9A [10]. This restricted expression 
pattern prevents removal of antibody-antigen complexes by irrelevant cells, which leads to a 
sustained antigen presentation. This sustained antigen presentation then promotes the 
generation of follicular helper T cells which drive B cell germinal centre development, while 
ensuring antigen is available to B cells as well as the antigen processing DCs. Targeting 
antigens to Sn-expressing macrophages might in a similar way represent a way of inducing 
immunity without the need to add strong adjuvant to the vaccine formulation. Previously, we 
have shown that antibody responses towards the model antigen HSA can be improved by 
using a pSn-specific mAb to target HSA towards pSn-expressing macrophages [13]. To 
circumvent the drawbacks associated with the chemical linkage of antigens, we recently 
developed a pSn-specific recombinant antibody [14]. This antibody allows targeted delivery 
of peptides or proteins towards pSn-expressing macrophages and thus represents an 
elegant tool to evaluate if targeting GnRH towards pSn-expressing macrophages can induce 
a GnRH-specific antibody response in the vaccinated animals, which ultimately might lead to 
immunocastration. 
Although non-mammalian production systems often result in high yields, mammalian 
systems are preferred for the production of many therapeutic proteins, especially those that 
require post-translational modifications such as glycosylation [15, 16]. For recombinant 
antibodies in particular, CHO and mouse NS0 and Sp2/0 cell lines are the most commonly 
used expression hosts [17, 18]. To be able to rapidly scale up productions, suspension cell 
cultures able to grow at high densities are preferred. In addition, chemically defined, serum-
free media – with no animal-derived components – have become the industry standard. 
Invitrogen’s Gibco CHO-S cells were the first suspension-adapted CHO cell line derivative 
available commercially and are accompanied by their own chemically defined, serum-free 
Chapter 4.2 | Development of a cell line expressing rec41D3-GnRH 
 
 96 
medium. In this study, we made use of this CHO-S cell line to develop suspension CHO cell 
lines expressing recombinant antibody-GnRH fusion constructs. 
 
4.2.2 MATERIALS AND METHODS 
 
4.2.2.1 CELL CULTURE  
HEK-293T were grown in DMEM medium supplemented with 10% heat-inactivated FBS, 2 
mM L-glutamine and 1 mM sodium pyruvate. CHO-K1 cells and CHO-K1 cells stably 
expressing recombinant pSn [19] were cultivated in F-12 medium supplemented with 10% 
FBS and 1mM sodium pyruvate. A mixture of antibiotics was added to both cell cultures and 
cell cultures were kept in a humidified 5% CO2 atmosphere at 37°C. Freestyle
TM CHO-S cells 
(Life Technologies) were cultivated in FreestyleTM CHO expression medium supplemented 
with 8 mM L-glutamine and 50000 units/l of penicillin and 50000 µg/l of streptomycin. Cell 
cultures were kept in a humidified 8% CO2 atmosphere at 37°C. 
 
4.2.2.2 PRODUCTION AND PURIFICATION OF REC41D3 AND REC13D12  
Construction of the plasmids encoding the pSn-targeting rec41D3 and its irrelevant isotype 
controle rec13D12 was described previously [14]. HEK-293T cells were transiently 
transfected with the plasmids using calcium phosphate and cultured in DMEM supplemented 
with 10% IgG depleted, heat-inactivated FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 
and a mixture of antibiotics in a humidified 5% CO2 atmosphere at 37°C. Culture supernatant 
was collected and recombinant IgG were purified from the supernatant using standard 
protein G sepharose chromatography following the manufacturer’s instructions (GE 
Healthcare). Fractions of the eluate containing the purified protein were pooled and the buffer 
was exchanged to DPBS (Life Technologies) by dialysis. Purified protein was stored at -70°C 
until use.  
 
4.2.2.3 DEVELOPMENT OF CHO-S CELLS EXPRESSING REC41D3- OR REC13D12-
GNRH  
 
To generate both rec41D3- and rec13D12-GnRH plasmids, a (G4S)2-GnRH DNA sequence 
was synthesized (Genscript Inc.) and introduced at the 3’ end of the heavy chain sequence 
of the antibodies by restriction enzyme digestion and ligation. Sequencing confirmed the 
fusion constructs were correctly assembled. CHO-S cells were transfected according to the 
manufacturer’s instructions (Life Technologies) using the cationic lipid-based FreestyleTM 
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MAX transfection reagent. 24 hours later, 600µg/ml Geneticin (Life Technologies) was added 
to the culture medium. Standard subculturing of cells was maintained and 7 days later, cells 
were seeded at 300 cells/well in 96-well plates. Control cells, mock-transfected and equally 
exposed to 600µg/ml Geneticin, had all died 7 days post mock-transfection. When 96-well 
plated cells reached confluency, culture supernatant was collected for ELISA screening and 
cells showing recombinant antibody expression were transferred to 24-well plates and 6-well 
plates afterwards. When confluency in a 6-well was obtained, cells were single cell cloned in 
96-well plates, while the remainder of the cells were stored in liquid nitrogen as back-up. 
Single cell clones were again screened by ELISA and cultured until confluency in a 6-well 
was obtained and cells were stored in liquid nitrogen. The 5 most promising clones of each 
fusion construct were kept in culture and scaled up to a 125 ml shaker flask (VWR 
international). Cells were not subcultured anymore to allow maximum protein accumulation in 
the shaker flasks. Cell viability was checked and supernatant was collected daily until all cells 
had died. Supernatants were checked on ELISA and western blot to determine the optimal 
time of harvesting supernatant. Subsequently, the best clone for rec41D3- and rec13D12-
GnRH was selected for further production of the fusion constructs.   
 
4.2.2.4 ENZYME-LINKED IMMUNO SORBENT ASSAY (ELISA) 
 
MaxiSorp® 96-well plates (Nunc) were incubated overnight with 0.1µg of goat anti-mouse 
polyclonal antibodies (H+L, Sigma) in PBS. Plates were subsequently washed and blocked 
with blocking buffer, containing 1% bovine serum albumin (R&D systems) and 0.05% Tween-
20. Ten-fold serial dilutions of supernatants in blocking buffer were subsequently incubated 
on the coated plates, followed by washing and incubation with peroxidase-labelled polyclonal 
goat-anti-mouse antibodies (Dako). Plates were washed and developed with a substrate 
solution (R&D systems), after which the reaction was stopped with 1M H2SO4 and the optical 
density at 450nm (OD450) was measured. All wash steps were performed with PBS with 
0.05% Tween-20, and all incubation steps were carried out at room temperature for 1h. To 
be able to determine expression levels in the supernatants, a standard curve was set up 
using mouse IgG antibodies (Sigma).    
 
4.2.2.5 PRODUCTION AND PURIFICATION OF REC41D3- AND REC13D12-GNRH 
 
The production of fusion constructs was scaled up by using 850cm² roller bottles (Corning 
Incorporated) put upright on an orbital shaker, each containing 600ml of cell culture, and kept 
in a humidified 8% CO2 atmosphere at 37°C. Cell viability was checked routinely and 
supernatant was harvested when all cells had died (2-3 weeks). Cell supernatants were 
Chapter 4.2 | Development of a cell line expressing rec41D3-GnRH 
 
 98 
stored at 4°C after addition of 0.2mM Pefabloc® (Sigma-Aldrich) to avoid proteolytic 
degradation until purification was performed. Fusion proteins were purified from the 
supernatant using standard protein G sepharose chromatography following the 
manufacturer’s instructions (GE Healthcare). Fractions of the eluate containing the purified 
protein were pooled and the buffer was exchanged to DPBS (Life Technologies) by dialysis. 
Purified protein was stored at -70°C until use. 
 
4.2.2.6 IMMUNOFLUORESCENCE STAINING AND CONFOCAL LASER SCANNING 
MICROSCOPY 
 
To evaluate expression of recombinant antibodies by single cell cloned CHO-S cells, cells 
were seeded on poly-L-lysine (Sigma) coated coverslips, fixed with 4% (w/v) 
paraformaldehyde (Sigma), permeabilized using 0.5% (w/v) saponin (Sigma) and stained 
with FITC-labelled goat-anti-mouse IgG. Cell nuclei were visualized using Hoechst 33342 
(Life Technologies).  
To evaluate pSn binding and endocytosis, CHO or CHO-pSn cells were seeded on poly-L-
lysine (Sigma) coated coverslips and incubated with 2µg/200µl purified rec41D3-GnRH or its 
isotype control rec13D12-GnRH for 1h at 37°C. Cells were then fixed with 4% (w/v) 
paraformaldehyde (Sigma), permeabilized using 0.5% (w/v) saponin (Sigma) and stained 
with AF594-labelled goat-anti-mouse IgG1 in addition to serum from an Improvac® 
immunocastrated pig in combination with FITC-labelled goat-anti-swine IgG. Cell nuclei were 
visualized using Hoechst 33342 (Life Technologies).  
Z-section images of samples were acquired using a Leica TCS SPE-II laser scanning 
spectral confocal system (Leica Microsystems GmbH) linked to a Leica DM2500 microscope 
(Leica Microsystems GmbH). Image acquisition was done using the Leica LAS AF confocal 
software package. 
 
4.2.2.7 SDS-PAGE, COOMASSIE BLUE STAINING AND WESTERN BLOT ANALYSIS 
OF REC41D3- AND REC13D12-GNRH 
 
Samples of purified proteins were mixed with (non-)reducing Laemmli buffer, boiled for 5 min 
and subjected to SDS-PAGE (6% non-reducing gel, 10% reducing gel) using a BioRad Mini 
Protean 3 system. For Coomassie Blue staining, the SDS-PAGE gel was incubated 
successively in Ultra Pure water, ImperialTM protein staining solution (Thermo Scientific) and 
Ultra Pure water as destaining solution. Alternatively, for Western blot analysis, proteins were 
transferred from the SDS-PAGE gel to a PVDF membrane (Membrane Hybond-P, GE 
Healthcare) via Western blotting (BioRad Mini Trans Blot). The membrane was blocked 
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overnight in PBS + 0.1% Tween 20 + 5% skimmed milk. Detection of recombinant antibodies 
was performed by subsequent incubation of the blot with peroxidase-labeled polyclonal goat 
anti-mouse antibodies (Dako), followed by visualization using enhanced chemiluminescence 
(ECL; GE Healthcare). Alternatively, GnRH peptides were detected using serum from an 
Improvac® immunocastrated pig in combination with peroxidase-labeled goat anti-swine 
antibodies (Jackson ImmunoResearch), followed by ECL visualization. 
 
4.2.3 RESULTS 
 
We previously described the development of a pSn-specific recombinant antibody rec41D3 
and an irrelevant isotype control rec13D12 [14]. In the present study, we generated fusion 
constructs of rec41D3 and rec13D12 containing four repeats of GnRH, separated from each 
other by a short spacer and separated from the antibodies by a GS linker. As GnRH contains 
at its N-terminus an uncommon amino acid pyroglutamic acid, which cannot be encoded as 
such in the genetic sequence, we chose to encode glutamine, of which pyroglutamic acid is a 
derivate. As previously shown by Turkstra et al., this N-terminal pyroglutamic acid can be 
replaced by alanine without negatively affecting immunocastration efficacy [20]. The amino 
acid sequence following the antibodies’ heavy chains is shown in Figure 2A.    
Suspension CHO cells were transfected with the rec41D3- or rec13D12-GnRH plasmid and 
exposed to Geneticin (G418) selection pressure 24 hours later. Transfected cells were 
subcloned twice as described in the methods section. Single cell clones were screened for 
high producers by ELISA and finally the best clone for both rec41D3- and rec13D12-GnRH 
was selected for further production of the fusion constructs. As shown in Figure 2B, both 
clones clearly showed expression of the recombinant antibody. To scale up productions, 
CHO-S cells were cultivated in roller bottle flasks put upright on an orbital shaker in a 
humidified 8% CO2 atmosphere at 37°C. Obtained yields of the fusion proteins were 500µg/l 
and 2mg/l for rec41D3- and rec13D12-GnRH respectively. 
Protein G purification of cell culture supernatants clearly yielded intact fusion proteins as 
shown by SDS-PAGE (Fig. 2C). Under non-reducing conditions, a shift in size compared to 
unmodified rec41D3 and rec13D12 was visible for both fusion proteins. Under reducing 
conditions, the antibody light chains remained unchanged, while the heavy chains shifted in 
size, showing the acquisition of extra protein sequences. The presence of the GnRH peptide 
at the heavy chains of rec41D3 and rec13D12 was further confirmed by Western blot 
analysis using mAb-specific antibodies and serum from an Improvac® immunocastrated pig 
(Fig. 2D).  
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Figure 2. Development of fusion constructs rec41D3-GnRH and rec13D12-GnRH and analysis 
of their internalization into pSn-expressing cells.  
(A) Primary amino acid sequence following the C-terminus of the antibodies’ heavy chains. GnRH 
peptides are indicated in bold. (B) Confocal microscopical analysis of fusion construct expression by 
single cell cloned CHO-S cells. Cells were plated on poly-L-lysine coated coverslips, fixed, 
permeabilized and stained with FITC-labelled goat-anti-mouse IgG. Scale bar: 30µm. (C) SDS-PAGE 
analysis of protein G purified rec41D3-GnRH and rec13D12-GnRH constructs in comparison to 
unmodified rec41D3 and rec13D12 respectively (D) Western blot analysis of rec41D3-GnRH and 
rec13D12-GnRH samples in comparison to unmodified rec41D3 and rec13D12 respectively using 
mouse immunoglobulin-specific goat polyclonal antibodies (GαM) or serum from an Improvac® 
immunocastrated pig (αGnRH). (E) Confocal microscopical analysis of rec41D3-GnRH internalization 
in CHO-pSn cells in comparison to its irrelevant control rec13D12-GnRH and in comparison to staining 
of CHO cells. Cells were incubated with rec41D3-GnRH or rec13D12-GnRH for 1 hour at 37°C, fixed, 
permeabilized and stained with AF594-labelled goat-anti-mouse IgG1 in addition to serum from an 
Improvac® immunocastrated pig in combination with FITC-labelled goat-anti-swine IgG. Images 
represent a single confocal z-section through the middle of the cell. Scale bar: 5µm. M, protein marker; 
-, antibody without GnRH; +, antibody with GnRH.  
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To further analyze whether rec41D3-GnRH is able to bind to pSn-expressing cells and is 
internalized afterwards, CHO cells expressing pSn (CHO-pSn) in comparison to regular CHO 
cells were incubated with the fusion protein for one hour at 37°C. As shown in Figure 2E, 
GnRH was co-internalized together with rec41D3 only in CHO-pSn cells. As a control, CHO 
and CHO-pSn cells were incubated with irrelevant, isotype matched rec13D12-GnRH fusion 
proteins. No binding and internalization was observed with this construct. Together, these 
data show that rec41D3-GnRH and rec13D12-GnRH proteins both contain the GnRH 
sequences at the C-terminus of the heavy chain and can be used in future vaccination 
experiments.  
 
4.2.4 DISCUSSION 
 
In the present study, FreestyleTM CHO-S cells were used to generate suspension CHO cell 
lines expressing antibody-GnRH fusion constructs. Both the pSn-targeting construct 
rec41D3-GnRH and its irrelevant isotype control rec13D12-GnRH were shown to be 
synthesized as fully assembled fusion proteins by the selected clones and could be purified 
from cell supernatants using standard protein G chromatography. In addition, rec41D3-
GnRH, but not rec13D12-GnRH, binds to and efficiently delivers its cargo to pSn-expressing 
cells, generating an elegant tool to evaluate pSn-directed GnRH targeting as an 
immunocastration strategy in future animal experiments.  
The production of a stable cell line starting from FreestyleTM CHO-S cells presents itself with 
a number of advantages. Firstly, CHO cells have been extensively used over the past 
decades for the production of clinical biopharmaceuticals, what makes it likely that regulatory 
approval will be more rapid for a novel CHO-produced biopharmaceutical than for one 
produced in a less well-known cell line [21]. Secondly, its chemically defined serum-free 
medium avoids regulatory issues concerning the use of animal-derived components in 
expression media. In addition, the CHO cell line has been adapted for suspension culture, 
which makes upscaling to larger volumes in for instance fed batch systems further down the 
line much easier. However, these advantages only hold true if a high-producing cell clone 
can be selected. Unfortunately, the cell clones generated in our study by Geneticin selection 
and standard limiting dilution procedures only yield 0.5mg/l for rec41D3-GnRH and 2mg/l for 
rec13D12-GnRH, which is not sufficient in an industrial setting, as cell lines are nowadays 
expected to produce at least 1g/l [22]. This lack of success is however perhaps not 
surprising, as spotting a high-producer clone in a transfected pool of cells has been 
described as “finding a needle in a haystack” [22]. To generate a stable cell line, exogenous 
DNA containing the gene of interest has to be integrated into a transcriptionally active site of 
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the host genome. As the integration is a random event, frequencies of integration at such 
active sites are very low [23]. Furthermore, many integrations take place at chromosomal 
sites susceptible to gene silencing [24]. With a limited number of clones screened, there is 
thus always a great possibility of missing the best candidate. Although a number of 
optimizations to the procedure used in this study can be considered, such as vector 
optimization, site-specific integration, the use of the DHFR or GS system instead of antibiotic 
selection or just the screening of enormous amounts of single cell clones, the procedure will 
always remain a time-consuming and resource-intensive one. For future product 
developments, it might therefore be more interesting to perform transient transfections of the 
CHO cells instead. Transient transfection has also gained increased industrial attention 
lately, as milligram to gram quantities of proteins are often required in the early development 
stages of biopharmaceuticals and precious time is lost when waiting for the generation of a 
stable cell line [25]. Although CHO cells for a long time have not been the host of choice for 
transient gene expression (TGE), because of the higher yields obtainable with low-cost 
transfection reagents in HEK293 cells, major effort has been invested on improving TGE in 
CHO cells, and productivities ranging from 10mg/l to >100mg/l can now be achieved [22]. Of 
interest however, transient transfection of the CHO-S cells used in this study with our pSn-
targeting antibody-GnRH fusion construct using the advised FreestyleTM MAX transfection 
reagent also only yielded 0.5-1mg/l of secreted antibody (data not shown). As this 
transfection reagent is expensive, production of sufficient amounts to perform animal 
experiments would represent an enormous cost. The relatively low-cost polyethylenimine 
(PEI) reagent has recently been successfully used to perform transient transfections of CHO 
cells with high productivity, and might thus represent a better alternative for future projects 
[26]. 
In conclusion, CHO cell lines were developed that express a pSn-targeting antibody-GnRH 
fusion construct or its irrelevant isotype control. The obtained production levels of the 
developed CHO cell lines is however not very high. Nevertheless, antibody-fusion proteins 
can be easily purified from the selected clone supernatants and a high purity is obtained. In 
addition, only purified pSn-targeting antibody-GnRH fusion proteins, and not their irrelevant 
controls, bind to and are internalized into pSn-expressing cells. These proteins can therefore 
be used to evaluate pSn-directed GnRH targeting as an immunocastration strategy in future 
animal experiments.  
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In current-day vaccinology it has become clear that some pathogens require a more rational 
vaccine design, as traditional inactivation or attenuation procedures sometimes fail to yield 
an effective and/or safe vaccine. As such, a wide range of vaccines under development now 
are based on isolated peptides, proteins or polysaccharides of pathogens, or naked DNA 
encoding a protective antigen [1]. These reductionist approaches can result in vaccines that 
are more immunologically defined and display a better safety profile than vaccines based on 
traditional approaches. One hurdle to overcome however, is the limited immunogenicity of 
the isolated antigens used. As such, targeting antigens directly to highly specialized antigen-
presenting cells is gaining increased attention. In this thesis, targeting antigens to 
macrophages via the receptor sialoadhesin (Sn; CD169; Siglec-1) was studied. This APC 
subset is abundantly present in spleen and lymph nodes, where they are strategically 
localized for antigen acquisition and processing [2]. In this part of the dissertation, the main 
results obtained in this thesis will be summarized and discussed in a broader context, with a 
main focus on future vaccine development.        
 
DEVELOPMENT OF A RECOMBINANT ANTIBODY TO TARGET PEPTIDES AND PROTEINS TO 
SN
+
 MACROPHAGES 
 
In Chapter 3 of this dissertation, a recombinant antibody rec41D3 allowing targeted delivery 
of peptides and proteins to Sn-expressing (Sn+) macrophages was developed and compared 
to the native monoclonal antibody 41D3. Rec41D3 was shown to specifically bind to porcine 
Sn with a comparable, high affinity as native 41D3. In addition, rec41D3 induced partial Sn 
endocytosis in primary macrophages and internalized antibody resided for prolonged times in 
early/late endosomes, just like native 41D3. Furthermore, genetic fusion constructs of the 
antibody with a peptide or a protein could be easily developed and the fusion proteins were 
produced by HEK293T cells and purified from the supernatant by standard protein G 
chromatography. Lastly, the peptide and protein fused to rec41D3 were shown to be co-
internalized together with rec41D3 into primary macrophages. For vaccine development 
based on targeting antigens to Sn+ macrophages, some important findings are described in 
the above sentences. First of all, a high specificity and affinity of the targeting molecule 
enhances the probability of an efficient delivery of the antigen to the APC to be targeted. In 
addition, the one-step production process of the antibody-antigen fusion construct can be 
considered a major advantage for practical reasons, as the antigen does not have to be 
produced and purified on its own, followed by chemical linkage to the antibody, but can 
benefit from the easy purification process based on the antibody’s binding capacity for 
protein G. Of course, proper folding of the antigen upon genetic fusion will still have to be 
ensured for each antigen. 
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Upon engagement of rec41D3 with Sn, partial endocytosis is observed in primary 
macrophages, while a substantial amount of rec41D3 remains visible at the cell surface. For 
the generation of humoral immune responses, this partial endocytosis might be of benefit. As 
it is necessary that antigen-specific B cells encounter their cognate antigen in order to 
expand and develop into antibody-forming cells [3, 4], rapid endocytosis of all antigen by the 
APCs might prevent this interaction from happening. Whether the observed partial 
endocytosis is due to the necessity of a high avidity before endocytosis can proceed or due 
to recycling of Sn to the macrophage surface with non-processed or partially processed 
antibody, or both, is unclear at this stage, but in any case, antigen would be available at the 
macrophage surface to be encountered by antigen-specific B cells. As Sn+ macrophages are 
abundantly present in close vicinity to B cells in secondary lymphoid tissue, this 
concentration of antigen by Sn+ macrophages in these tissues might thus be an important 
asset. Sn+ subcapsular sinus (SCS) macrophages, which are localized at the SCS of lymph 
nodes, are known to be important for the capture of specific antigens and the subsequent 
display of these antigens to the underlying B cell follicles, as shown in Figure 1 [5-7].  
 
Figure 1. Multiple modes for the encounter of lymph node follicular B cells with antigen.  
(a) Particulate antigens (such as immune complexes and viral particles) are captured and displayed by 
SCS macrophages and are then encountered directly by cognate B cells or are transported by 
noncognate B cells to follicular dendritic cells (FDCs) for later encounter with cognate B cells. (b) 
Soluble antigens of small hydrodynamic radius (in some cases released from large antigens by 
proteolysis) access the follicle via gaps in the SCS lining or via conduits and are then encountered by 
cognate B cells. (c) Antigens too large to enter passively into lymphatic vessels are carried into the 
follicle-proximal cortex inside DCs and are then recycled to the DC cell surface to enable encounter by 
cognate B cells. Figure adapted from Jason G Cyster [7].  
 
As seen from Figure 1a, SCS macrophages capture antigens by their ‘heads’ protruding into 
the sinus, and transport it via their ‘neck’ tightly inserted across the lymphatic lining cell layer 
towards their long ‘tail’ processes that extend into the underlying follicle. The precise nature 
of this antigen movement however, has not been resolved up till now. Two models are 
proposed where antigen is either transported by translocation or transcytosis, as shown in 
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Figure 2. Either of these two models proposed probably also shows how rec41D3 travels 
upon engagement with Sn. If transcytosis occurs, this might be due to recycling of Sn itself or 
can be initiated by the neonatal Fc receptor (FcRn), which is known to bind internalized 
antibodies in non-degradative endosomes to transport it back to the cell surface [8].  
 
Figure 2. Models for the transport of antigen from the sinus to the follicular surface of the 
subcapsular sinus (SCS) macrophage.  
Particles in the lymph percolate through the SCS and some are captured by unknown receptors on the 
SCS macrophage, whereas excess material reaches medullary sinuses and is phagocytosed and 
degraded by medullary macrophages. In model 1 (top right), particulate antigen is retained on the SCS 
macrophage surface, undergoes fragmentation and moves unidirectionally on the cell surface by 
unknown mechanisms from the SCS to the follicle, where it is displayed to migrating B cells. In model 
2 (bottom right), the particulate antigen is endocytosed into vesicles, transported directionally within 
the cell and then returned to the cell surface for display. Over a period of hours, antigen that is not 
removed by migrating B cells is probably degraded by the SCS macrophage. Figure adapted from 
Jason G Cyster [7].  
 
Once the antigen enters the follicle, it is displayed to migrating B cells. Another question 
remaining however is whether a very high affinity of the targeting antibody for Sn is the best 
choice in this respect. B cells need to be able to process the antigen to allow presentation via 
their MHC molecules in order to obtain the necessary T cell help for the induction of antibody 
production. If the antigen is too strongly attached to the macrophage, this process might not 
be able to proceed efficiently. The question if B cells can acquire antigen that is targeted to 
Sn+ macrophages by rec41D3 will be an important question to resolve. Similarly, in DC 
targeting studies, one is still trying to resolve the question how B cells acquire their antigen 
[3]. Is it antigen not bound to DCs, attached to the DC before endocytosis or taken up by 
DCs that is rerouted to the DC surface [3]? APC targeting strategies for vaccination would 
thus surely benefit from finding an answer to these questions.  
Interestingly, antibodies endocytosed by Sn on primary macrophages reside for prolonged 
times in early endosomes, a cell compartment where loading of antigen onto MHCI 
molecules can occur, a process described as cross-presentation [9]. A recent study by 
Chatterjee et al. targeted identical antigens to either CD40, the mannose receptor or DEC-
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205 by the use of respective mAbs and they found an inverse relationship between 
internalization or antigen degradation and the amount of cross-presentation [10]. Antigens 
destined for more degradative late endosomes were poorly cross-presented relative to the 
same antigens targeted to early endosomes, an effect that was independent of the amount of 
antigen internalized. This observation is also in agreement with reports describing an 
enhanced CD8+ T cell proliferation after antigen targeting towards Sn by the use of Sn-
specific mAbs [11, 12]. This can be of particular interest for vaccination strategies aiming at 
elimination of antigen-bearing cells, e.g. cells that harbour intracellular pathogens or tumour 
cells that express tumour-specific antigens.  
Although early endosomes are the major compartment where antibodies reside after Sn 
internalization, around 30% of internalized antibodies can be detected in late endosomes, 
suggesting acidification of the early endosomes and progression through the endo-lysosomal 
pathway. Here, antigen loading on MHCII molecules can occur which can stimulate the 
activation of CD4+ T cells. Interestingly, liposomes coated by Sn-specific sugar ligands are 
rapidly endocytosed into Sn-expressing cells and predominantly accumulate in lysosomes 
[13]. This might suggest a differential processing of antigen targeted to Sn depending on the 
delivery method of the antigen and/or the size of the particles presented. As an explanation, 
the authors claim that Sn is a recycling receptor and that antibodies bound to Sn are less 
likely to detach from Sn in early endosomes than sugar-coated liposomes. While antibodies 
bound to Sn might thus recycle together with Sn to the cell surface, sugar-coated liposomes 
would detach from Sn in the early endosomes and progress towards lysosomal 
compartments. Further research will have to confirm this. Especially, experiments with sugar-
coated liposomes on primary macrophages could be informative, as previous studies made 
use of mouse Sn transduced CHO cells. Nevertheless, the theory of Sn recycling to the cell 
surface with antibody still bound to it might be an important feature to keep in mind for the 
development of antibody-antigen fusion constructs. While possibly beneficial for the 
interaction with B cells and the induction of CD8+ T cell immunity, the induction of CD4+ T cell 
immunity can be impaired. If detachment of the antigen from Sn in early endosomes is 
needed to induce robust CD4+ T cell responses, adding a cleavable linker between the 
targeting antibody and the antigen might be interesting to pursue. Cleavable linkers are 
intensively studied for tumour targeting purposes where toxins are linked to tumour targeting 
antibodies, as in these studies the toxin should not detach from the antibody before it is 
internalized into the tumour cells to reduce off-target effects of the toxin [14]. Results 
obtained from these studies could potentially be applied to rec41D3-antigen conjugates as 
well to achieve separation of the antigen from the antibody once internalized into Sn+ 
macrophages.      
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EVALUATION OF VIRAL PEPTIDE TARGETING TO pSN USING A PORCINE REPRODUCTIVE 
AND RESPIRATORY SYNDROME VIRUS VACCINATION-CHALLENGE MODEL 
  
In Chapter 4.1 of this dissertation, we evaluated the induced immune response upon 
targeted delivery of a viral peptide to porcine Sn+ macrophages. The viral peptide was a 
linear B cell epitope of glycoprotein 4 (GP4) of PRRSV, which is known to be a target of 
virus-neutralizing antibodies. Four copies of the selected PRRSV epitope were genetically 
fused to the Sn-targeting recombinant antibody rec41D3 or to an irrelevant isotype control 
rec13D12. Fusion proteins were shown to be efficiently purified from HEK293T cell 
supernatants and subsequently, only Sn-specific fusion proteins were shown to bind to and 
to be internalized into Sn-expressing cells. Immunizations of pigs with the resulting fusion 
proteins were carried out after which a viral challenge was performed.  
Upon vaccination, no peptide-specific IgG responses could be detected. This observation 
was rather unexpected, as we previously showed that a single, non-adjuvanted injection of 
HSA linked to an antibody generated a HSA-specific antibody response. Clearly, peptide 
immunizations are more challenging than protein immunizations, and a number of reasons 
for the apparent lack of response in our experiments can be thought of. Firstly, appropriate 
CD4+ T cell epitopes, which are essential for a good immune response, might be lacking from 
the targeting recombinant antibody, thereby impeding the induction of robust T cell help. The 
incorporation of a PADRE epitope engineered to bind most SLA molecules with high affinity 
is an established method to resolve such shortcomings. Secondly, progression through the 
endo/lysosomal pathway of the fusion protein might be insufficient to yield substantial MHCII 
presentation of CD4+ T cell epitopes. Also, a longer serum half life of the HSA construct 
might contribute to the discrepancy with the results obtained with the HSA study. Albumin 
has been shown to engage with FcRn yielding recycling to the extracellular milieu after initial 
internalization [8]. The induction of antibody responses upon antigen targeting towards 
Clec9A on DCs in the absence of adjuvant is also presumed to be due to the long serum half 
life of the targeting construct [15]. Sustained antigen presentation is believed to encourage 
development of follicular helper T cells which drive the B cell germinal centre response [3, 
15]. A longer serum half life of the HSA targeting construct might thus also contribute to the 
better antibody response upon primo vaccination. The FcRn however also engages with the 
Fc parts of antibodies, so it remains to be established whether the HSA construct indeed 
displays a longer serum half life than the fusion proteins used in this study. Another point to 
take into consideration is that the conformation of the antibody-antigen construct in vivo 
might hamper engagement of the antigen with B cell receptors, although we did show in vitro 
that the antigen is accessible for epitope-specific monoclonal antibodies. Another possible 
reason for the lack of peptide specific antibody responses is that no adjuvant was 
incorporated into the vaccine formulation, which can result in insufficient co-stimulatory 
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molecules present on the macrophage surface to strongly prime naive CD4+ T cells. On the 
other hand, if all co-stimulation would be absent, immunology textbooks teach that tolerance 
to recall antigen should be induced instead of a more profound immune response upon 
booster vaccination (in our case a viral challenge) [4]. Taken together, it is clear that some 
priming of the immune response had occurred. A booster vaccination and/or the addition of 
adjuvant to the vaccine formulation can help pave the way towards the induction of effective 
immune responses before viral challenge. After all, neutralizing antibody responses were 
observed soon after viral challenge, and a minor beneficial effect on viral load was 
established as well.    
Interestingly though, the advantage of targeting a PRRSV peptide antigen with rec41D3 to 
Sn+ macrophages in comparison to the linkage of the antigen to an irrelevant isotype control 
antibody was rather modest and largely not statistically significant. Three plausible causes 
for this observation are evident: 1/ the targeting antibody did not reach its receptor efficiently, 
2/ the targeting antibody does not allow efficient transfer of the antigen towards B cells or 3/ 
the irrelevant isotype control antibody is equally taken up and presented by Sn+ 
macrophages. Immunizations were performed intramuscularly. Depending on the size of the 
injected material, efficient drainage into local lymphatics is established. By whole-body 
imaging, subcutaneously injected fluorescent microspheres 20-200 nm in diameter have 
been found to readily gain access to lymphatics, whereas particles 500-2000 nm in diameter 
are inefficient in reaching draining lymph nodes unless carried by cells [7, 16]. Antibodies, 
having dimensions smaller than 20 nm [17], should thus theoretically efficiently drain into 
lymphatics. However, we did not check the drainage in vivo so we cannot exclude the 
possibility of retention of the antibody-antigen fusions at the site of injection. If so, fusion 
constructs would be preferentially taken up by local dendritic cells and transported to the 
draining lymph nodes, and consequently, the immune outcomes of both fusion constructs 
would be comparable. Antigen display by dendritic cells in the absence of DC maturation 
however most often results in the induction of tolerance to recall antigen [18, 19], adding up 
to the unlikelihood of this theory. As mentioned before, the high affinity of rec41D3 (pM 
range, Chapter 3) for Sn, might compromise the transfer of antigen from the Sn+ 
macrophages towards B cells. In this respect, it might be interesting to perform an 
experiment where antibodies with different affinities for Sn are used to target an antigen 
towards Sn+ macrophages. Many effective technologies have been developed to rapidly 
affinity mature antibody molecules [20]. Many are based on display technologies, such as 
phage and yeast display, and involve the creation of a ‘secondary’ library through 
diversification of the V genes, and subsequent selection and screening for higher affinity 
variants [20, 21]. In our case, such technologies could be employed to create antibodies with 
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a range of lower affinities for Sn than rec41D3. Of course, lowering the affinity can also 
compromise efficient targeting, possibly reducing the benefit of a better transfer towards B 
cells. Lastly, immune-complexes have been shown before to be captured by Sn+ SCS 
macrophages and to be subsequently delivered to B cells in the underlying follicles [22]. 
Capture of the immune-complexes was either due to engagement with Fcγ receptors on the 
macrophages, engagement with complement receptor CR3 (also called Mac1 or CD11b-
CD18) or other unknown receptors. Obviously, both fusion constructs used in our study can 
be captured by SCS macrophages in a similar way, reducing the benefit of targeting directly 
to Sn.     
Another point to mention, is that the targeting study conducted was never intended to yield 
an effective PRRSV vaccine. Rather, the vaccination set-up was intended to yield a proof-of-
concept for future vaccine developments based on targeting antigens towards Sn+ 
macrophages. PRRSV has been extensively studied in our laboratory over the past few 
years and animal studies with PRRSV have been routinely performed. In addition, a linear 
epitope was identified on GP4 of PRRSV that is a target for virus-neutralizing antibodies [23, 
24]. This epitope thus seemed an ideal candidate to test our targeting vaccine potential in a 
vaccination-challenge set-up. For the development of an effective PRRSV vaccine however, 
this epitope has some drawbacks. This epitope has been shown to be part of a highly 
variable and evolutionary flexible region [25, 26], and as a result, antibodies against this 
peptide would only show neutralizing activity against homologous virus. Furthermore, the 
GP4 epitope has been shown to be highly susceptible to antibody-mediated selective 
pressure in vitro [23], and the emergence of antibody-escape mutant viruses has later been 
shown in vivo as well [27]. To analyze if such phenomenon had occurred in our experiment, 
synthesized ORF4 cDNA of serum samples of day 31, 33, 38 and 49 for the 500µg rec41D3-
GP4 group and of day 49 for all other treatment groups were sequenced. All ORF4 
sequences obtained were identical to the original challenge virus, except for one animal in 
the 500µg pSn-targeting group (□, Figure 3, Chapter 4.1) at day 49, which displayed a 
mutation from serine to leucine in our targeted epitope (FRPHGVLAAQEKISFG), most likely 
affecting the capacity of antibodies generated against the original sequence to neutralize this 
mutant virus. The induction of peptide-specific antibodies in this animal was high, and this 
might thus represent an antibody-escape mutant virus. Nevertheless, at day 56 no virus 
could be detected in serum samples anymore, showing that at that time other aspects of 
PRRSV specific immunity are capable of blocking virus replication. This observation does 
show however that due to the high flexibility of PRRSV, an RNA virus prone to mutations, 
efficient vaccines should probably focus on inducing antibodies to multiple sites. In addition, 
when focussing on only one epitope, antibody titres might have to be exceptionally high to be 
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able to cover enough GP4 molecules on each virion to inhibit infection. This reasoning might 
explain why antibody titres obtained in our experiments were still insufficient to efficiently 
inhibit viral infection of primary macrophages. Even when focussing on multiple B cell 
epitopes however, the question will remain if humoral immunity alone is sufficient to tackle 
PRRSV and if the induction of additional arms of the immune system will be necessary to 
provide sufficient immune pressure on the virus.       
    
DEVELOPMENT OF A SUSPENSION CHO CELL LINE EXPRESSING A CANDIDATE 
IMMUNOCASTRATION VACCINE  
 
In Chapter 4.2 of this dissertation, suspension CHO cell lines were developed expressing 
fusion constructs of the pSn-targeting recombinant antibody rec41D3 or its irrelevant isotype 
control rec13D12 with four repeats of a GnRH peptide. Fusion proteins could be easily 
purified from the selected clone supernatants and high purities were obtained. Furthermore, 
rec41D3-GnRH was shown to bind to and to be internalized into pSn-expressing cells, while 
no staining (or weak background staining) was observed with isotype control rec13D12-
GnRH. Although production levels of the fusion proteins were low (0.5mg/l for rec41D3-
GnRH and 2mg/l for rec13D12-GnRH) compared to yields obtained in industry settings, the 
fusion proteins obtained could be used in future animal experiments evaluating pSn-directed 
GnRH targeting as an immunocastration strategy.  
Considering the results obtained in our previous study targeting a B cell epitope of PRRSV 
towards Sn+ macrophages, a single non-adjuvanted injection of rec41D3-GnRH will probably 
not yield a significant anti-GnRH antibody response. After all, GnRH is a self-peptide and 
thus we are basically facing the challenge of inducing an autoimmune response. A prime-
boost schedule of the fusion proteins would be more interesting to evaluate, and adjuvant 
can be co-administered to evaluate the addition of maturation stimuli. Ideally, co-
administered adjuvant should direct the immune system towards the induction of strong 
humoral immune responses, making Alum a valuable candidate [28]. In addition, adjuvant 
can be physically linked to the targeting antibody, reducing potential harmful effects of 
systemic adjuvant administration. In the field, administration of the commercially available 
Improvac® vaccine occasionally results in death of the animal within minutes due to the 
induction of an anaphylactic shock. A reduction of the overall immunogenicity of such 
vaccine without compromising efficacy would thus clearly be beneficial.    
GnRH is a hormone that is equally present in human beings, highlighting the risks associated 
with potential self-injections when administering the commercially available Improvac® 
vaccine. As the antigen dose is lowered considerably in our targeting construct and rec41D3 
does not bind to human Sn, the risks associated with self-injections of our vaccine would be 
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reduced due to the lack of targeting in humans. However, as seen in Chapter 4.1, rec13D12 
can induce a priming of the immune response as well, thus potentially inducing a priming of 
the immune response in humans as well. As the enhancement of the immune response by 
coupling the antigen to rec13D12 can however be Fcγ receptor mediated, Fab fragments or 
scFv of rec41D3 and rec13D12 could be engineered starting from our rec41D3 and 
rec13D12 plasmids to eliminate Fcγ receptor involvement. GnRH can be fused to these 
fragments and resulting fusion constructs can be used to evaluate Sn-directed targeting of 
GnRH for immunocastration. In addition, bispecific Fab fragments or scFv could be 
engineered to include an anti-CD40 moiety for the delivery of costimulation. Furthermore, 
nanoparticles (NP) could be coated with the Fab fragments or scFv to target the NP towards 
Sn+ macrophages. GnRH can be coated onto the NP as well or encapsulated inside the NP 
or both. Most importantly, NP can carry adjuvant inside, reducing potentially harmful 
systemic effects. In this way, a species-specific immunocastration vaccine could be 
developed with both a better safety profile for the animals receiving it as well as for the 
individual administering it.       
 
FUTURE PERSPECTIVES   
 
To finalize this general discussion, some topics are highlighted which can be of importance 
for future developments in Sn-targeting research. 
Porcine lymph nodes 
Porcine lymph nodes have a structure that is called inverted, as discussed in the section ‘Sn 
expression and regulation’ of Chapter 1 of this dissertation. Afferent lymphatics enter the 
lymph node centrally at the capsule at one or more sites and penetrate via the trabeculae 
deep into B cell and T cell areas [29]. Occasionally, branches may arise from the afferent 
lymphatics outside the lymph node and join with a SCS where B cell follicles are located 
peripherally [30]. The lymph penetrates into the diffuse tissue and then filters into the 
peripheral sinuses, which converge and form several efferent vessels at the periphery of the 
node [29]. Sn+ macrophages have been identified at the subcapsular and medullary sinuses 
in pigs [31] and thus appear, just like in the other species studied, readily positioned to 
sample incoming lymph for antigens. An important remark however is that in rodents, it has 
been shown that medullary Sn+ macrophages fit the classical macrophage definition of being 
strongly phagocytic cells that rapidly degrade internalized material [7, 32], while SCS Sn+ 
macrophages have a low rate of antigen internalization and degradation [7, 32]. SCS 
macrophages also have a lower rate of depletion by clodronate-containing liposomes that kill 
cells after internalization than do medullary macrophages, which is also consistent with their 
different rates of phagocytosis [33]. In rodents, it has also been shown that it are these SCS 
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macrophages that are responsible for the capture of antigens like virus-sized beads, 
opsonized phycoerythrin, vesicular stomatitis virus, vaccinia virus and adenovirus particles 
within minutes of their subcutaneous injection and for each of these antigen types, the cells 
make the captured material accessible to B cells that migrate over their follicular tail 
processes (Figure 1a) [5, 7, 22, 34]. It remains to be established in pigs whether medullary 
and SCS macrophages present the same characteristics as they do in rodents. If so, the 
question is whether the inverted lymph flow in pigs permits the acquisition of equal amounts 
of antigen by SCS macrophages as in rodents. On the other hand, our targeting strategy 
targets antigen towards Sn, present on both SCS and medullary macrophages, and 
internalization via Sn that we have observed so far is always partial with a slow rate of 
progression down the endo/lysosomal pathway. In this way, antigen should be available for 
the surrounding B cells in the medulla of porcine lymph nodes. However, it remains to be 
established whether Sn internalization is identical in porcine medullary macrophages. Taken 
together, it would be interesting to study in pigs how our targeting antibody carrying an 
antigen travels and whether or not antigen is readily made available to B cells. Of course, the 
feasability of such an experiment is not in the range of a comparable experiment in mice at 
all. Isolation of porcine medullary and SCS macrophages for further experiments in vitro can 
yield valuable information as well, although significant optimization will be necessary to 
specifically sort these macrophage subsets.   
Antigen handling by Sn+ macrophages  
Although it has been established that (one of) the function(s) of Sn+ macrophages in spleen 
and lymph nodes is to sample incoming antigens, the mechanisms by which these 
macrophages proceed in their antigen handling are not completely understood. Yet, there is 
a consensus that SCS macrophages and MMM in the spleen function to concentrate antigen. 
As discussed before, SCS macrophages have been shown to capture diverse types of 
antigen and to display them to underlying B cells. Cognate B cells can acquire antigen 
directly from SCS macrophages via their B cell receptor or non-cognate B cells can carry 
antigen from the macrophages to follicular DCs, where cognate B cells can sample them to 
acquire their cognate antigen [7]. Although it is tempting to speculate that MMM in the spleen 
function in a similar way to capture blood-borne antigens and transport them to B cells, this 
has not been visualized up till now [35]. What has been shown though, is that MMM provide 
a confined area of viral replication necessary to allow the accumulation of sufficient antigen 
for the efficient induction of adaptive immunity [36]. Here, it is tempting to speculate that SCS 
macrophages can function in a similar way and SCS macrophages have indeed been shown 
to be permissive to viral infection [37, 38]. In the lymph nodes, medullary macrophages also 
express Sn and these macrophages share some markers and the property of being highly 
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phagocytic with marginal zone macrophages of the spleen, which however only show low 
expression levels of Sn [39]. It is envisioned that these two macrophage subsets relate to 
each other as do SCS macrophages and MMM. Here, no antigen concentration is observed, 
but instead captured antigen is rapidly degraded and their destruction of pathogens draining 
from sites of infection should help to prevent systemic spread [40]. Upon pathogen infection, 
these macrophages can also secrete inflammatory cytokines to ensure further action of the 
innate immune response [35]. Taken together, marginal zone macrophages and their 
medullary counterparts appear to resemble the phenotype of a classical macrophage 
supporting the innate immune response, while SCS macrophages and their MMM 
counterparts also have a prominent role in the induction of adaptive immunity.  
Although the importance of SCS macrophages and MMM for the induction of adaptive 
immunity appears to be undisputed, the question whether they are solely required for capture 
and transfer of antigen or whether they play a direct role in the activation of naive T 
lymphocytes clearly is still a matter of debate, and more research is necessary to clarify this 
issue. The ability of SCS macrophages and MMM to present antigen in the context of MHC 
class I is not questioned, as SCS macrophages can be killed by CD8+ T cells during 
Toxoplasma infection [41], while MMM can be killed by CD8+ T cells during Plasmodium 
chabaudi infection [42]. However, it is questioned whether these macrophages express 
sufficient amounts of co-stimulatory molecules to support naive T cell priming [39], and 
whether these macrophages only contribute to naive T cell priming by their transport of 
antigen towards DCs. Studies with subcutaneous vaccinia virus infections in mice showed 
that 85% of the infected lymph node cells were Sn+ macrophages, with the majority of these 
being the SCS macrophages [43]. Antigen-specific CD8+ T cells accumulated in proximity to 
these macrophages in interfollicular regions, but the authors claim that most of the CD8+ T 
cells contacts were with DCs, and priming was more successful via DCs [37, 43]. However, 
CD11c-DTR mice were used to study the antigen-presenting contribution of DCs versus 
macrophages and many lymph node macrophages express sufficient amounts of CD11c to 
be ablated by DT treatment of CD11c-DTR mice [39, 44]. Consistent with this, a ~10-fold 
reduction in vaccinia virus-infected macrophages was noted in the DT-treated CD11c-DTR 
mice. Only the toxin-resistant fraction of macrophages thus contributes to the results 
obtained following DT treatment. Similarly, Backer et al. attributed the potent CD8+ T cell 
response observed after antigen targeting to MMM in the spleen to transfer of the antigen to 
CD8+  DCs [11]. However, DCs were purified from mice by a CD11c MACS procedure for in 
vitro evaluation of T cell activation and thus, it is possible that macrophages were also 
included in these assays. A study by Asano et al. on the other hand showed that 
subcutaneous vaccination with irradiated tumour cells activated antigen-specific CD8+ T cells 
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to elicit a protective antitumor immune response and that this effect was abolished by 
selective depletion of Sn+ macrophages in the lymph nodes [45]. In this study however, also 
CD11chi cells (also expressing Sn) were involved in the antigen presentation to the CD8+ T 
cells which also expressed CD8α, and it may be argued that these cells actually are Sn+ 
CD8α+ DCs, that either express Sn by themselves or gain Sn expression by bleb acquisition 
from macrophages [39, 46]. This bleb acquisition has been proposed as a mechanism used 
by macrophages to transport antigen towards DCs (and lymphocytes), although the authors 
can not rule out the possibility that the blebs arise during tissue preparations [47]. One study 
that has not been argued against yet is a study by Barral et al. showing that Sn+ 
macrophages can present lipid antigens in a CD1d dependent manner to iNKT cells, leading 
to iNKT cell activation and population expansion in the lymph nodes [48]. Although purified 
CD11chi DCs were also able to activate iNKT cells in vitro, they were unable to activate iNKT 
cells when recovered from draining lymph nodes from immunised animals, suggesting they 
do not have access to the antigen in vivo. Also, Kawasaki et al. used high-affinity glycan 
ligand–bearing liposomes to selectively deliver lipid antigens to Sn+ macrophages via the Sn 
endocytic pathway [49]. They found that ligand-targeted liposomes were captured by Sn+ 
macrophages and potently primed iNKT cells in liver and spleen and that these effects 
occurred in an Sn-dependent manner, as no activation was seen with the targeted liposomes 
in Sn-deficient mice. As iNKT cells are however a specialized subset of classical αβ T 
lymphocytes, it has not been definitely established yet whether Sn+ macrophages are able to 
directly prime naive CD8+ T cells and thus further research is required to resolve this issue. 
Also, research is lacking concerning the priming of CD4+ T cells by Sn+ macrophages, either 
directly or indirectly. Backer et al. showed modest stimulation of CD4+ T cells in vitro after in 
vivo administration of OVA conjugated to an Sn-specific mAb and ex vivo restimulation of 
splenocytes with OVA peptide [11]. In our study, the lack of antigen-specific antibody 
induction upon vaccination might also be attributed to a modest or absent CD4+ T cell 
stimulation. Clearly, further research is required to find out whether Sn+ macrophages can 
stimulate CD4+ T cell responses in vivo, either directly or indirectly. 
Route of immunization 
Although it is clear that there are a number of similarities between lymph node SCS 
macrophages and splenic MMM (both depend on CSF-1, B cells and lymphotoxin, are prone 
to viral infection and are situated at the interface of the follicle and sinus), there are also 
notable distinctions. SCS macrophages readily capture immune complexes, while MMM do 
not [39]. This may reflect anatomical differences of the tissues but could also relate to 
intrinsic differences in these cells that match their functions with the types of pathogens and 
antigens they typically encounter. As such, it might also be interesting to perform a targeting 
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experiment where antibody-antigen fusion constructs are administered intraveneously, so 
fusion constructs would predominantly be captured in the spleen. As MMM do not capture 
immune complexes, differences between targeting construct and non-targeting construct 
might be more pronounced in such experiment. Also, in pig lymph nodes we are not sure yet 
whether Sn-targeting fusion constructs are as efficiently transferred to B cells as it might be 
in rodents due to the inversed lymph flow present. In addition, both SCS and medullary 
macrophages in lymph nodes share equal expression levels of Sn, while MMM have a 
significantly higher expression level of Sn compared to marginal zone macrophages. This 
might lead to a more efficient targeting to the macrophages involved in antigen presentation. 
However, expression levels remain to be established in pigs, where Sn expression is 
observed in the marginal zone and elliptical vessels [31], for which the latter may be 
comparable to the periarterial macrophage sheaths observed in humans.        
Both intramuscular and intraveneous antigen delivery will predominantly yield systemic 
immunity. Although this is of major importance against infections, the induction of mucosal 
immunity is also gaining increased attention. After all, many pathogens enter the body via 
mucosal sites and a line of defense at these sites thus obviously represents a major benefit. 
It is envisioned mucosal immunizations (e.g. oral, pulmonary, sublingual and nasal) will also 
gain importance because of the possibility to yield needle-free vaccines, which have the 
advantage that they are easy to use/administer and do not require trained health care 
workers [50]. As discussed in Chapter 1, Sn expression has been observed in the lungs of 
rats, mice, humans and pigs and in the intestines of rats, mice and humans (not examined in 
pigs), making it interesting to evaluate the outcome of differential administration routes of 
antigen-bearing Sn-targeting construct.   
Antigen delivery 
In this thesis, a recombinant antibody was developed to target antigens towards Sn+ 
macrophages. Antibodies have a high specificity and affinity for their target, which makes 
them ideal molecules for this purpose. Besides antibodies however, an extensive toolbox of 
antibody derivates has been developed and a comparison of different targeting moieties for 
their efficiency of targeting antigen towards Sn+ macrophages and the resulting immune 
outcomes would be interesting. In addition, an extensive set of nanoparticles for antigen 
delivery has been developed and these molecules can be used in targeting research as well 
by the coating of the targeting moiety upon the nanoparticle. This again broadens the 
possibilities to target antigen towards Sn+ macrophages. In addition, some nanoparticles 
have the advantage that they can carry adjuvant inside, or have adjuvanting properties, 
which can significantly reduce possible side-effects of systemic adjuvant delivery. Taken 
together, a large array of antigen delivery tools exists and it would be interesting to 
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investigate whether these different antigen delivery vehicles can positively influence immune 
responses upon Sn targeting.       
To target or not to target? 
DC targeting studies most often aim at reaching a single DC subset in order to drive the 
immune system towards a specific immune response. For example, CD8α+ DCs in mice are 
thought to be the DC subset capable of most potently priming CD8+ T cell responses. 
Targeting antigens towards these CD8α+ DCs by Clec9A however also appears to be an 
interesting strategy to induce robust humoral immunity as well [3]. The proposed human 
equivalent of mouse CD8α+ DCs is the BDCA3+ DC subset. This was based on phenotypic 
characteristics, the expression of particular transcription factors, and the fact that they cross-
present antigen to CD8+ T cells [51, 52]. Nevertheless, a recent study reported that BDCA3+ 
dermal DCs suppressed immune responses by the constitutive production of IL-10 and the 
induction of regulatory T cells [53]. In addition, studies have reported cross-presentation of 
various forms of antigen by plasmacytoid DCs [54-56], thought to be mainly involved in 
innate immune stimulation. These observations might raise the question whether putting 
labels on different DC subsets is actually possible and whether it is not the environment in 
which the DCs reside that determines their functional specialisation. Without a doubt, certain 
differentiated DC subsets will be intrinsically better at performing specific immune steering 
functions, but (re-)programming of DCs by using an appropriate immune stimulus might yield 
desired immune responses as efficiently as specifically targeting the antigens towards the 
‘best suited’ DC subset, raising the question: why bother targeting DC subsets? Can it be 
that it is more interesting to find vaccine formulations that are most efficiently taken up by 
APCs in general and finding the right stimuli to program them towards the desired immune 
response? Building on to that idea, Sn+ macrophages can be important cells to study. They 
are located in spleen and lymph nodes at the borders of incoming blood and lymph 
respectively. Having a vaccine composition that efficiently drains into the lymph combined 
with an Sn-targeting moiety enables capture by Sn+ macrophages in lymph nodes. Providing 
the right stimulus on the other hand might trigger these macrophages to secrete cytokines 
that provide the immune environment to steer the immune response in the wanted direction. 
Furthermore, Sn+ SCS macrophages can transfer antigen to cognate B cells or non-cognate 
B cells that carry the antigen towards follicular DCs where cognate B cells have the 
opportunity to sample the antigens. Intriguingly, bleb formation by Sn+ macrophages has 
been proposed to be a mechanism of antigen transfer towards DCs, which can upon antigen 
retrieval further drive the immune response [47]. Taking these observations into 
consideration, Sn+ macrophages can be ideal candidates for antigen delivery and finding out 
how they can be best reached and activated is most interesting to pursue.           
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CONCLUSIVE REMARK   
 
Vaccination is by far the greatest success within the field of immunology to date. Current 
immunotherapeutic approaches seek to continue this success story by refining the classical 
vaccine approach [51]. One clear trend is the shift towards more complex but highly 
controlled vaccine design. To facilitate this, fundamental knowledge on the immunological 
mechanisms underlying immune responses is necessary. Different APC subsets have been 
defined and knowledge on how they can be properly reached and activated will provide 
extremely valuable information for further vaccine design. Ultimately, a full exploitation of the 
immune system is envisioned which can pave the way for the design of vaccines that are 
safe and capable of treating chronic infections, cancer and even autoimmune diseases. Sn+ 
macrophages are one of these APC subsets that due to their characteristics and anatomical 
location at the sites where effective immune responses are generated represent an attractive 
target for antigen delivery. Yet, many questions need to be answered before Sn targeting can 
be effectively harnessed, especially how these macrophages handle antigen internalized via 
Sn, how these macrophages exactly interact with other immune cells, and what the best way 
may be to get them activated to drive the generation of humoral and cellular immunity. 
Answers to these challenges will however shed light on how to exploit the full potential of this 
intriguing cell subset for next generation vaccines.   
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SUMMARY 
 
Classic strategies for the development of vaccines are attenuation or complete inactivation of 
pathogens. Although these vaccines prove successful in many instances, many infectious 
diseases still exist for which the development of an effective vaccine remains elusive based 
on these traditional approaches (e.g. HIV, malaria, tuberculosis,M). In addition, continuously 
increasing safety demands for novel vaccine formulations encourage the search for more 
rational vaccine designs. As such, a wide range of vaccines under development now are 
based on isolated peptides, proteins or polysaccharides of pathogens, or naked DNA 
encoding a protective antigen. Although promising, as this can lead to the development of 
vaccines that are more immunologically defined and safer than many existing vaccines, such 
antigens are often poorly immunogenic and require the addition of an immune-stimulating 
compound to generate an effective immune response. As a consequence, finding safe, yet 
efficient ways to boost immunity has become an increasingly important area of research in 
current-day vaccinology.  
The ultimate goal of a vaccine is to induce an antigen-specific memory immune response. To 
facilitate this, an interaction between antigen-loaded APCs and naive lymphocytes needs to 
take place in secondary lymphoid tissues. Therefore, one way to improve the efficiency of a 
vaccine is to improve the efficiency by which antigen is encountered by APCs. As such, 
targeting antigen to uptake receptors expressed on the surface of APCs is increasingly 
studied. As the dogma establishes that DCs are the most efficient APCs stimulating naive 
lymphocytes, most targeting studies have been focused on DCs and their different subtypes. 
However, recently also Sn+ macrophages are gaining increased attention as targets for 
vaccination strategies as their location in spleen and lymph nodes appears to be ideal for 
antigen capture and presentation [7]. These macrophages and more precisely the immune 
stimulatory effect of directly targeting antigens towards them, is the subject of this 
dissertation.  
To start this dissertation, the current knowledge on targeting antigens towards APCs as a 
vaccination strategy is summarised in Chapter 1. In addition, the available literature on Sn 
and Sn+ macrophages is reviewed which highlights the importance of this macrophage 
subset in the stimulation of immune responses. To finalize this chapter, an overview is given 
of targeting molecules already applied for targeting antigens to APCs and targeting 
molecules that could be implemented in this research area in the near future. 
In Chapter 2, the aims of this dissertation are formulated. 
Chapter 3 is dedicated to the development of a recombinant antibody that can be used to 
target peptides or proteins to Sn+ macrophages. Previous research results of our laboratory 
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had shown that porcine antibody responses to the model antigen HSA could be enhanced by 
chemically coupling HSA to an Sn-specific mAb. Although successful, this system implies 
that the antigen to be targeted is independently produced and purified, which translates into 
significant optimization for each separate conjugate. Also, chemical coupling to antibodies 
depends on the presence and distribution of reactive groups, e.g. primary amines on lysine 
residues, that can be located in or near the antigen-binding region. Upon coupling, this might 
result in partial or complete loss of the antibody’s capacity to bind to the target antigen. In 
addition, there is limited stoichiometric control because of the large number of reactive 
groups present in an antibody, leading to a heterogeneous mixture that makes batch to batch 
consistency hard to effectuate. To overcome these problems associated with chemical 
conjugation of a cargo to an Sn-specific mAb, a versatile recombinant antibody vector was 
developed. This recombinant antibody rec41D3 was shown to specifically bind to porcine Sn 
with a comparable affinity as the native monoclonal antibody. In addition, rec41D3 also 
induced Sn endocytosis in primary macrophages and resided for prolonged times in 
early/late endosomes. Subsequently, two fusion proteins were generated, one containing a 
V5 peptide tag and one containing an eGFP molecule, and were shown to be efficiently 
produced in HEK-293T cells and easily purified using standard protein G chromatography. 
Furthermore, both V5 and eGFP were shown to be co-internalized together with rec41D3 into 
Sn-expressing primary macrophages, confirming the development of a versatile antibody 
vector to evaluate Sn-directed targeting strategies in a porcine animal model.   
In Chapter 4, the technology developed in Chapter 3 was applied to generate fusion proteins 
for PRRSV vaccination and immunocastration.  
In part 4.1, a linear B cell epitope, present on GP4 of PRRSV and known to be a target of 
virus-neutralizing antibodies, was selected and introduced at the C-terminus of rec41D3 and 
its irrelevant isotype control. During the course of an immune response to PRRSV, the 
induction of virus-neutralizing antibodies is hampered, and thus we wished to evaluate if 
targeting a neutralizing epitope towards pSn-expressing macrophages could enhance the 
induction of epitope-specific and virus-neutralizing antibodies. As such, a single dose of the 
resulting fusion constructs was used to immunize pigs and four weeks later, a viral challenge 
was performed. Upon vaccination, no peptide-specific IgG responses could be detected. 
After viral challenge however, it was clear that the IgG response against this specific peptide 
developed more rapidly compared to an infection in non-immunized animals, with the most 
pronounced induction of IgG responses in the group that had received a 500µg Sn-targeting 
fusion construct. Also, neutralizing antibody responses after PRRSV challenge were 
enhanced in animals receiving a single 500µg intramuscular dose of the Sn-targeting fusion 
protein, although correlations between the two read-outs were hard to effectuate. Lastly, a 
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minor beneficial effect on viral clearance was observed. Together, these data show that viral 
peptide targeting to porcine Sn-expressing macrophages can improve the anti-viral immune 
response, but also show that more research will be needed to further explore vaccination 
potential. 
In part 4.2, a potential immunocastration vaccine candidate was developed. As 
immunocastration relies on the induction of antibodies against gonadotropin releasing 
hormone (GnRH), a 10 amino acid peptide, four copies of GnRH were genetically fused to 
our recombinant Sn-targeting antibody. For the production of recombinant antibodies, the 
most commonly used expression systems are mammalian cells growing in suspension, so as 
to enable the rapid scale up of productions. In addition, chemically defined, serum-free media 
– with no animal-derived components – have become industry standard to further simplify 
regulatory approval. In this study, we made use of a commercially available suspension 
adapted CHO cell line to develop cell lines expressing recombinant antibody-GnRH fusion 
constructs. Subsequently, antibody-fusion proteins could be easily purified from the selected 
clone supernatants and a high purity was obtained. Furthermore, only Sn-targeting fusion 
proteins were shown to specifically bind to and to be internalized into Sn-expressing cells. 
These fusion proteins are therefore ready to be used in future animal experiments to 
evaluate pSn-directed GnRH targeting as an immunocastration strategy. 
Finally, in Chapter 5, the main findings of this dissertation are recapitulated and discussed in 
a broader context, with a main focus on future vaccine development. Combining literature 
with the results obtained in this thesis results in many questions remaining on the way Sn+ 
macrophages capture and handle incoming antigen. In addition, further research is needed 
to explore ways to most efficiently reach these Sn+ macrophages in vivo and get them 
activated to drive the generation of humoral and cellular immunity. Answers to these 
challenges will however shed light on how to exploit the full potential of this intriguing cell 
subset for next generation vaccines.   
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SAMENVATTING 
 
Klassieke methoden voor het vervaardigen van vaccins zijn het attenueren of inactiveren van 
pathogenen. Hoewel deze vaccins in veel gevallen succesvol blijken, bestaan er nog steeds 
verscheidene infectieuze ziekten waarvoor de ontwikkeling van een beschermend vaccin niet 
mogelijk bleek tot op heden (vb. HIV, malaria, tuberculosis,M). Bijkomend worden er steeds 
strengere veiligheidseisen gesteld voor het op de markt brengen van nieuwe vaccins, 
waardoor er een noodzaak blijkt aan een meer rationeel ontwerp van vaccins. Zo zijn heel 
wat vaccins in ontwikkeling vandaag gebaseerd op geïsoleerde peptiden, eiwitten of 
polysacchariden van pathogenen, of op naakt DNA dat codeert voor een beschermend 
antigeen. Hoewel dit zeer beloftevol lijkt om te komen tot vaccins die beter immunologisch 
gedefinieerd en veiliger zijn dan vele reeds bestaande vaccins, blijken dergelijke antigenen 
echter vaak zwak immunogeen en vereisen zij de toevoeging van een adjuvans om tot een 
beschermende immuunrespons te komen. Bijgevolg krijgt de zoektocht naar veilige, maar 
efficiënte manieren om immuniteit op te wekken veel aandacht in huidig vaccinatie 
onderzoek. 
Het ultieme doel van een vaccin is het opwekken van een antigeen-specifieke 
immuunrespons die in staat is te beschermen tegen een toekomstige besmetting met het 
pathogeen. Om dit te bewerkstelligen, is het noodzakelijk dat antigeen-presenterende cellen 
(APC) die geladen zijn met het antigeen kunnen in contact komen met naïve lymfocyten in 
secundaire lymfoïde organen. Een manier om de efficiëntie van een vaccin te verbeteren, 
kan dan ook zijn om de efficiëntie van de manier waarop APC in contact komen met antigeen 
te verbeteren. Dit inzicht heeft geleid tot onderzoek waarbij antigeen gestuurd wordt richting 
het oppervlak van APC door het gebruik van een molecule die een receptor op het oppervlak 
van de APC herkent. Dendritische cellen worden over het algemeen beschouwd als de 
meest efficiënte APC en bijgevolg werd ook het meeste onderzoek tot dusver gericht naar 
het bereiken van dendritische cellen en hun verschillende subtypes. Recent kregen echter 
ook sialoadhesine-expresserende (Sn+) macrofagen meer wetenschappelijke aandacht 
omwille van hun locatie in milt en lymfeknopen waar bloed en lymfe die antigenen bevatten, 
circuleren. Het sturen van antigenen richting deze macrofagen en de evaluatie van de 
resulterende immuunrespons, is het onderwerp van deze doctoraatsthesis. 
Deze doctoraatsthesis start met een samenvatting van de huidige kennis over het sturen van 
antigenen richting APC voor vaccinatiedoeleinden (Hoofdstuk 1). Bijkomend wordt een 
overzicht gegeven van de tot op heden beschikbare literatuur over Sn en Sn+ macrofagen, 
wat de immuunstimulerende rol van dit celtype in de verf zet. Om het hoofdstuk af te sluiten, 
wordt tot slot een overzicht gegeven van reeds gebruikte moleculen voor het sturen van 
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antigenen richting APC en eveneens van moleculen die onderzocht kunnen worden voor 
deze doeleinden in de toekomst. 
In Hoofdstuk 2 worden de doelstellingen van deze thesis voorgesteld. 
Hoofdstuk 3 is voorbehouden voor de ontwikkeling van een recombinant antilichaam 
(rec41D3) dat gebruikt kan worden voor het sturen van peptiden of eiwitten richting Sn+ 
macrofagen. Voorgaand onderzoek aan het laboratorium voor Virologie had reeds 
aangetoond dat antistof responsen tegen het model antigeen HSA in het varken verbeterd 
konden worden wanneer HSA chemisch gekoppeld werd aan een Sn-specifiek monoklonaal 
antilichaam. Dit experiment was succesvol, maar chemische koppeling van een antigeen aan 
een antilichaam impliceert dat het antigeen eerst afzonderlijk geproduceerd en opgezuiverd 
dient te worden, wat zich vertaalt in aanzienlijke optimalisatie voor elk gewenst conjugaat. 
Chemische koppeling aan antilichamen is ook afhankelijk van de aanwezigheid en de 
distributie van reactieve groepen, zoals primaire amines op lysine residuen, die in of nabij het 
antigeen-bindend domein kunnen gelegen zijn. Na koppeling kan dit mogelijk tot resultaat 
hebben dat de affiniteit van het antilichaam voor het antigeen gedeeltelijk of volledig verloren 
gaat. Bijkomend is er ook weinig controle over hoeveel antigenen zullen binden op het 
antilichaam en op welke locatie van het antilichaam, aangezien heel wat reactieve groepen, 
en dus mogelijke koppelingsplaatsen, aanwezig zijn. Dit leidt tot een heterogene verzameling 
van conjugaten, wat het moeilijk maakt gelijkvormigheid in de verschillende producties te 
verkrijgen. Om aan deze problemen tegemoet te komen werd een recombinante 
antilichaamvector gemaakt die toelaat eiwitsequenties toe te voegen aan de C-terminus van 
de zware keten van het antilichaam. Het recombinante antilichaam vertoonde een 
gelijkaardige affiniteit voor Sn als het natieve antilichaam en induceerde, na binding met Sn,  
Sn endocytose in primaire macrofagen. De recombinante antilichamen vertoonden, net als 
het natieve antilichaam, een trage progressie door de endo/lysosomale weg en verbleven 
meer specifiek voor verlengde tijd aanwezig in vroege endosomen. Bijkomend werd een 
fusie-eiwit gemaakt van rec41D3 met een V5 peptide tag en een fusie-eiwit van rec41D3 met 
eGFP. Beide eiwitten werden geproduceerd in het supernatans van HEK293T cellen na 
transfectie en konden makkelijk opgezuiverd worden aan de hand van proteïne G 
chromatografie. Bijkomend werd aangetoond dat V5 en eGFP samen met rec41D3 
geïnternaliseerd werden in primaire macrofagen. Dit toont aan dat een aanpasbare 
antilichaamvector gemaakt werd die gebruikt kan worden om Sn-gerichte 
vaccinatiestrategieën uit te testen in een porcien diermodel.     
In Hoofdstuk 4 van deze thesis werd de technologie ontwikkeld in Hoofdstuk 3 toegepast 
om fusie-eiwitten te maken voor PRRSV vaccinatie en immunocastratie.    
Chapter 6 | Samenvatting 
 
 131 
In deel 4.1 werd een lineaire B cel epitoop aanwezig op GP4 van PRRSV geselecteerd en 
geïntroduceerd aan de C-terminus van rec41D3 en een irrelevante isotype controle. Deze 
epitoop is een gekend doelwit voor virus-neutralizerende antilichamen. Tijdens de 
immuunrespons volgend op een PRRSV infectie verloopt deze inductie van virus-
neutralizerende antilichamen echter zeer inefficiënt en aldus wensten wij te evalueren of het 
gericht sturen van deze epitoop richting Sn+ macrofagen de inductie van epitoop-specifieke 
en virus-neutralizerende antilichamen kon verbeteren. Een enkele dosis van de fusie-eiwitten 
werd toegediend aan varkens en vier weken later werden de dieren geïnfecteerd met het 
PRRSV virus. Na vaccinatie konden echter nog geen peptide-specifieke IgG responsen 
gedetecteerd worden. Na virale infectie werd echter duidelijk dat de peptide-specifieke 
immuunrespons zich sneller ontwikkelde in gevaccineerde ten opzichte van niet-
gevaccineerde dieren, met het meest uitgesproken effect zichtbaar bij de dieren die een 
eenmalige 500µg dosis ontvangen hadden van het Sn-gerichte fusie-eiwit. Bijkomend was 
ook de neutralizerende antilichaamrespons verhoogd na infectie in deze groep, hoewel de 
correlatie met de peptide-specifieke respons moeilijk te trekken bleek. Tot slot werd ook een 
matige verbetering van de viremie na infectie vastgesteld in deze groep. Deze data tonen 
aan dat het sturen van een viraal peptide naar Sn+ macrofagen de anti-virale 
immuunrespons kan verbeteren. Deze data tonen echter ook aan dat meer onderzoek nodig 
zal zijn om het vaccinatiepotentieel van deze vaccinatiestrategie verder uit te pluizen. 
In deel 4.2 werd een kandidaat immunocastratievaccin ontwikkeld. Immunocastratie is 
gebaseerd op het opwekken van antilichamen tegen gonadotropin releasing hormone 
(GnRH), wat een peptide is dat bestaat uit 10 aminozuren. Vier herhalingen van dit peptide 
werden genetisch gekoppeld aan het Sn-gerichte rec41D3 en een irrelevante isotype 
controle. Voor de productie van recombinante antilichamen zijn cellen van dierlijke afkomst 
de meest gebruikte expressiesystemen. Bijkomend worden suspensiecellen geprefereerd 
omwille van de makkelijke opschalingmogelijkheden. Chemisch gedefinieerde media worden 
gebruikt zodat geen dierlijke componenten in het productiemedium aanwezig zijn. In deze 
studie maakten wij gebruik van een commercieel beschikbare suspensie CHO cellijn om 
cellijnen te onwikkelen die de antilichaam-GnRH fusie-eiwitten constitutief tot expressie 
brengen. Antilichaam-GnRH fusies konden makkelijk opgezuiverd worden uit het 
supernatans van de geselecteerde clones en een hoge zuiverheid werd verkregen. 
Bijkomend konden enkel de Sn-gerichte fusie-eiwitten binden met Sn en werden enkel deze 
eiwitten naar binnen getrokken in Sn-expresserende cellen. Deze fusie-eiwitten kunnen nu 
verder gebruikt worden in toekomstige vaccinatie-experimenten.      
Tot slot worden in Hoofdstuk 5 de belangrijkste bevindingen van deze thesis samengevat 
en bediscussieerd in een bredere context, met een focus op toekomstige vaccinontwikkeling. 
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Een combinatie van de beschikbare literatuur en de resultaten behaald in deze thesis tonen 
aan dat veel vragen onopgelost blijven over de manier waarop Sn+ macrofagen inkomend 
antigeen vangen en verder verwerken. Bijkomend is het duidelijk dat verder onderzoek 
noodzakelijk is om uit te zoeken wat de beste manier is om deze macrofagen in vivo te 
bereiken en deze te activeren zodat ze de inductie van een humorale en cellulaire immuniteit 
bewerkstelligen. Het oplossen van deze vragen kan echter leiden naar diepgaand inzicht in 
het potentieel van dit intrigerend celtype voor de ontwikkeling van een nieuwe generatie 
vaccins.   
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